Prins reactions and compounds useful for synthesis of halichondrin macrolides and analogs thereof
The synthesis of soft sponge macrolide was simplified through methods such as Prince reaction and Sakurai reaction, and solved the problems of synthesis complexity and low efficiency in the prior art, and achieved efficient preparation of soft sponge macrolide or its analog.
Patent Information
- Application Number
- CN202410870977.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-01-03
- Filing Date
- 2019-01-03
- Publication Date
- 2024-11-05
AI Technical Summary
The prior art is difficult to effectively synthesize soft sponge macrolide and its analogues, and the existing methods are complex and inefficient.
Soft spongein macrolide or its analogs were synthesized by methods such as Prince reaction and Sakurai reaction, and the target compound was generated by reaction of specific compound structures and Lewis acids.
A simplified synthesis path is provided, which improves the preparation efficiency and purity of soft spongein macrolide or its analogues, and solves the problems of complexity and low efficiency of existing methods.
Smart Images

Figure SMS_2 
Figure SMS_3 
Figure SMS_4
Abstract
Description
This application is a divisional application of the invention patent application with the application date of January 3, 2019, application number 201980007225.0, and name “Prince reaction and compounds that can be used to synthesize spongin macrolide and its analogs”. background The present invention relates to intermediates that can be used to synthesize pharmaceutically active macrolide compounds, and methods for synthesizing macrolide compounds. Halichondrin B is an effective anticancer agent originally isolated from the sea sponge Halichondriaokadai and subsequently discovered in Axinella sp., Phakellia carteri, and Lissodendoryx sp. The total synthesis of Halichondrin B was published in 1992 (Aicher, TD et al., J. Am. Chem. Soc. 114:3162-3164). Further synthesis and structure-activity relationship studies are disclosed in U.S. Patent Nos. 5,338,865 and 5,436,238, as well as in Towle et al., Annual Meeting of the American Association for Cancer Research, April 6-10, 2002, 5721 and Wang et al., Bioorg. Med. Chem. Lett., 10:1029-1032, 2000. Eribulin mesylate (also known as E7389, and the mesylate salt of B1939) are non-taxane microtubule dynamics inhibitors that are structurally simplified synthetic analogs of halichondrin B. Methods and intermediates for synthesizing certain halichondrin B analogs and intermediates are described in: International Publication Nos. WO 2005 / 118565, WO 2009 / 046308, WO 2009 / 064029, and WO 2009 / 124237, WO 2015 / 066729, and WO 2016 / 179607; U.S. Patent No. 6,214,865; Austad et al., Synlett 24(3):333-337, 2013; Austad et al., Synlett. 24(3):327-332, 2013; and Chase et al., Synlett 24(3):323-326, 2013. New methods for synthesizing halichondrin and its analogs, such as macrolide analogs, are needed. SUMMARY OF THE INVENTION In general, the present invention provides methods and compounds that can be used to prepare macrocyclic intermediates in the synthesis of halichondrin macrolides or their analogs. In particular, the methods disclosed herein can be used to prepare halichondrin macrolides or their analogs via a synthesis involving a Prins reaction that forms a C.23-C.24 bond. As described herein, the Prins reaction precursor can be prepared using a Sakurai reaction.
[0003] In one aspect, the present invention provides a method for preparing a compound of formula (A): in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group, or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H and P2 is absent, H, optionally substituted alkyl or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) n OP5, wherein P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group, and P5 is H, optionally substituted alkyl, or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group, or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the following: wherein each P' is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl group; Each Q1 is independently OR A SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)R A NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each independently represents H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl, or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxyl protecting group; R4 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, in Each P7 is independently H or a hydroxy protecting group; and R8 is -CH2CH2-COOR C 、-CH=CH-COOR C 、-CH2CH2-SO2R D or -CH=CH-SO2R D ; R6 is H, optionally substituted alkyl or optionally substituted arylalkyl; Each Y is independently -COOR C or-SO2R D ; Each RC and , when present, is independently optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; and Each R D Where present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl.
[0004] The method comprises preparing a compound of formula (A) from a compound of formula (B), a compound of formula (C) and R5OH, wherein R5 is an optionally substituted acyl group. The compound of formula (B) is: wherein all variables are as described for compounds of formula (A).
[0005] The compound of formula (C) is: R4-R7, (C) Wherein R7 is -CHO or And each R 7A is independently optionally substituted alkyl.
[0006] In some embodiments, preparing a compound of formula (A) comprises reacting a compound of formula (B), a compound of formula (C), R5OH, and a Lewis acid, such as an oxophilic Lewis acid (eg, boron trifluoride or a solvate thereof).
[0007] In certain embodiments, the method further comprises preparing a compound of formula (B) comprising reacting a compound of formula (D), a compound of formula (E), and a second Lewis acid.
[0008] The compound of formula (D) is: wherein all variables are as described for compounds of formula (B).
[0009] The compound of formula (E) is: where R S is a silyl group, and R6 is as described for the compound of formula (B).
[0010] In some embodiments, the second Lewis acid is an oxophilic second Lewis acid (e.g., boron trifluoride or a solvate thereof). In specific embodiments, the Lewis acid and the second Lewis acid are the same. In further embodiments, the Lewis acid and the second Lewis acid are different.
[0011] In certain embodiments, the preparation of the compound of formula (B) and the preparation of the compound of formula (A) are carried out in a one-pot conversion. In other embodiments, the method further comprises epimerizing the reaction product of the compound of formula (D), the compound of formula (E) and the second Lewis acid.
[0012] In another aspect, the present invention provides a method for preparing a compound of formula (B). The compound of formula (B) can be used as a reactant in the Prins reaction described herein. The method comprises preparing the compound of formula (B) from a compound of formula (D) and a compound of formula (E).
[0013] The compound of formula (B) is: in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group, or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) n OP5, wherein P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P5 is H, an optionally substituted alkyl group, or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group, or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the group consisting of: wherein each P' is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl group; Each Q1 is independently OR A SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)R A NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each independently represents H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl, or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxyl protecting group; R6 is H, optionally substituted alkyl or optionally substituted aryl; and Y is independently -COOR C or-SO2R D ; R C When present, is optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; and R D Where present, is optionally substituted aryl or optionally substituted non-enolizable alkyl.
[0014] The compound of formula (D) is: wherein all variables are as described for compounds of formula (B).
[0015] The compound of formula (E) is: where R S is a silyl group, and R6 is as described for the compound of formula (D).
[0016] In some embodiments, preparing the compound of formula (B) comprises reacting a compound of formula (D), a compound of formula (E), and a Lewis acid, such as an oxophilic Lewis acid (eg, boron trifluoride or a solvate thereof).
[0017] In certain embodiments, the method further comprises epimerizing the reaction product of the compound of formula (D), the compound of formula (E), and the Lewis acid.
[0018] In another aspect, the present invention provides a method for preparing a halichondrin macrolide or an analog thereof.
[0019] In certain embodiments, the halichondrin macrolide or analog thereof is: Halichondrin macrolide or its analogues, in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group, or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) nOP5, wherein P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group, and P5 is H, optionally substituted alkyl, or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group, or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the following: wherein each P' is independently H or a hydroxyl protecting group; A1, A2 and A3 are each independently H or OP", wherein each P" is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl group; Each Q1 is independently OR A SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)R A NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each independently represents H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl, or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; and X1 is -CH2- or -O-.
[0020] In certain embodiments, the method comprises (A) preparing a compound of formula (IA) from a compound of formula (IIC), a compound of formula (III) and R5OH, wherein R5 is an optionally substituted acyl group; and (B) Preparation of halichondrin macrolide or its analogues from the compound of formula (IA).
[0021] The compound of formula (IA) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; R4 is in Each P7 is independently H or a hydroxyl protecting group; R8 is -CH2CH2-COOR C 、-CH=CH-COOR C 、-CH2CH2-SO2R D or -CH=CH-SO2R D ; Each R C and , when present, is independently optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; and Each R D when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; R5 is optionally substituted acyl; and The remaining variables are as described for the halichondrin macrolide or analogs thereof.
[0022] The compound of formula (IIC) is: wherein all variables are as described for compounds of formula (IA).
[0023] The compound of formula (III) is: R4-R7, (III) Wherein R7 is -CHO or Each R 7A is independently optionally substituted alkyl; and R4 is as described for the compound of formula (IA).
[0024] In certain embodiments, the method comprises: (A) preparing a compound of formula (IVB) from a compound of formula (IIA), a compound of formula (IIB), a compound of formula (IIIA), a compound of formula (IVA), and R5OH, wherein R5 is an optionally substituted acyl group; (B) preparing a compound of formula (IVC) from a compound of formula (IVB); (C) preparing a compound of formula (IVD) from a compound of formula (IVC); and (D) Preparation of halichondrin macrolide or its analogues from the compound of formula (IVD).
[0025] The compound of formula (IIA) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; Each R D when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; R E -CHO or -CH (1+m) (OR F ) (2 - m) , in m is 1, and R F is a hydroxyl protecting group, or m is 0, and (i) Each R F are independently alkyl or hydroxy protecting groups, or (ii) Two Rs F Combine to form an alkylene group; and the remaining variables are as described for the halichondrin macrolide or analogs thereof.
[0026] The compound of formula (IIB) is: where R S It is a silyl group.
[0027] The compound of formula (IIIA) is: R 4A -R7, (IIIA) in R 4A for where R C is optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl, and each P7 is independently H or a hydroxy protecting group; R7 is -CHO or Each R 7A is independently optionally substituted alkyl.
[0028] The compound of formula (IVA) is: in Each P9 is independently a hydroxyl protecting group; R9 is -CHO or -COOH; (a1)R 10 is H or a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (a2)R 10 is H or a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (a3)R 10 and R 11 Combine to form a bond, and R 12 is H; (b1)A1 and R 14 Combined to form oxo, R 13 is H or a hydroxyl protecting group, and R 15 is H; or (b2) A1 is H or -OP", and: (i)R 13 is H or a hydroxyl protecting group, and R 14 and R 15 Combine to form a double bond; or (ii)R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; and (c1)R 16 is H, and P8 is H or a hydroxyl protecting group; or (c2)R 16 Combines with P8 to form a double bond; and Each P" when present is independently H or a hydroxy protecting group.
[0029] The compound of formula (IVB) is: in X1 is -O-, -C(Y)2-, -CH(Y)- or -CH2-; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxyl protecting group; and R G for in R5 is optionally substituted acyl; and X2 is H or -CH2-X 2A -CH2-CH=CH2, where X 2A -O-, -C(R H )2-or-NR I -, where each R H are independently H or -COOR J , R I is an N-protecting group, and R J C 1-6 alkyl; and The remaining variables are as described for the compound of formula (IIA) and the compound of formula (IVA).
[0030] The compound of formula (IVC) is: in L1 is Wherein L2 and L3 combine to form a bond; and the remaining variables are as described for the compound of formula (IVB).
[0031] The compound of formula (IVD) is: wherein A1 and A2 are each independently H or -OP", and the remaining variables are as described for the compound of formula (IVC).
[0032] In other embodiments, step (A) comprises: (E) preparing a compound of formula (IA) from a compound of formula (IIA), a compound of formula (IIIA) and R5OH, wherein the compound of formula (IA) is: where R 4A as described for the compound of formula (IIIA), and the remaining variables are as described above for the compound of formula (IA); and (F) Preparation of a compound of formula (IVB) from a compound of formula (IF) and a compound of formula (IVA).
[0033] In further embodiments, step (E) comprises reacting a compound of formula (IIA), a compound of formula (IIIA), R5OH, and a Lewis acid, such as an oxophilic Lewis acid such as boron trifluoride or a solvate thereof.
[0034] In other embodiments, step (F) comprises making R 4A reacting with a diol cleavage agent, and reacting with (R C O)2P(O)-CH2-COOR C The Horner-Wadsworth-Emmons reaction was performed to produce R 4A
[0035] In other embodiments, step (F) comprises making R 4A Reaction with a 1,2-reducing agent and further reaction with an allylic halide or allylic pseudohalide.
[0036] In other embodiments, R9 is -CHO, X1 is -C(Y)2-, -CH(Y)-, or -CH 2- , and step (A) comprises using Base treatment reacts R9 with R1(CH(Y)2 or -CH2(Y)). In other embodiments, X1 is -O-, and step (A) comprises esterifying R1(-OP6, wherein P6 is H) with R9(-COOH).
[0037] In some embodiments, step (B) comprises reacting a compound of formula (IVB) with an olefin metathesis catalyst.
[0038] In a specific embodiment, P9 is H, R 16 is H, and step (C) comprises: Oxidation of a compound of formula (IVC) to produce a compound of formula (IVCa): wherein all variables are as described for the compound of formula (IVC); and reacting the compound of formula (IVCa) with a 1,4-reducing agent to produce the compound of formula (IVD).
[0039] In certain embodiments, prior to preparing the compound of formula (IVC), the compound of formula (IVB) is or is converted to a compound of formula (IVBa), wherein the compound of formula (IVBa) is: wherein all variables are as described for the compound of formula (IVB).
[0040] In a further embodiment, preparing a halichondrin macrolide or an analog thereof comprises reacting a compound of formula (IVD) with a hydroxy protecting group removing agent.
[0041] In other embodiments, the method comprises: (A) preparing a compound of formula (VB) from a compound of formula (IIA), a compound of formula (IIB), a compound of formula (IIIB), a compound of formula (VA) and R5OH, wherein R5 is an optionally substituted acyl group; (B) preparing a compound of formula (VC) from a compound of formula (VB), and (C) Preparation of halichondrin macrolide or its analogues from the compound of formula (VC).
[0042] The compound of formula (IIA) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; R D when present, optionally substituted aryl or optionally substituted non-enolizable alkyl; R E -CHO or -CH (1+m) (OR F ) (2-m) , in m is 1, and R F is a hydroxyl protecting group, or m is 0, and (i) Each R F are independently alkyl or hydroxy protecting groups, or (ii) Two RsF Combine to form an alkylene group; and the remaining variables are as described for the halichondrin macrolide or analogs thereof.
[0043] The compound of formula (IIB) is: where R S It is a silyl group.
[0044] The compound of formula (IIIB) is: R 4B -R7, (IIIB) in R 4B is but-3-en-1-yl, wherein each P7 is independently H or a hydroxyl protecting group; and R7 is -CHO or Each R 7A is independently optionally substituted alkyl.
[0045] The compound of formula (VA) is: in a specifies an (R)-stereocenter and Z is sulfonate, chloro, bromo or iodo; or a specifies an (S)-stereocenter and Z is OR 16 , where R 16 is a hydroxyl protecting group; (a1)R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (a2)R 10 is a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (a3)R 10 and R 11 Combine to form a bond, and R 12 is H; (b1)A1 and R 14 Combined to form oxo, R 13 is a hydroxyl protecting group, and R 15 is H; or (b2) A1 is H or -OP", and: (i)R 13 is a hydroxyl protecting group, and R14 and R 15 Combine to form a double bond; or (ii)R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; Y1 is iodine, bromine or triflate; R9 is -CHO or -COOH; P9 is each independently a hydroxy protecting group, and X3 is oxo; or two P9 groups and X3, together with the atoms to which they are attached, combine to form a ketal; and Each P" is independently a hydroxy protecting group.
[0046] The compound of formula (VB) is: in X1 is -CH2-, -CH(Y)-, -C(Y)2- or -O-, wherein each Y is independently -COOR C or-SO2R D ; Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; Each R D and , when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; and R k for R5 is optionally substituted acyl; and The remaining variables are as described for the compound of formula (VA) and the compound of formula (IIA).
[0047] The compound of formula (VC) is: in L1 is Wherein L2 and L3 combine to form a bond; b specifies the (S)-stereocenter if a specifies the (R)-stereocenter; and b specifies the (R)-stereocenter if a specifies the (S)-stereocenter; and The remaining variables are as described for the compound of Formula (VB).
[0048] In certain embodiments, step (A) comprises: (D) preparing a compound of formula (ID) from a compound of formula (IIA), a compound of formula (IIB), a compound of formula (IIIB) and R5OH, wherein R5 is an optionally substituted acyl group, and wherein the compound of formula (ID) is: wherein all variables are as described for the compound of formula (IIA), the compound of formula (IIB), the compound of formula (IIIB), and R5OH; and (E) Preparation of a compound of formula (VB) from a compound of formula (ID) and a compound of formula (VA).
[0049] In some embodiments, preparing a compound of formula (ID) comprises reacting a compound of formula (IIC), a compound of formula (IIIB), R5OH, and a Lewis acid, such as an oxophilic Lewis acid (eg, boron trifluoride or a solvate thereof).
[0050] In certain embodiments, step (D) comprises a Sakurai reaction between a compound of formula (IIA) and a compound of formula (IIB) to prepare a compound of formula (IIC), and a Prince reaction between a compound of formula (IIC), a compound of formula (IIIB), and R5OH.
[0051] In a further embodiment, the compound of formula (IIC) is: wherein all variables are as described for compounds of formula (IIA).
[0052] In other embodiments, X1 is -CH2-, -CH(Y)-, or -C(Y) 2- , and step (A) comprises using Base treatment reacts R9 (wherein R9 is -CHO) with R1 (-CH(Y)2 or -CH2(Y)) to produce -CO-X1-. In another embodiment, X1 is -O-, and step (A) comprises esterifying R9 (-COOH) with R1 (-OP6, wherein P6 is H) to produce -CO-X1-.
[0053] In other embodiments, step (B) comprises reacting a compound of formula (VB) with a Cr(II) salt and a Ni(II) salt. In other embodiments, step (C) comprises a step of nucleophilic ring closure of a compound of formula (VC). In other embodiments, two P9 groups and X3, together with the atoms to which they are attached, combine to form a ketal. In some embodiments, R 10 and R 11 combines to form a bond, and R 12 is H. In certain embodiments, R4B is but-3-en-1-yl, and step (A) comprises reacting but-3-en-1-yl with a dihydroxylating agent to produce R 4B and cleaved by reaction with a diol cleavage agent
[0054] In certain embodiments, R 4B for And step (A) comprises making Reacts with an oxidizing agent capable of converting the alcohol into a carbonyl.
[0055] In other embodiments, R 4B for And step (A) comprises cracking by reacting with a diol cracking agent
[0056] In other embodiments, the method comprises: (A) preparing a compound of formula (IF) from a compound of formula (IIA), a compound of formula (IIB), a compound of formula (IIIC) and R5OH, wherein R5 is an optionally substituted acyl group; (B) preparing a compound of formula (IG) from a compound of formula (IF), and (C) preparing a halichondrin macrolide or an analog thereof from a compound of formula (IG) and one or more intermediates.
[0057] The compound of formula (IF) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; Each R D when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; R 4C for where R C is optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl, and each P7 is independently H or a hydroxy protecting group; R5 is optionally substituted acyl; and The remaining variables are as described for the halichondrin macrolide or analogs thereof.
[0058] The compound of formula (IIA) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; R D when present, optionally substituted aryl or optionally substituted non-enolizable alkyl; R E -CHO or -CH (1+m) (OR F ) (2-m) , in m is 1, and R F is a hydroxyl protecting group, or m is 0, and (i) Each R F are independently alkyl or hydroxy protecting groups, or (ii) Two Rs F combine to form an alkylene group; and The remaining variables are as described for the compound of formula (IF).
[0059] The compound of formula (IIB) is: where R S It is a silyl group.
[0060] The compound of formula (IIIC) is: R 4C -R7, (IIIC) Wherein R7 is -CHO or Each R 7A are independently optionally substituted alkyl, and R 4C As described for the compound of formula (IF).
[0061] The compound of formula (IG) is: in R EI for and The remaining variables are as described for the compound of formula (IF).
[0062] In some embodiments, step (B) comprises making R 4C React with a diol cleavage agent to produce an aldehyde, which reacts with (R C O)2P(O)-CH2-COOR C Reaction to produce R 4C
[0063] In certain embodiments, step (B) comprises reducing R with a 1,4-reducing agent. 4C To generate R 4C
[0064] In a further embodiment, step (B) comprises reducing R with an allylic reducing agent 4C To generate R 4C
[0065] In another embodiment, step (B) comprises reducing R with a 1,2-reducing agent. 4C To generate E1 The carbonyl group in .
[0066] In another embodiment, the reduction of R 4C The steps include generating R 4C esterification reaction.
[0067] In a specific embodiment, step (B) comprises making R 4C and can convert alcohol into R E1 The carbonyl group reacts with an oxidant.
[0068] In certain embodiments, one or more intermediates are compounds of formula (VIA): in R 10A -CH2-CH=CH2, -(CH2)2-CH=CH2 or -(CH2)3-OP 10 ; R 10 、R 13 , P9 and P 10 are each independently a hydroxyl protecting group; A1 is H or -OP"; and Y1 is chlorine, bromine, iodine, trifluoromethanesulfonate or trialkylsilane; and step (C) comprising: (D) Preparation of a compound of formula (VIB) from a compound of formula (IG) and a compound of formula (VIA).
[0069] The compound of formula (VIB) is: in L4 is R1 is -OP6 or -CH(Y), wherein P6 is H or a hydroxy protecting group, and Y is -COOR C or -CHO; A1 and R 14 Combined to form oxo, R 13 is H or a hydroxyl protecting group, and R 15 is H; or A1 is H or -OP", and: (i)R 13 is H or a hydroxyl protecting group, and R 14 and R 15 Combine to form a double bond; or (ii)R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; Each P9 is independently a hydroxy protecting group, and X3 is oxo or X3 and the carbon atom to which it is attached together are -(CH(OP 11 ))-, where P 11 is H or a hydroxy protecting group; or two P9 groups and X3, together with the atoms to which they are attached, combine to form a ketal; and the remaining variables are as described for the compound of formula (VIA) and the compound of formula (IG).
[0070] In other embodiments, step (D) comprises reacting the compound of formula (VIA) and the compound of formula (IG) with a Cr(II) salt and a Ni(II) salt.
[0071] In other embodiments, R 10A is -CH2-CH=CH2, and step (C) comprises: (E) a compound of formula (VIB) and R 17 -CH2CH=CH2 prepares a compound of formula (VIC), wherein R 17is -COOH or a metal or metalloid moiety; (F) preparing a compound of formula (VID) from a compound of formula (VIC); and (G) Preparation of halichondrin macrolide or its analogues from the compound of formula (VID).
[0072] The compound of formula (VIC) is: in L5 is X1 is -CH2- or -O-; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxy protecting group; and the remaining variables are as described for the compound of Formula (VIB).
[0073] The compound of formula (VID) is: in L1 is wherein L2 and L3 combine to form a bond; and The remaining variables are as described for the compound of formula (VIC).
[0074] In some embodiments, R1 is -CH2(Y), X1 is -CH2-, X4 is oxo or -(CH(OP 12 ))-, and step (E) comprises reacting a compound of formula (VIB) with R 17 -CH2CH=CH2 reaction, where R 17 In other embodiments, R1 is -OP6, P6 is H, X1 is -O-, X4 is oxo, and step (E) comprises reacting with R 17 -CH2CH=CH2(where R 17 In other embodiments, the preparation step (F) comprises reacting the compound of formula (VIC) with an olefin metathesis catalyst. In other embodiments, step (G) comprises reacting the compound of formula (VID) with a hydroxy protecting group removing agent.
[0075] In certain embodiments, R 10A -CH2-CH2-CH=CH2, R1 is -OP6 or -CH2(Y), wherein P6 is H or a hydroxyl protecting group, and Y is -COOR C, and step (C) comprises: (H) a compound of formula (VIB) and R 17 -CH=CH2 prepares a compound of formula (VIE), wherein R 17 is -COOH or a metal or metalloid moiety; (I) preparing a compound of formula (VIF) from a compound of formula (VIE); and (J) Preparation of halichondrin macrolide or its analogues from the compound of formula (VIF).
[0076] The compound of formula (VIE) is: in L6 is X1 is -CH2- or -O-; and X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxy protecting group; and the remaining variables are as described for the compound of Formula (VIB).
[0077] The compound of formula (VIF) is: in L1 is wherein L2 and L3 combine to form a bond; and The remaining variables are as described for the compound of Formula (VIE).
[0078] In some embodiments, step (I) comprises reacting a compound of formula (VIE) with an olefin metathesis catalyst. In particular embodiments, step (J) comprises reacting a compound of formula (VIF) with a hydroxy protecting group removing agent.
[0079] In certain embodiments, R 10A -(CH2) 3- OP 10 , and step (C) comprises: (K) a compound of formula (VIB) and (R C O)2P(O)-CH2-R P Prepare a compound of formula (VIG) wherein each R C are independently optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl, and R P is H or -COOH; (L) preparing a compound of formula (VIF) from a compound of formula (VIG); and (M) Preparation of halichondrin macrolide or its analogues from the compound of formula (VIF).
[0080] The compound of formula (VIG) is: in L7 is X1 is -CH2- or -O-; and The remaining variables are the same as for the compound of formula (VIB) and (R C O)2P(O)-CH 2- R P As stated.
[0081] The compound of formula (VIF) is: in L1 is wherein L2 and L3 combine to form a bond; and X4 is oxo; and The remaining variables are as described for the compound of formula (VIG).
[0082] In a further embodiment, the preparation step (K) comprises reacting a compound of formula (VIB) with (R C O)2P(O)-CH2-R P Reaction, where R P is H and R1 is -CH2(Y). In another embodiment, the preparation step (K) comprises using (R C O)2P(O)-CH2-R P Esterify the compound of formula (VIB), wherein R P is -COOH and R1 is -OP6, wherein P6 is H. In other embodiments, step (M) comprises reacting the compound of formula (VIF) with a hydroxy protecting group removing agent.
[0083] In some embodiments, step (C) comprises: (N) preparing a compound of formula (VIIB) from a compound of formula (IG) and a compound of formula (VIIA); (O) preparing a compound of formula (VIIC) from a compound of formula (VIIB); and (P) Preparation of halichondrin macrolide or its analogues from the compound of formula (VIIC).
[0084] The compound of formula (VIIA) is: in (i)R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (ii)R 10 is a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (iii)R 10 and R 11 Combine to form a bond, and R 12 is H; R9 is -CH2-OP" or -COOP"; R 13 and each P9 is independently a hydroxy protecting group; A1 is H or -OP"; Each P" is independently H or a hydroxy protecting group; and Y1 is chlorine, bromine, iodine, triflate or trialkylsilane.
[0085] The compound of formula (VIIB) is: in L4 is R1 is -OP6, -CH2(Y) or -CH(Y)2, wherein P6 is H or a hydroxy protecting group, and Y is -COOR C or -CHO; A1 and R 14 Combined to form oxo, R 13 is H or a hydroxyl protecting group, and R 15 is H; or A1 is H or -OP", and: (i)R 13 is H or a hydroxyl protecting group, and R 14 and R 15 Combine to form a double bond; or (ii)R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; R9 is -CHO or -COOP"; Each P9 is independently a hydroxy protecting group, and X3 is oxo or X3 together with the carbon atom to which it is attached is -(CH(OP 11 ))-, where P11 is H or a hydroxyl protecting group; or two P9 groups and X3 are combined with the atoms to which they are attached to form a ketal; and The remaining variables are as described for the compound of formula (IG) and the compound of formula (VIIA).
[0086] The compound of formula (VIIC) is: in L1 is Wherein L2 and L3 combine to form a bond; X1 is -CH2-, -CH(Y)-, -C(Y)2- or -O-, wherein each Y is independently -COOR C or-SO2R D ; Each R C When present, is independently optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; and each R D when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxy protecting group; and the remaining variables are as described for the compound of Formula (VIIB).
[0087] In certain embodiments, step (N) comprises reacting a compound of formula (VIIA) and a compound of formula (IH) with a Cr(II) salt and a Ni(II) salt. In a specific embodiment, step (O) comprises an esterification reaction between R1(-OP6, wherein P6 is H) and R9(-COOH). In a further embodiment, step (O) comprises a reaction between R1(-CH(Y)2 or -CH2(Y)) and R9(-CHO). In another embodiment, step (P) comprises reacting a compound of formula (VIIC) with a hydroxy protecting group removing agent.
[0088] In other embodiments, the method comprises: (A) preparing a compound of formula (VIID) from a compound of formula (IIA), a compound of formula (IIB), a compound of formula (IIIC), a compound of formula (VIIA), and R5OH, wherein R5 is an optionally substituted acyl group; (B) preparing a compound of formula (VIIE) from a compound of formula (VIID); and (C) Preparation of halichondrin macrolide or its analogues from the compound of formula (VIIC).
[0089] The compound of formula (IIA) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; Each R D when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; R E -CHO or -CH (1+m) (OR F ) (2-m) , in m is 1, and R F is a hydroxyl protecting group, or m is 0, and (i) Each R F are independently alkyl or hydroxy protecting groups, or (ii) Two Rs F combine to form an alkylene group; and The remaining variables are as described for the halichondrin macrolide or analogs thereof.
[0090] The compound of formula (IIB) is: where R S It is a silyl group.
[0091] The compound of formula (IIIC) is: R 4C -R7, (IIIC) in R7 is -CHO or Each R 7A is independently optionally substituted alkyl; R 4C for wherein each P7, when present, is independently H or a hydroxy protecting group.
[0092] The compound of formula (VIIA) is: in (i)R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (ii)R 10 is a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (iii)R 10 and R 11 Combine to form a bond, and R 12 is H; R9 is -CHO or -COOH; R 13 and each P9 is independently a hydroxy protecting group; A1 is H or -OP", wherein P" is H or a hydroxyl protecting group; and Y1 is chlorine, bromine, iodine, triflate or trialkylsilane.
[0093] The compound of formula (VIID) is: in X1 is -CH2-, -CH(Y)-, -C(Y)2- or -O-, wherein each Y is independently -COOR C or-SO2R D ; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxyl protecting group; R L for in R 18 is -CHO or -CH2OP7; R5 is optionally substituted acyl; and The remaining variables are as described for the compound of formula (IIA).
[0094] The compound of formula (VIIE) is: in L1 is Wherein L2 and L3 combine to form a bond; Each P9 is independently a hydroxy protecting group, and X3 is oxo or X3 together with the carbon atom to which it is attached is -(CH(OP 11 ))-, Among them, P 11 is H or a hydroxyl protecting group; and The remaining variables are as described for the compound of Formula (VIID).
[0095] In some embodiments, step (A) comprises: (D) preparing a compound of formula (IIC) from a compound of formula (IIA) and a compound of formula (IIB); (E) preparing a compound of formula (IF) from a compound of formula (IIC), a compound of formula (IIIC) and R5OH; and (F) Preparation of a compound of formula (VIIB) from a compound of formula (VIIA) and a compound of formula (IF).
[0096] The compound of formula (IIC) is: wherein the variables are as described for the compound of formula (IIA).
[0097] The compound of formula (IF) is: wherein the variables are as described for the compound of formula (IIC), the compound of formula (IIIC) and R5OH.
[0098] In certain embodiments, preparing a compound of Formula (IF) comprises reacting a compound of Formula (IIC), a compound of Formula (IIIC), R5OH, and a Lewis acid, such as an oxophilic Lewis acid (eg, boron trifluoride or a solvate thereof).
[0099] In certain embodiments, step (F) comprises: (G) preparing a compound of formula (IH) from a compound of formula (IF); and (H) A compound of formula (VIID) is prepared from a compound of formula (IH) and a compound of formula (VIIA).
[0100] The compound of formula (IH) is: wherein the variables are as described for the compound of formula (IF).
[0101] In some embodiments, preparing step (G) comprises reacting the compound of formula (IF) with an allylic reducing agent.
[0102] In certain embodiments, step (A) comprises reducing R with a 1,2-reducing agent. 4C
[0103] In a particular embodiment, step (A) comprises reducing R with a 1,4-reducing agent. 4C to produce a reduced product, and reducing the reduced product with a 1,2-reducing agent.
[0104] In a further embodiment, step (A) comprises reducing R with an allylic reducing agent 4C to produce an acid product, and reducing the acid product with a 1,2-reducing agent capable of converting the carboxylic acid to an aldehyde.
[0105] In another embodiment, step (A) comprises cleaving R with a diol cleavage agent. 4C To produce aldehyde, aldehyde (R C O)2P(O)-CH2-COOR C Reaction to produce an enoate, which is reduced with a 1,4-reducing agent to produce R 4C And make R 4C Reaction with a 1,2-reducing agent capable of converting the carboxylic acid into an aldehyde.
[0106] In other embodiments, step (A) comprises an esterification reaction between R1 (-OP6, wherein P6 is H) and R9 (-COOH). In other embodiments, step (A) comprises a reaction between R1 (-CH(Y)2 or -CH2(Y)) and R9 (-CHO). In other embodiments, step (B) comprises reacting a compound of formula (VIID) with a Cr(II) salt and a Ni(II) salt. In other embodiments, step (C) comprises reacting a compound of formula (VIIE) with a hydroxy protecting group removing agent.
[0107] In some embodiments, the method comprises: (A) preparing a compound of formula (VIIIB) from a compound of formula (VIIIA), a compound of formula (IIA), a compound of formula (IIB), and a compound of formula (IIIC) and R5OH, wherein R5 is an optionally substituted acyl group; (B) preparing a compound of formula (VIIIC) from a compound of formula (VIIIB); and (C) Preparation of halichondrin macrolide or its analogues from the compound of formula (VIIIC).
[0108] The compound of formula (IIA) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; Each R D when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; R E -CHO or -CH (1+m) (OR F ) (2-m) , in m is 1, and R F is a hydroxyl protecting group, or m is 0; (i) Each R F are independently alkyl or hydroxy protecting groups, or (ii) Two Rs F combine to form an alkylene group; and The remaining variables are as described for the halichondrin macrolide or analogs thereof.
[0109] The compound of formula (IIB) is: where R S It is a silyl group.
[0110] The compound of formula (IIIC) is: R 4C -R7, (IIIC) in R 4C for in Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; Each P7, when present, is independently H or a hydroxy protecting group; R7 is -CHO or Each R 7A is independently optionally substituted alkyl.
[0111] The compound of formula (VIIIA) is: in (i)R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (ii)R 10 is a hydroxyl protecting group, and R4 and R5 combine to form a double bond; or (iii)R 10 and R 11 Combine to form a bond, and R 12 is H; R9 is -CHO or -COOH; and Each P9 and R 13 are independently hydroxy protecting groups.
[0112] The compound of formula (VIIIB) is: in X1 is -CH2-, -CH(Y)-, -C(Y) 2- or -O-, wherein each Y is independently -COOR C or-SO2R D ; R M for in R5 is optionally substituted acyl; and X3 is oxo or X3 together with the carbon atom to which it is attached is -(CH(OP 11 ))-, where P 11 is H or a hydroxyl protecting group; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxy protecting group; and the remaining groups are as described for the compound of formula (IIA) and the compound of formula (VIIIA).
[0113] The compound of formula (VIIIC) is: in L1 is Wherein L2 and L3 combine to form a bond; A1 is H or -OP", wherein P" is H or a hydroxyl protecting group; and The remaining variables are as described for the compound of Formula (VIIIB).
[0114] In certain embodiments, step (A) comprises: (D) preparing a compound of formula (IIC) from a compound of formula (IIA) and a compound of formula (IIB); (E) preparing a compound of formula (IF) from a compound of formula (IIC), a compound of formula (IIIC) and R5OH; (F) preparing a compound of formula (IJ) from a compound of formula (IF); and (G) Preparing a compound of formula (VIIIB) from a compound of formula (VIIIA) and a compound of formula (IJ).
[0115] The compound of formula (IIC) is: wherein the variables are as described for the compound of formula (IIA).
[0116] The compound of formula (IF) is: wherein the variables are as described for the compound of formula (IIA), the compound of formula (IIIC), and R5OH.
[0117] The compound of formula (IJ) is: wherein the variables are as described for the compound of formula (VIIIB).
[0118] In certain embodiments, step (D) comprises reacting a compound of formula (IIB), a compound of formula (IIA), and a Lewis acid (e.g., the Lewis acid is an oxophilic Lewis acid (e.g., boron trifluoride or a solvate thereof)). In further embodiments, step (E) comprises reacting a compound of formula (IIC), a compound of formula (IIIC), R5OH, and a Lewis acid (e.g., the Lewis acid is an oxophilic Lewis acid (e.g., boron trifluoride or a solvate thereof)). In other embodiments, the Lewis acid in step (D) and the Lewis acid in step (E) are different. In other embodiments, the Lewis acid in step (D) and the Lewis acid in step (E) are the same.
[0119] In some embodiments, step (F) comprises using an allylic reducing agent to Convert to
[0120] In a specific embodiment, step (A) comprises making R 4C Reaction with a 1,2-reducing agent produces a product, and the product reacts with a vinyl nucleophile.
[0121] In certain embodiments, step (A) comprises making R 4C The product is reacted with a 1,4-reducing agent to produce a product, the product is reduced with a 1,2-reducing agent to produce a reduced product, and the reduced product is reacted with a vinyl nucleophile.
[0122] In other embodiments, step (A) comprises making R 4C It reacts with an allylic reducing agent to produce an acid, which is reduced with a 1,2-reducing agent to produce a reduced product, and the reduced product is reacted with a vinyl nucleophile.
[0123] In another embodiment, step (A) comprises cleaving R with a diol cleavage agent. 4C To produce aldehyde, the aldehyde is reacted with (R C O)2P(O)-CH2-COOR C The enoate is reacted to produce an enoate, the enoate is reacted with a 1,4-reducing agent to produce a product, the product is reduced with a 1,2-reducing agent to produce a reduced product, and the reduced product is reacted with a vinyl nucleophile.
[0124] In other embodiments, step (A) comprises an esterification reaction between R1 (-OP6, wherein P6 is H) and R9 (-COOH).
[0125] In other embodiments, step (A) comprises the reaction between R1 (-CH(Y)2 or -CH2(Y)) and R9 (wherein R9 is -CHO). In other embodiments, step (B) comprises reacting the compound of formula (VIIIB) with an olefin metathesis catalyst. In other embodiments, step (C) comprises reacting the compound of formula (VIIIC) with a hydroxy protecting group removing agent.
[0126] In some embodiments, the method comprises: (A) preparing a compound of formula (IXB) from a compound of formula (IXA), a compound of formula (IIB), a compound of formula (IIA), a compound of formula (IIIE), and R5OH, wherein R5 is an optionally substituted acyl group; and (B) Preparation of halichondrin macrolide or its analogues from the compound of formula (IXB).
[0127] The compound of formula (IXA) is: in R9 is -CHO or -COOP"; (a1)R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (a2)R 10 is a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (a3)R 10 and R 11 Combine to form a bond, and R 12 is H; A1 and R 14 Combined to form oxo, R 13 is H or a hydroxyl protecting group, and R 15 is H; or A1 is H or -OP", and: (i)R 13 is H or a hydroxyl protecting group, and R 14 and R 15 Combine to form a double bond; or (ii)R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; R O is -CHO, -CH2OP”, -CH=CH2, -CH(OP”)CH2OP”, -C(O)-CH2P(O)(OR C )2 or halogen; Each R C and , when present, is independently optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; and Each P" is independently H or a hydroxy protecting group; and Each P9 is independently a hydroxy protecting group.
[0128] The compound of formula (IIA) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; Each R D when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; RE -CHO or -CH (1+m) (OR F ) (2-m) , in m is 1, and R F is a hydroxyl protecting group, or m is 0, and (i) Each R F are independently alkyl or hydroxy protecting groups, or (ii) Two Rs F combine to form an alkylene group; and The remaining variables are as described for the halichondrin macrolide or analogs thereof.
[0129] The compound of formula (IIIE) is: R 4E -R7, (IIIE) in R 4E for in Each P7 is independently H or a hydroxy protecting group; and R8 is -CH2CH2-COOR C 、-CH=CH-COOR C 、-CH2CH2-SO2R D or -CH=CH-SO2R D ; and R7 is -CHO or Each R 7A is independently optionally substituted alkyl.
[0130] The compound of formula (IIB) is: where R S It is a silyl group.
[0131] The compound of formula (IXB) is: in X1 is -CH2-, -CH(Y)-, -C(Y)2- or -O-; L1 is Wherein L2 and L3 combine to form a bond; R5 is an optionally substituted acyl group; A1 and R 14 Combined to form oxo, R 13 is H or a hydroxyl protecting group, and R15 is H; or A1 is H or -OP", and: (i)R 13 is H or a hydroxyl protecting group, and R 14 and R 15 Together with the atoms to which they are attached, they form double bonds; or (ii)R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; Each P9 is independently H or a hydroxy protecting group, and X3 is oxo, or X3 and the atom to which it is attached are combined to form -(CH(OP 11 ))-, where P 11 is H or a hydroxyl protecting group; or The two P9 and X3 combine with the atoms to which they are attached to form a ketal; R 19A is H, -OP" or Y, and R 19B H; or R 19A and R 19B Together with the atoms to which they are attached, they form a double bond; and The remaining variables are as described for the compound of formula (IXA) and the compound of formula (IIA).
[0132] In some embodiments, step (A) comprises making R E (-CHO) is reacted with a compound of formula (IIB) and a first Lewis acid to produce a structure group.
[0133] In certain embodiments, step (A) comprises making the structure The group reacts with R7, R5OH and a second Lewis acid to produce the structure group.
[0134] In a specific embodiment, the first Lewis acid and / or the second Lewis acid is an oxophilic Lewis acid (e.g., boron trifluoride or a solvate thereof). In a further embodiment, the first Lewis acid is identical to the second Lewis acid. In other embodiments, the first Lewis acid is identical to the second Lewis acid.
[0135] In other embodiments, step (A) comprises R 4E Converted into structure and make the group O (-C(O)-CH2P(O)(OR C)2) React under Horner-Wadsworth-Emmons reaction conditions.
[0136] In other embodiments, step (A) comprises making R 4E With R O (-CHO) reacts under Claisen reaction conditions, where R8 is -CH2CH2-COOR C or -CH2CH2-SO2R D .
[0137] In other embodiments, step (A) comprises R 4E Converted into structure and the group is combined with R O Reaction under Nozaki-Hiyama-Kishi reaction conditions, wherein R8, when present, is -CH2CH2-COOR C or -CH=CH-COOR C , and R 14 and R 15 Combine to form a double bond.
[0138] In some embodiments, step (A) comprises reacting R1(-OP6) and R9 under esterification reaction conditions to produce structure -X 1- C (O) - group, wherein P6 is H, R9 is -COOH, and X1 is -O-. In certain embodiments, step (A) comprises reacting R1 (-CH (Y) 2 or -CH2 (Y)) with R9 under Claisen reaction conditions to produce a group of structure -X1-C (O) -, wherein R9 is -CHO, and X1 is -C (Y) 2 - or -CH (Y) -, respectively. In a specific embodiment, step (B) comprises reacting a compound of formula (IXB) with a hydroxy protecting group removing agent. In another embodiment, D' is OP1, wherein P1 is an alkyl group. In other embodiments, D is H. In other embodiments, A is the following structure:
[0139] In other embodiments, k is 0. In other embodiments, R3 is -(CH2) n NP3P4 or -(CH2) n OP5, wherein n is 0. In other embodiments, D' is H. In some embodiments, A and D combine to form the following structure: wherein the bond to the oxygen atom originates from the carbon atom to which D is attached in formula (IA), and Where R3 is -(CH2) n NP3P4 or -(CH2) n OP5, where n is 2.
[0140] In certain embodiments, k is 1, and E is optionally substituted alkyl. In particular embodiments, G is O.
[0141] In another aspect, the present invention provides a method for preparing an intermediate in the synthesis of a halichondrin macrolide or an analog thereof.
[0142] In some embodiments, the intermediate is: Wherein R7 is -CHO or and Each R 7A are independently an alkyl or hydroxy protecting group; or Two R's 7A Combined to form an optionally substituted alkylene group.
[0143] In certain embodiments, the method comprises: (A) a compound of formula (Z1) and Prepare a compound of formula (Z2) wherein each R O is independently an optionally substituted alkyl group, wherein the compound of formula (Z1) is: in Each R 20A are independently a hydroxy protecting group, or two R 20A Together with the atoms to which they are attached, they form an acetal, ketal, cyclic carbonate, dicarbonyl-dioxy group, or silylene-dioxy group; Each R 20B are independently a hydroxy protecting group, or two R 20B Together with the atoms to which they are attached, they form an acetal, ketal, cyclic carbonate, dicarbonyl-dioxy group, or silylene-dioxy group; P 12A is H; P 12B is H or a hydroxyl protecting group; And the compound of formula (Z2) is: (B) a compound of formula (Z2) and Prepare a compound of formula (Z3) wherein each R 21 is independently an optionally substituted alkyl group, wherein the compound of formula (Z3) is: (C) preparing a compound of formula (Z4) from a compound of formula (Z3), wherein the compound of formula (Z4) is: wherein X5 is a halogen; (D) preparing a compound of formula (Z5) from a compound of formula (Z4), wherein the compound of formula (Z5) is: in R 20A is H or a hydroxyl protecting group; and Each R 20B are independently H or a hydroxyl protecting group, or two R 20B Together with the atoms to which they are attached, they form an acetal, ketal, cyclic carbonate, dicarbonyl-dioxy group, or silylene-dioxy group; (E) A compound of formula (Z5) and R 7A OH prepares a compound of formula (Z6) (F) a compound of formula (Z6) and Prepare a compound of formula (Z7) wherein each R 22 are independently optionally substituted alkyl, and the compound of formula (Z7) is: and (G) Preparation of a compound of formula (Z) from a compound of formula (Z7).
[0144] In a specific embodiment, step (E) comprises reacting a compound of formula (Z5) with R 7A OH and In a further embodiment, step (F) comprises reacting a compound of formula (Z6) with a diol cleavage agent to produce an aldehyde product, and reacting the aldehyde product with The reaction is carried out under Horner-Wadsworth-Emmons reaction conditions. In another embodiment, step (G) comprises reacting the compound of formula (Z6) with a 1,4-reducing agent.
[0145] In other embodiments, the intermediate is: in R7 is -CHO or and Each R 7A are independently an alkyl or hydroxy protecting group; or Two R's 7ACombined to form an optionally substituted alkylene group; R8 is -CH2CH2-COOR C 、-CH=CH-COOR C 、-CH2CH2-SO2R D or -CH=CH-SO2R D ; R C and R, when present, is independently optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; D Where present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl.
[0146] In other embodiments, the method comprises: (A) a compound of formula (Z1) and Prepare a compound of formula (Z2) wherein each R O is independently an optionally substituted alkyl group, wherein the compound of formula (Z1) is: in Each R 20A are independently a hydroxy protecting group, or two R 20A Together with the atoms to which they are attached, they form an acetal, ketal, cyclic carbonate, dicarbonyl-dioxy group, or silylene-dioxy group; Each R 20B are independently a hydroxy protecting group, or two R 20B Together with the atoms to which they are attached, they form an acetal, ketal, cyclic carbonate, dicarbonyl-dioxy group, or silylene-dioxy group; P 12A is H; P 12B is H or a hydroxyl protecting group; And the compound of formula (Z2) is: (B) a compound of formula (Z2) and Prepare a compound of formula (Z3) wherein each R 21 is independently an optionally substituted alkyl group, wherein the compound of formula (Z3) is: (C) preparing a compound of formula (Z4) from a compound of formula (Z3), wherein the compound of formula (Z4) is: wherein X5 is a halogen; (D) preparing a compound of formula (Z5) from a compound of formula (Z4), wherein the compound of formula (Z5) is: in R 20A is H or a hydroxyl protecting group; and Each R 20B are independently H or a hydroxyl protecting group, or two R 20B Together with the atoms to which they are attached, they form an acetal, ketal, cyclic carbonate, dicarbonyl-dioxy group, or silylene-dioxy group; (E) A compound of formula (Z5) and R 7A OH prepares a compound of formula (Z5A), wherein the compound of formula (Z5A) is: in R 20A is H or a hydroxyl protecting group; and Each R 20B are independently H or a hydroxyl protecting group, or two R 20B Together with the atoms to which they are attached, they form an acetal, ketal, cyclic carbonate, dicarbonyl-dioxy group, or silylene-dioxy group; (F) preparing a compound of formula (Z5B) from a compound of formula (Z5A), wherein the compound of formula (Z5B) is: where R 23 H or -OR 20A ; and (G) a compound of formula (Z5B) and Prepare a compound of formula (Z8) wherein each R 22 is independently optionally substituted alkyl.
[0147] In another embodiment, step (E) comprises reacting a compound of formula (Z5) with R 7A OH and In other embodiments, step (F) comprises reacting two R 20B In another embodiment, step (E) or step (F) further comprises reacting -OR 20A (where R 20A is an optionally substituted acyl group) with an allylic reducing agent. In other embodiments, step (G) comprises reacting a compound of formula (Z5B) with The reaction is carried out under Horner-Wadsworth-Emmons reaction conditions to prepare a compound of formula (Z8), wherein R8 is -CH=CH-COOR Cor -CH=CH-SO2R D In other embodiments, step (G) further comprises wherein R8 is -CH=CH-COOR C or -CH=CH-SO2R D The compound of formula (Z8) is reacted with a 1,4-reducing agent to prepare a compound of formula (Z8), wherein R8 is -CH2CH2-COOR C or -CH2CH2-SO2R D In other embodiments, preparing the compound of formula (Z2) comprises reacting the compound of formula (Z1) with In some embodiments, step (B) comprises reacting a compound of formula (Z2) with a 1,2-reducing agent to produce a reduced product, and reacting the reduced product with The reaction is carried out under Horner-Wadsworth-Emmons reaction conditions. In certain embodiments, step (C) comprises replacing the free hydroxyl group in the compound of formula (Z3) with a halogen. In a specific embodiment, step (D) comprises subjecting the compound of formula (Z4) to reducing metal conditions.
[0148] In another aspect, the invention provides a compound of Formula (II), (IID), (IIE), (IIF), (IIG), (IIH), (IIi), (IVAb), (VAb), (VIIAa), (VIAa), (VIIID), (IXD), (IXF), (IXG), (Z), (Z1), (Z2), (Z3), (Z4), (Z5), (Z5A), (Z5B), or (Z6).
[0149] The compound of formula (II) is in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group, or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) n OP5, wherein P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group, and P5 is H, optionally substituted alkyl, or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group, or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the following: wherein each P' is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl group; Each Q1 is independently OR A SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)R A NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R Beach independently represents H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl, or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxyl protecting group; R6 is H, optionally substituted alkyl or optionally substituted aryl; and Y is independently -COOR C or-SO2R D ; R C When present, is optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; and R D Where present, is optionally substituted aryl or optionally substituted non-enolizable alkyl.
[0150] The compound of formula (VIIAa) is: in R7 is -CH2OP A , -CHO or Each R 7A is independently optionally substituted alkyl; R9 is -CH2-OP", -CHO or -COOP"; (i)R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (ii)R 10 is a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (iii)R 10 and R 11 Combine to form a bond, and R 12 is H; A1 and R 14 Combined to form oxo, R 13 is H or a hydroxyl protecting group, and R 15 is H; or A1 is H or -OP", and: (i)R 13 is H or a hydroxyl protecting group, and R 14 and R 15Combine to form a double bond; or (ii)R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; Each P" is independently H or a hydroxy protecting group; and Each P9 is independently a hydroxy protecting group, and X3 is oxo or X3 together with the carbon atom to which it is attached is -(CH(OP 11 ))-, where P 11 is H or a hydroxyl protecting group; or two P9 groups and X3 are combined with the atoms to which they are attached to form a ketal.
[0151] The compound of formula (VIAa) is: in R7 is -CHO or Each R 7A is independently optionally substituted alkyl; R 10A -CH2-CH=CH2, -(CH2) 2- CH=CH2 or -(CH2)3-OP 10 ; R 10 and P 10 are each independently a hydroxyl protecting group; A1 and R 14 Combined to form oxo, R 13 is H or a hydroxyl protecting group, and R 15 is H; or A1 is H or -OP", and: (i)R 13 is H or a hydroxyl protecting group, and R 14 and R 15 Combine to form a double bond; or (ii)R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; and Each P9 is independently a hydroxy protecting group, and X3 is oxo or X3 together with the carbon atom to which it is attached is -(CH(OP 11 ))-, where P 11 is H or a hydroxyl protecting group; or two P9 groups and X3 are combined with the atoms to which they are attached to form a ketal.
[0152] The compound of formula (IID) or (IIF) is: in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group, or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) n OP5, wherein P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P5 is H, an optionally substituted alkyl group, or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group, or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the group consisting of: wherein each P' is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl group; Each Q1 is independently OR A SR A 、SO2R A 、OSO2R A NR B R A NRB (CO)R A NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each independently represents H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl, or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; X1 is -CH2- or -O-; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxyl protecting group; and R E -CHO or -CH (1+m) (OR F ) (2-m) ,in m is 1, and R F is a hydroxyl protecting group, or m is 0, and (i) Each R F are independently alkyl or hydroxy protecting groups, or (ii) Two Rs F Combine to form an alkylene group.
[0153] Compounds of formula (IIE) or (IIG): in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6An unsaturated hydrocarbon skeleton which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group, or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) n OP5, wherein P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P5 is H, an optionally substituted alkyl group, or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group, or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the group consisting of: wherein each P' is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl group; Each Q1 is independently OR A SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)R A NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)ORA 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each independently represents H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl, or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; X1 is -CH2- or -O-; and X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxyl protecting group.
[0154] The compound of formula (IIH) is: in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group, or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) nOP5, wherein P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P5 is H, an optionally substituted alkyl group, or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group, or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the group consisting of: wherein each P′ is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl group; Each Q1 is independently OR A SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)R A NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each independently represents H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl, or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; Each R C is independently optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; X1 is -CH2- or -O-; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P12 is H or a hydroxyl protecting group; and R E -CHO or -CH (1+m) (OR F ) (2-m) ,in m is 1, and R F is a hydroxyl protecting group, or m is 0, and (i) Each R F are independently alkyl or hydroxy protecting groups, or (ii) Two Rs F Combine to form an alkylene group.
[0155] The compound of formula (IIi) is: in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group, or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) n OP5, wherein P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P5 is H, an optionally substituted alkyl group, or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group, or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the group consisting of: wherein each P′ is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl group; Each Q1 is independently OR A SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)R A NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each independently represents H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl, or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; Each R C are independently optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl; and X1 is -CH2- or -O-.
[0156] The compound of formula (VIIID) is: in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6An unsaturated hydrocarbon skeleton which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group, or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) n OP5, wherein P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P5 is H, an optionally substituted alkyl group, or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group, or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the group consisting of: wherein each P′ is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl group; Each Q1 is independently OR A SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)R A NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)ORA 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each independently represents H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl, or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; X1 is -CH2-, -CH(Y)-, -C(Y) 2- or -O-, wherein each Y is independently -COOR C or-SO2R D ; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxyl protecting group; Each P9 and R 13 are independently hydroxy protecting groups; (i)R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (ii)R 10 is a hydroxyl protecting group, and R4 and R5 combine to form a double bond; or (iii)R 10 and R 11 combines to form a bond, and R 12 is H; R M1 for in R5 is an optionally substituted acyl group; P 13 is H or a hydroxyl protecting group; and R 4C for where R C is optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl; and P7, when present, is independently H or a hydroxy protecting group.
[0157] The compound of formula (IVAb) is: in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group, or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) n OP5, wherein P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group, and P5 is H, optionally substituted alkyl, or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group, or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the following: wherein each P′ is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl group; Each Q1 is independently OR A SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)RA NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each independently represents H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl, or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; X1 is -CH2-, -CH(Y)-, -C(Y)2- or -O-, wherein each Y is independently -COOR C or-SO2R D ; Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; Each R D when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxyl protecting group; Each P9 is independently a hydroxyl protecting group; (a1)R 10 is H or a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (a2)R 10 is H or a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (a3)R 10 and R 11 combines to form a bond, and R 12 is H; (b1)A1 and R 14Combined to form oxo, R 13 is H or a hydroxyl protecting group, and R 15 is H; or (b2) A1 is H or -OP", and: (i)R 13 is H or a hydroxyl protecting group, and R 14 and R 15 Combine to form a double bond; or (ii)R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; and (c1)R 16 is H, and P8 is H or a hydroxyl protecting group; or (c2)R 16 Combines with P8 to form a double bond; and Each P" when present is independently H or a hydroxy protecting group.
[0158] The compound of formula (VAb) is: in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group, or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) nOP5, wherein P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group, and P5 is H, optionally substituted alkyl, or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group, or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the following: wherein each P′ is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl group; Each Q1 is independently OR A SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)R A NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each independently represents H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl, or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; a specifies an (R)-stereocenter, and Z is sulfonate, chloro, bromo, or iodo; or a specifies an (S)-stereocenter, and Z is OR 16 , where R 16 is a hydroxyl protecting group; X1 is -CH2-, -CH(Y)-, -C(Y)2- or -O-, wherein each Y is independently -COOR C or-SO2R D ; Each P9 is independently a hydroxy protecting group, and X3 is oxo; or two P9 groups and X3, together with the atoms to which they are attached, combine to form a ketal; Y1 is iodine, bromine or triflate; Each R C When present, is independently optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; and each R D when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; (a1)R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (a2)R 10 is a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (a3)R 10 and R 11 Combine to form a bond, and R 12 is H; (b1)A1 and R 14 Combined to form oxo, R 13 is a hydroxyl protecting group, and R 15 is H; or (b2) A1 is H or -OP", and: (i)R 13 is a hydroxyl protecting group, and R 14 and R 15 Combine to form a double bond; or (ii)R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; and Each P" is independently a hydroxy protecting group.
[0159] The compound of formula (IXD) is: in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C2-6 An unsaturated hydrocarbon skeleton which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group, or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) n OP5, wherein P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P5 is H, an optionally substituted alkyl group, or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group, or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the group consisting of: wherein each P′ is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl group; Each Q1 is independently OR A SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)R A NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each independently represents H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl, or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; X1 is -CH2-, -CH(Y)-, -C(Y)2- or -O-, each Y is independently -COOR C or-SO2R D ; Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; Each R D when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxyl protecting group; R7 is -CHO, -CH2OP A or Each R 7A is independently optionally substituted alkyl; (i)R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (ii)R 10 is a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (iii)R 10 and R 11 combines to form a bond, and R 12 is H; A1 and R 14 Combined to form oxo, R 13 is H or a hydroxyl protecting group, and R 15 is H; or A1 is H or -OP", and (i) R13 is H or a hydroxyl protecting group, and R 14 and R 15 Together with the atoms to which they are attached, they form double bonds; or (ii)R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; each P9 is independently H or a hydroxyl protecting group, each P9 is independently a hydroxyl protecting group, and X3 is oxo, or X3 and the atom to which it is attached are combined to form -(CH(OP 11 ))-, where P 11 is H or a hydroxy protecting group; or two P9 and X3 are combined with the atoms to which they are attached to form a ketal; and R 19A is H, -OP" or Y, and R 19B H; or R 19A and R 19B Together with the atoms to which they are attached they form double bonds.
[0160] The compound of formula (IXF) is: in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group, or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) nOP5, wherein P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P5 is H, an optionally substituted alkyl group, or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group, or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the group consisting of: wherein each P′ is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl group; Each Q1 is independently OR A SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)R A NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each independently represents H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl, or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; X1 is -CH2-, -CH(Y)-, -C(Y)2- or -O-, wherein each Y is independently -COOR C or-SO2R D ; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12))-, where P 12 is H or a hydroxyl protecting group; Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; Each R D when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; R O is -CHO, -CH2OP”, -CH=CH2, -CH(OP”)CH2OP”, -C(O)-CH2P(O)(OR C )2 or halogen; (i) R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (ii)R 10 is a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (iii)R 10 and R 11 combines to form a bond, and R 12 is H; A1 and R 14 Combined to form oxo, R 13 is H or a hydroxyl protecting group, and R 15 is H; or A1 is H or -OP", and (i) R 13 is H or a hydroxyl protecting group, and R 14 and R 15 Together with the atoms to which they are attached, they form double bonds; or (ii)R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; each P9 is independently H or a hydroxyl protecting group; and P", P9 and P 13 Each is independently H or a hydroxyl protecting group.
[0161] The compound of formula (IXG) is: in R7 is -CHO, -CH2OP A or Each R 7A is independently optionally substituted alkyl; (i)R 10is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (ii)R 10 is a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (iii)R 10 and R 11 combines to form a bond, and R 12 is H; A1 and R 14 Combined to form oxo, R 13 is H or a hydroxyl protecting group, and R 15 is H; or A1 is H or -OP", and (i) R 13 is H or a hydroxyl protecting group, and R 14 and R 15 Together with the atoms to which they are attached, they form double bonds; or (ii)R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; each P9 is independently H or a hydroxyl protecting group, each P9 is independently a hydroxyl protecting group, and X3 is oxo, or X3 and the atom to which it is attached are combined to form -(CH(OP 11 ))-, where P 11 is H or a hydroxy protecting group; or two P9 and X3 are combined with the atoms to which they are attached to form a ketal; and R 19A is H, -OP" or Y, and R 19B H; or R 19A and R 19B Together with the atoms to which they are attached they form double bonds.
[0162] In another aspect, the present invention provides a compound of Formula (Z), (Z1), (Z2), (Z3), (Z4), (Z5), (Z5A), (Z5B) or (Z6) as described herein.
[0163] In the halichondrin macrolide and halichondrin macrolide analog structures herein, when P1 is absent, D and D' are each independently H or optionally substituted alkyl, and when P2 is absent, L is -C(O)-.
[0164] definition The compounds useful in the present invention may be isotopically labeled compounds. Useful isotopes include hydrogen, carbon, nitrogen, and oxygen (e.g., 2 H.3 H. 13 C. 14 C. 15 N. 18 O and 17 O). Isotopically labeled compounds can be prepared by using a readily available isotopically labeled reagent instead of a non-isotopically labeled reagent to synthesize the compound.
[0165] For any of the following chemical definitions, the number following the atomic symbol represents the total number of atoms of that element present in the particular chemical moiety. As will be appreciated, other atoms (e.g., hydrogen atoms) or substituents as described herein may be present as needed to satisfy the valences of the atoms. For example, an unsubstituted C2 alkyl group has the formula -CH2CH3. When used with the groups defined herein, references to the number of carbon atoms include the divalent carbons in acetal and ketal groups, but do not include the carbonyl carbon in acyl, ester, carbonate, or carbamate groups. References to the number of oxygen, nitrogen, or sulfur atoms in a heteroaryl group include only those atoms that form part of the heterocycle.
[0166] "Acetal" refers to -O-(CHR)-O-, where R is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted arylalkyl, or the R group is a bond to a carbon atom listed within an intermediate as shown in Formula 1 or within a halichondrin macrolide or an analog thereof.
[0167] "Acetyl" refers to an acyl group where R is -CX n H 3-n , wherein n is 0, 1, 2 or 3, and each X is independently alkoxy or halogen, provided that when n is 3, each X is independently halogen, and when n is 2, both X groups are independently halogen or both X groups are independently alkoxy. Acetyl groups can be substituted (i.e., n is 1, 2 or 3) or unsubstituted (i.e., n is 0).
[0168] "Acyl" refers to -C(O)R, where R is H, alkyl, alkenyl, aryl, or arylalkyl. In exemplary acyl groups, R is H, C 1-12 Alkyl (e.g., C 1-8 、C 1-6 、C 1-4 、C 2-7 、C 3-12 or C 3-6 Alkyl), C 2-12 Alkenyl (e.g., C 2-8 、C 2-6 、C 2-4 、C 3-12 or C 3-6 alkenyl), C 6-20 Aryl (e.g., C 6-14 、C6-10 、C 8-20 or C 8-14 Aryl), monocyclic C 1-6 Heteroaryl (e.g., monocyclic C 1-4 or C 2-6 Heteroaryl), C 4-19 Heteroaryl (e.g., C 4-10 Heteroaryl), (C 6-14 )Aryl(C 1-6 )alkyl, (C 1-6 )heteroaryl(C 1-6 )alkyl, or (C 4-9 )heteroaryl(C 1-6 ) alkyl. As defined herein, any heteroaryl present in an acyl group has 1-4 heteroatoms independently selected from O, N, and S. An acyl group may be unsubstituted or substituted (e.g., an optionally substituted acyl group). In an optionally substituted acyl group, the substituent R is H, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted aryl group, or an optionally substituted arylalkyl group. In some embodiments, an acyl group is C 2-10 acyl group.
[0169] "Acylating agent" refers to a compound that reacts with an amine or hydroxyl group to produce an amide or ester, respectively. The acylating agent has the formula R-LG, where R is an acyl group, and LG is a halogen, a carbonate, or -OR', where R' is an acyl group.
[0170] "Alkoxide" refers to an anionic compound RO - , wherein R is an alkyl group. The counterion of the alkoxide can be an alkali metal cation, an alkaline earth metal cation, or a tetraalkylammonium cation. The alkoxide can be optionally substituted in the same manner as the alkyl group.
[0171] "Alkoxy" refers to -OR, where R is alkyl. Alkoxy groups can be optionally substituted in the same manner as alkyl groups.
[0172] "Alkoxyalkyl" refers to -OR, where R is an alkyl group substituted with an alkoxy group. The individual portions of the alkoxyalkyl group may be optionally substituted in the same manner as the alkyl group.
[0173] "Alkoxyaryl" refers to -R'(R") n , wherein n is 1 or 2, R' is arylene and R" is alkoxy, as defined herein. R' may also be optionally substituted in the same manner as aryl. R" may be optionally substituted in the same manner as alkyl.
[0174] "Alkoxyarylalkyl" refers to -R'(R)(R'") n), wherein n is an integer from 1 to 3, R' is an alkylene group, R" is an arylene group, and R'" is an alkoxy group, as defined herein. R' may be optionally substituted in the same manner as an alkyl group. R" may also be optionally substituted in the same manner as an aryl group. R'" may be optionally substituted in the same manner as an alkyl group.
[0175] Unless otherwise specified, "alkyl" refers to a linear or branched saturated cyclic (ie, cycloalkyl) or acyclic hydrocarbon group of 1 to 12 carbon atoms. 1-6 Alkyl. Exemplary alkyl groups include C 1-8 、C 1-6 、C 1-4 、C 2-7 、C 3-12 and C 3-6 Alkyl. Specific examples include methyl, ethyl, 1-propyl, 2-propyl, 2-methyl-1-propyl, 1-butyl, 2-butyl, and the like. The alkyl group may be optionally substituted with 1, 2, 3, or 4 substituents selected from halogen, hydroxy, alkoxy, aryloxy, arylalkyloxy, amino, oxo, alkylthio, alkylenedisulfide, alkylamino, [alkenyl]alkylamino, [aryl]alkylamino, [arylalkyl]alkylamino, dialkylamino, silyl, sulfonyl, cyano, nitro, carboxyl, and azido.
[0176] "Alkylamino" refers to -NHR, where R is alkyl. "[Alkenyl]alkylamino" refers to -NRR', where R is alkyl and R' is alkenyl. "[Aryl]alkylamino" refers to -NRR', where R is alkyl and R' is aryl. "[Arylalkyl]alkylamino" refers to -NRR', where R is alkyl and R' is arylalkyl. "Dialkylamino" refers to -NR2, where each R is an independently selected alkyl group.
[0177] "Alkylaryl" refers to -R'(R") n , wherein n is an integer from 1 to 3, R' is an arylene group, and R" is an alkyl group. The alkylaryl group may be optionally substituted in the same manner as defined for each R' and R" group.
[0178] "Alkylene" refers to a polyvalent alkyl group. An alkylene group can be optionally substituted in the same manner as an alkyl group. An alkylene group can be a divalent alkylene group. For example, a C1 alkylene group is -CH2-.
[0179] "Alkylenedisulfide" refers to -S-alkylene-S-. Alkylenedisulfide groups may be optionally substituted in the same manner as alkylene groups.
[0180] "Alkylhaloaryl" refers to -R'(R") n-R'", wherein n is an integer from 1 to 5 and R' is arylene, R" is halogen, and R'' is alkylene, as defined herein. R' may also be optionally substituted in the same manner as aryl. R'' may also be optionally substituted in the same manner as alkyl.
[0181] "Alkylthio" refers to -SR, where R is alkyl. Alkylthio groups can be optionally substituted in the same manner as alkyl groups.
[0182] Unless otherwise specified, "alkenyl" refers to a linear or branched, cyclic or acyclic hydrocarbon group of 2-12 carbon atoms and containing one or more carbon-carbon double bonds. 2-6 Exemplary alkenyl groups include C 2-8 、C 2-7 、C 2-6 、C 2-4 、C 3-12 and C 3-6 Alkenyl. Specific examples include ethenyl (i.e., vinyl), 1-propenyl, 2-propenyl (i.e., allyl), 2-methyl-1-propenyl, 1-butenyl, 2-butenyl (i.e., crotyl), etc. Alkenyl can be optionally substituted in the same manner as alkyl. Alkenyl used in any context herein can also be substituted with aryl.
[0183] "Acylamino" refers to -NHR, where R is acyl. Acylamino groups may be optionally substituted in the same manner as acyl groups.
[0184] "Aminal" refers to -O-CR2-NR'-, where each R is independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted arylalkyl, or two R groups together are optionally substituted alkylene, and R' is H or an N-protecting group. In particular, R' can be an N-protecting group (e.g., Boc).
[0185] "Amino" refers to -NR2, wherein N and R2 are combined to form an azido group, or each R is independently H or an N-protecting group, or two Rs are combined to form an N-protecting group. When each R is H, the amino group can be unmasked, or when at least one R is not H, it can be masked. Thus, an optionally masked amino group can be a masked or unmasked amino group.
[0186] "Aminoalkyl" refers to -R'(R") n , wherein n is 1 or 2, R' is alkylene, and R" is amino, as defined herein. R' may be optionally substituted in the same manner as alkyl.
[0187] "Aryl" refers to a monocyclic or polycyclic ring system having one or more aromatic rings, wherein the ring system is carbocyclic. Exemplary aryl groups include C6-20 、C 6-15 、C 6-10 、C 8-20 and C 8-15 Aryl. Preferred aryl groups are C 6-10 Aryl. Specific examples of carbocyclic aryl groups include phenyl, indanyl, indenyl, naphthyl, phenanthrenyl, anthracenyl, and fluorenyl. The aryl group may be optionally substituted with 1, 2, 3, 4, or 5 substituents selected from alkyl, alkenyl, aryl, arylalkyl, halogen, alkoxy, aryloxy, arylalkyloxy, alkylthio, alkylenedisulfide, alkylamino, [alkenyl]alkylamino, [aryl]alkylamino, [arylalkyl]alkylamino, dialkylamino, silyl, sulfonyl, cyano, nitro, carboxyl, and azido.
[0188] "Arylalkyl" refers to -R'R", wherein R' is alkylene and R" is aryl. Arylalkyl groups may be optionally substituted in the same manner as defined for each R' and R" group.
[0189] "Arylalkyloxy" refers to -OR, where R is arylalkyl. Arylalkyloxy groups may be optionally substituted in the same manner as defined for arylalkyl groups.
[0190] "Arylene" refers to a polyvalent aromatic group. Arylene can be optionally substituted in the same manner as aryl. For example, C6 arylene is phenylene.
[0191] "Aryloxy" refers to -OR, where R is aryl. Aryloxy groups may be optionally substituted in the same manner as aryl groups.
[0192] "Azide" refers to -N3.
[0193] "Borate" refers to -OB(R)O-, where R is alkyl, alkenyl, aryl, arylalkyl, alkoxy, or 2,6-diacetamidophenyl. The borate may be substituted when R is substituted alkyl, substituted alkenyl, substituted aryl, substituted arylalkyl, or substituted alkoxy. Alternatively, the borate may be unsubstituted when R is unsubstituted alkyl, unsubstituted alkenyl, aryl, unsubstituted arylalkyl, unsubstituted alkoxy, or 2,6-diacetamidophenyl.
[0194] "Carbamate" refers to a group that, when a hydroxy protecting group, has the formula -OC(O)NR2, or, when an amine protecting group, has the formula -NR'-C(O)OR, wherein each R and R' is independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted arylalkyl.
[0195] "Carbonate" refers to -OC(O)OR, where R is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted arylalkyl.
[0196] "Carbonyl" refers to -C(O)-.
[0197] "Carboxyl" refers to -C(O)OH in free acid, ionized or salt form.
[0198] "Carboxylic acid" refers to R-OH, where R is an optionally substituted acyl group.
[0199] "Carboxylic acid anhydride" refers to ROR, where each R is independently an optionally substituted acyl group.
[0200] "Cyclic carbonate" refers to -OC(O)O- as part of a ring.
[0201] "Dicarbonyl" refers to -C(O)-C(O)-. Dicarbonyl-dioxy (dioxo) is -OC(O)-COO-.
[0202] "Ester" refers to a -OC(O)R group, wherein -C(O)R is an optionally substituted acyl group.
[0203] "Ether" refers to -OR, where R is alkyl, alkenyl, arylalkyl, silyl, or 2-tetrahydropyranyl. Ethers may be optionally substituted as defined for each R group.
[0204] "Halichondroitin macrolide" refers to a lactone comprising a carbon 1-30 structure as shown in Formula 1, wherein carbons 29 and 30 form part of a five- or six-membered ring.
[0205] "Haloalkyl" refers to -R'(R") n , wherein n is an integer from 1 to 5 and R' is alkylene and R" is halogen, as defined herein. R' may also be optionally substituted in the same manner as alkyl.
[0206] "Haloaryl" refers to -R'(R") n , wherein n is an integer from 1 to 5 and R' is an arylene group and R" is a halogen, as defined herein. R' may also be optionally substituted in the same manner as an aryl group.
[0207] "Haloarylalkyl" refers to -R'(R)(R') n ), wherein n is an integer from 1 to 5 and R' is alkylene, R" is arylene, and R'" is halogen, as defined herein. R' may also be optionally substituted in the same manner as alkyl. R" may also be optionally substituted in the same manner as aryl.
[0208] "Halogen" refers to fluorine, chlorine, bromine or iodine.
[0209] Unless otherwise indicated, "heterocyclyl" refers to a 5-, 6-, or 7-membered ring containing one, two, three, or four heteroatoms independently selected from nitrogen, oxygen, and sulfur. The 5-membered ring has zero to one double bond, and the 6- and 7-membered rings have zero to two double bonds. Certain heterocyclyl groups contain 1 to 9 carbon atoms. Other such groups may contain up to 12 carbon atoms. The term "heterocyclyl" also refers to heterocyclic compounds having a bridged polycyclic structure in which one or more carbon and / or heteroatoms bridge two non-adjacent monocyclic ring members, such as quinuclidine. The term "heterocyclyl" includes bicyclic, tricyclic and tetracyclic groups, wherein any of the above heterocyclic rings is fused with one, two or three carbon rings (e.g., an aromatic ring, a cyclohexane ring, a cyclohexene ring, a cyclopentane ring, a cyclopentene ring), or is fused with another monocyclic heterocyclic ring, such as indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, benzofuranyl, benzothienyl, etc. Examples of fused heterocyclic rings include tropane and 1,2,3,5,8,8a-hexahydroindolizine. Heterocyclic groups include pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridinyl, piperidinyl, homopiperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, quinolinyl, Isoquinolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, thiazolidinyl, isothiazolyl, isoindazolyl, triazolyl, tetrazolyl, oxadiazolyl, purinyl, thiadiazolyl (such as 1,3,4-thiadiazole), tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, dihydroindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, pyranyl, dihydropyranyl, dithiazolyl, benzofuranyl, benzothienyl, etc. Other exemplary heterocyclic groups include: 2,3,4,5-tetrahydro-2-oxo-oxazolyl; 2,3-dihydro-2-oxo-1H-imidazolyl; 2,3,4,5-tetrahydro-5-oxo-1H-pyrazolyl (e.g., 2,3,4,5-tetrahydro-2-phenyl-5-oxo-1H-pyrazolyl); 2,3,4,5-tetrahydro-2,4-dioxo-1H-imidazolyl (e.g., 2,3,4,5-tetrahydro-2,4-dioxo-5-methyl-5-phenyl-1H-imidazolyl) ; 2,3-dihydro-2-thioxo-1,3,4-oxadiazolyl (e.g., 2,3-dihydro-2-thioxo-5-phenyl-1,3,4-oxadiazolyl); 4,5-dihydro-5-oxo-1H-triazolyl (e.g., 4,5-dihydro-3-methyl-4-amino-5-oxo-1H-triazolyl); 1,2,3,4-tetrahydro-2,4-dioxopyridinyl (e.g., 1,2,3,4-tetrahydro-2,4-dioxo-3,3-diethylpyridinyl);2,6-dioxo-piperidinyl (e.g., 2,6-dioxo-3-ethyl-3-phenylpiperidinyl); 1,6-dihydro-6-oxopyrimidinyl; 1,6-dihydro-4-oxopyrimidinyl (e.g., 2-(methylthio)-1,6-dihydro-4-oxo-5-methylpyrimidin-1-yl); 1,2,3,4-tetrahydro-2,4-dioxopyrimidinyl (e.g., 1,2,3,4-tetrahydro-2,4-dioxo-3-ethylpyrimidinyl); 1,6-dihydro-6-oxo-pyridazinyl (e.g., 1,6-dihydro-6-oxo-3-ethylpyridazinyl); 1,6-dihydro-6-oxo-1,2,4-triazinyl (e.g., 1,6-dihydro-5-isothiazolinyl); propyl-6-oxo-1,2,4-triazinyl); 2,3-dihydro-2-oxo-1H-indolyl (such as 3,3-dimethyl-2,3-dihydro-2-oxo-1H-indolyl and 2,3-dihydro-2-oxo-3,3'-spiropropane-1H-indol-1-yl); 1,3-dihydro-1-oxo-2H-isoindolyl; 1,3-dihydro-1,3-dioxo-2H-isoindolyl; 1H-benzopyrazolyl (such as 1-(ethoxycarbonyl)-1H-benzopyrazolyl); 2,3-dihydro-2-oxo-1H-benzimidazolyl (such as 3-ethyl-2,3-dihydro-2-oxo-1H-benzimidazolyl); 2 ,3-dihydro-2-oxo-benzoxazolyl (e.g. 5-chloro-2,3-dihydro-2-oxo-benzoxazolyl); 2,3-dihydro-2-oxo-benzoxazolyl; 2-oxo-2H-benzopyranyl; 1,4-benzodioxane; 1,3-benzodioxane; 2,3-dihydro-3-oxo, 4H-1,3-benzothiazinyl; 3,4-dihydro-4-oxo-3H-quinazolinyl (e.g. 2-methyl-3,4-dihydro-4-oxo-3H-quinazolinyl); 1,2,3,4-tetrahydro-2,4-dioxo-3H-quinazolinyl (e.g. 1-ethyl-1,2,3,4-tetrahydro-2,4 -dioxo-3H-quinazolinyl); 1,2,3,6-tetrahydro-2,6-dioxo-7H-purinyl (such as 1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purinyl); 1,2,3,6-tetrahydro-2,6-dioxo-1H-purinyl (such as 1,2,3,6-tetrahydro-3,7-dimethyl-2,6-dioxo-1H-purinyl); 2-oxobenzo[c,d]indolyl; 1,1-dioxo-2H-naphtho[1,8-c,d]isothiazolyl; and 1,8-naphthylenedicarboxamido. Heterocyclic groups also include groups of the formula:; in F' is selected from -CH2-, -CH2O- and -O-, and G' is selected from -C(O)- and -(C(R')(R")) v-, wherein R' and R" are each independently selected from hydrogen or an alkyl group of one to four carbon atoms, and v is 1 to 3, and includes groups such as 1,3-benzodioxolyl, 1,4-benzodioxanyl, etc. Any heterocyclic group mentioned herein may be optionally substituted by one, two, three, four or five substituents independently selected from the following: (1) alkanoyl (such as formyl, acetyl, etc.); (2) alkyl (such as alkoxyalkylene, alkylsulfinylalkylene, aminoalkylene, azidoalkylene, acylalkylene, haloalkylene (such as perfluoroalkyl), hydroxyalkylene, nitroalkylene or mercaptoalkoxyalkylene) groups. ); (3) alkenyl; (4) alkynyl; (5) alkoxy (e.g., perfluoroalkoxy); (6) alkylsulfinyl; (7) aryl; (8) amino; (9) aryl-alkylene; (10) azido; (11) cycloalkyl; (12) cycloalkyl-alkylene; (13) cycloalkenyl; (14) cycloalkenyl-alkylene; (15) halogen; (16) heterocyclyl (e.g., heteroaryl); (17) (heterocyclyl)oxy; (18) (heterocyclyl)aza; (19) hydroxy; (20) oxo; (21) nitro; (22) thiol; (23) mercaptoalkoxy; (24) -(CH2) q CO2R A , wherein q is an integer from 0 to 4, and R A Selected from (a) alkyl, (b) aryl, (c) hydrogen, and (d) aryl-alkylene; (25)-(CH2) q CONR B R C , wherein q is an integer from 0 to 4 and wherein R B and R C independently selected from (a) hydrogen, (b) alkyl, (c) aryl, and (d) aryl-alkylene; (26)-(CH2) q SO2R D , wherein q is an integer from 0 to 4 and wherein R D Selected from (a) alkyl, (b) aryl, and (c) aryl-alkylene; (27)-(CH2) q SO2NR E R F , wherein q is an integer from 0 to 4 and wherein R E and R F Each is independently selected from (a) hydrogen, (b) alkyl, (c) aryl, and (d) aryl-alkylene; (28) mercapto; (29) aryloxy; (30) cycloalkyloxy; (31) arylalkoxy; (31) heterocyclyl-alkylene (such as heteroaryl-alkylene); (32) silyl; (33) cyano; and (34) -S(O)R H , where R His selected from the group consisting of (a) hydrogen, (b) alkyl, (c) aryl, and (d) aryl-alkylene. In some embodiments, each of these groups may be further substituted as described herein. For example, the alkylene of the aryl-C1-alkylene or heterocyclyl-C1-alkylene may be further substituted with an oxo group to provide the corresponding aroyl and (heterocyclyl)acyl (oyl) substituents. In addition, when a heterocyclyl group is present in a bioreversible group of the present invention, it may be substituted with an ester, thioester, or disulfide group as defined herein, which is attached to a conjugating moiety, a hydrophilic functional group, or an auxiliary moiety.
[0210] As used herein, "heterocyclylalkyl" refers to an alkyl group substituted with a heterocyclyl group. The heterocyclyl group and the alkyl portion may be substituted as described herein for each group.
[0211] "Hydroxyalkyl" refers to -R'(R") n , wherein n is 1 or 2, R' is alkylene and R" is hydroxy, as defined herein. R' may also be optionally substituted in the same manner as alkyl.
[0212] "Hydroxyaryl" refers to -R'(R") n , wherein n is 1 or 2, R' is an arylene group and R" is a hydroxyl group, as defined herein. R' may also be optionally substituted in the same manner as an aryl group.
[0213] "Hydroxyl" refers to -OH.
[0214] "Hydroxy protecting group" refers to any group that can protect the oxygen atom to which it is attached from reaction or bonding. Hydroxy protecting groups are known in the art and are described, for example, in Wuts, Greene, Protective Groups in Organic Synthesis, Wiley-Interscience, 4th edition, 2006. Exemplary protecting groups (having an oxygen atom attached thereto) are independently selected from esters, carbonates, carbamates, sulfonates, and ethers. In exemplary ester hydroxy protecting groups, R of the acyl group is C 1-12 Alkyl (e.g., C 1-8 、C 1-6 、C 1-4 、C 2-7 、C 3-12 and C 3-6 Alkyl), C 2-12 Alkenyl (e.g., C 2-8 、C 2-6 、C 2-4 、C 3-12 and C 3-6 alkenyl), carbocyclic C 6-20 Aryl (e.g., C 6-15 、C 6-10 、C 8-20and C 8-15 Aryl), monocyclic C 1-6 Heteroaryl (e.g., C 1-4 and C 2-6 Heteroaryl), C 4-19 Heteroaryl (e.g., C 4-10 Heteroaryl), (C 6-15 )Aryl(C 1-6 )alkyl, (C 4-19 )heteroaryl(C 1-6 )alkyl or (C 1-6 )heteroaryl(C 1-6 ) alkyl. Specific examples of acyl groups for esters include formyl, benzoylformyl, acetyl (e.g., unsubstituted or chloroacetyl, trifluoroacetyl, methoxyacetyl, triphenylmethoxyacetyl, and p-chlorophenoxyacetyl), 3-phenylpropionyl, 4-oxopentanoyl, 4,4-(ethylenedisulfide)pentanoyl, pivaloyl (Piv), vinylpivaloyl, crotonyl, 4-methoxy-crotonyl, naphthoyl (e.g., 1- or 2-naphthoyl), and benzoyl (e.g., unsubstituted or substituted, for example, p-methoxybenzoyl, phthaloyl (including salts such as triethylamine and potassium salts), p-bromobenzoyl, and 2,4,6-trimethylbenzoyl). As defined herein, any heteroaryl group present in the ester has 1-4 heteroatoms independently selected from O, N, and S. In exemplary carbonate hydroxy protecting groups, R is C 1-12 Alkyl (e.g., C 1-8 、C 1-6 、C 1-4 、C 2-7 、C 3-12 and C 3-6 Alkyl), C 2-12 Alkenyl (e.g., C 2-8 、C 2-6 、C 2-4 、C 3-12 and C 3-6 alkenyl), carbocyclic C 6-20 Aryl (e.g., C 6-15 、C 6-10 、C 8-20 and C 8-15 Aryl), monocyclic C 1-6 Heteroaryl (e.g., C 1-4 and C 2-6 Heteroaryl), C 4-19 Heteroaryl (e.g., C 4-10 Heteroaryl), (C 6-15 )Aryl(C 1-6 )alkyl, (C 4-19 )heteroaryl(C 1-6 )alkyl or (C 1-6 )heteroaryl(C1-6 )alkyl. Specific examples include methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, tert-butyl, p-nitrobenzyl, and benzyl carbonates. As defined herein, any heteroaryl group present in the carbonate has 1-4 heteroatoms independently selected from O, N, and S. In exemplary carbamate hydroxy protecting groups, each R is independently H, C 1-12 Alkyl (e.g., C 1-8 、C 1-6 、C 1-4 、C 2-7 、C 3-12 and C 3-6 Alkyl), C 2-12 Alkenyl (e.g., C 2-8 、C 2-6 、C 2-4 、C 3-12 and C 3-6 alkenyl), carbocyclic C 6-20 Aryl (e.g., C 6-15 、C 6-10 、C 8-20 and C 8-15 Aryl), monocyclic C 1-6 Heteroaryl (e.g., C 1-4 and C 2-6 Heteroaryl), C 4-19 Heteroaryl (e.g., C 4-10 Heteroaryl), (C 6-15 )Aryl(C 1-6 )alkyl, (C 4-19 )heteroaryl(C 1-6 )alkyl or (C 1-6 )heteroaryl(C 1-6 ) alkyl. Specific examples include N-phenyl and N-methyl-N-(o-nitrophenyl) carbamates. As defined herein, any heteroaryl group present in a carbamate group has 1-4 heteroatoms independently selected from O, N, and S. Exemplary ether hydroxy protecting groups include C 1-12 Alkyl (e.g., C 1-8 、C 1-6 、C 1-4 、C 2-7 、C 3-12 and C 3-6 Alkyl), C 2-12 Alkenyl (e.g., C 2-8 、C 2-6 、C 2-4 、C 3-12 and C 3-6 alkenyl), (C 6-15 )Aryl(C 1-6)alkyl, (C 4-19 )heteroaryl(C 1-6 )alkyl, (C 1-6 )heteroaryl(C 1-6 )alkyl, (C 1-6 ) alkoxy (C 1-6 )alkyl, (C 1-6 )alkylthio (C 1-6 )alkyl, (C 6-10 )Aryl(C 1-6 ) alkoxy (C 1-6 ) alkyl and silyl (e.g., tri(C 1-6 alkyl)silyl, tri(C 6-10 Aryl or C 1-6 heteroaryl) silyl, di(C 6-10 Aryl or C 1-6 Heteroaryl) (C 1-6 alkyl)silyl and (C 6-10 Aryl or C 1-6 Heteroaryl)di(C 1-6 alkyl)silyl). Specific examples of alkyl ethers include methyl and tert-butyl, and an example of an alkenyl ether is allyl. Ether hydroxy protecting groups can be used to protect carboxyl groups (e.g., with C 1-12 Alkyl (e.g., C 1-8 、C 1-6 、C 1-4 、C 2-7 、C 3-12 and C 3-6 Alkyl), (C 6-15 )Aryl(C 1-6 )alkyl, (C 1-6 ) alkoxy (C 1-6 )alkyl, (C 1-6 )alkylthio (C 1-6 )alkyl, or (C 6-10 )Aryl(C 1-6 ) alkoxy (C 1-6) alkyl protecting carboxyl group). Examples of alkoxyalkyls and alkylthioalkyls that can be used as ether hydroxy protecting groups include methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl and β-(trimethylsilyl)ethoxymethyl. Examples of arylalkyls that can be used as ether hydroxy protecting groups include benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, triphenylmethyl (trityl), o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, naphthylmethyl and 2- and 4-picolyl ethers. Specific examples of silyl ethers include trimethylsilyl (TMS), triethylsilyl (TES), tert-butyldimethylsilyl (TBS), tert-butyldiphenylsilyl (TBDPS), triisopropylsilyl (TIPS) and triphenylsilyl (TPS) ether. An example of an arylalkyloxyalkyl ether is benzyloxymethyl ether. As defined herein, any heteroaryl groups present in an ether group have 1 to 4 heteroatoms independently selected from O, N, and S. Ortho or 1,3-diols can be protected (e.g., to produce a "cyclic protected diol") with a diol protecting group such as an acetal (e.g., containing C 1-6 alkylene), ketal (e.g., containing C 3-6 Alkylene or C 3-6 Examples of acetal and ketal groups include methylene-dioxy, ethylidene-dioxy, benzylidene-dioxy, isopropylidene-dioxy, cyclohexylidene-dioxy, and cyclopentylidene-dioxy. An example of a cyclic silylene group is di-tert-butylsilylene. Another diol protecting group is 1,1,3,3-tetraisopropylsiloxanediyl. Examples of cyclic borate esters include methyl, ethyl, phenyl, and 2,6-diacetamidophenyl borate. Protecting groups can be substituted as known in the art; for example, aryl and arylalkyl groups (e.g., phenyl, benzyl, naphthyl, or pyridyl) can be replaced by C 1-6 Alkyl, C 1-6 Alkoxy, nitro, cyano, carboxyl or halogen substitution. Alkyl (such as methyl, ethyl, isopropyl, n-propyl, tert-butyl, n-butyl and sec-butyl) and alkenyl (such as vinyl and allyl) can also be substituted with oxo, arylsulfonyl, halogen and trialkylsilyl. Preferred protecting groups are TBS and Piv. Orthogonal protecting groups are removed under different conditions, as known in the art.
[0215] "Imido" refers to -NR2, where each R is independently an optionally substituted acyl group.
[0216] "Ketal" refers to -O-CR2-O-, where each R is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted arylalkyl, or both R groups together are optionally substituted alkylene, or each R group is a bond to a carbon atom listed within an intermediate as shown in Formula 1 or within a halichondrin macrolide or an analog thereof.
[0217] "Macrocycle" refers to a compound containing at least one n-membered ring, where n is equal to or greater than 10.
[0218] "Non-enolizable" refers to a group that, alone or in combination with the group to which it is attached, is not capable of forming an enol group via a deprotonation / reprotonation sequence. For example, a "non-enolizable alkyl" group may be bonded to a sulfone group or a carbonyl group via a quaternary carbon atom (i.e., a carbon atom not bonded to a hydrogen atom).
[0219] "N-protecting group" refers to a group that protects a nitrogen atom in a molecule from participating in one or more undesired reactions (e.g., oxidation reactions or certain nucleophilic and electrophilic substitutions) during chemical synthesis. Commonly used N-protecting groups are disclosed in Wuts, Greene's Protective Groups in Organic Synthesis, Wiley-Interscience, 4th edition, 2006. Exemplary N-protecting groups include: acyl groups (e.g., formyl, acetyl, trifluoroacetyl, propionyl, pivaloyl, tert-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthaloyl, o-nitrophenoxyacetyl, α-chlorobutyryl, benzoyl, 4-chlorobenzoyl, and 4-bromobenzoyl); sulfonyl-containing groups (e.g., benzylsulfonyl, p-toluenesulfonyl, o-nitrobenzenesulfonyl, and p-nitrobenzenesulfonyl); carbamate-forming groups (e.g., benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, , 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-biphenyl)-1-methylethoxycarbonyl, α,α-dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxycarbonyl, tert-butoxycarbonyl, diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2,-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl, cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl and phenylthiocarbonyl), arylalkyl groups (e.g., triphenylmethyl); silyl groups (e.g., trimethylsilyl); and imine-forming groups (e.g., diphenylmethylene). Preferred N-protecting groups are acetyl, benzoyl, phenylsulfonyl, p-toluenesulfonyl, p-nitrobenzenesulfonyl, o-nitrobenzenesulfonyl, tert-butoxycarbonyl (Boc) and benzyloxycarbonyl (Cbz).
[0220] "Oxo" or (O) refers to =0.
[0221] "Pharmaceutically acceptable salts" refers to salts that are, within the scope of sound medical judgment, suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reaction, etc., and that match a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., J. Pharmaceutical Sciences 66: 1-19, 1977, and Pharmaceutical Salts: Properties, Selection, and Use, (Eds. P.H. Stahl and C.G. Wermuth), Wiley-VCH, 2008. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate, etc. A preferred salt is the methanesulfonate salt.
[0222] "Pseudohalogen" refers to -O-SO2R, where R is optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl. Non-limiting examples of pseudohalogen include trifluoromethanesulfonate and nonaflate.
[0223] "Silyl" refers to -SiR3, where each R is independently alkyl, alkenyl, aryl, or arylalkyl. Examples of silyl groups include tris(C 1-6 alkyl)silyl, tri(C 6-10 Aryl or C 1-6 heteroaryl) silyl, di(C 6-10 Aryl or C 1-6 Heteroaryl) (C 1-6 alkyl)silyl and (C 6-10 Aryl or C 1-6 Heteroaryl)di(C 1-6It should be understood that when the silyl group includes two or more alkyl, alkenyl, aryl, heteroaryl or arylalkyl groups, these groups are independently selected. As defined herein, any heteroaryl group present in the silyl group has 1-4 heteroatoms independently selected from O, N and S. The silyl group can be optionally substituted in the same manner as defined for each R group.
[0224] "Silylene" refers to -SiR2-, where each R is independently alkyl, alkenyl, aryl, arylalkyl, or alkoxy. "Dialkylsilylene" refers to a silylene group where each R is an alkyl group. Silylene groups may be optionally substituted in the same manner as defined for each R group. A silylene-dioxy group is a group having the formula -O-SiR2-O-.
[0225] "Strong base" means A base whose conjugate acid has a pKa greater than or equal to 13. Non-limiting examples of strong bases include alkyl alkali metals (e.g., butyllithium or Schlosser's base), Grignard reagents (e.g., alkyl magnesium halides), alkali metal or alkaline earth metal alkoxides, alkali metal or alkaline earth metal amides (e.g., diisopropylamide, tetramethylpiperidine, or bis(trimethylsilyl)amide), and phosphazene bases (e.g., Schwesinger bases). Non-limiting examples of alkali metal amides are lithium diisopropylamide, lithium tetramethylpiperidinium, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, and potassium bis(trimethylsilyl)amide.
[0226] "Sulfonamide" refers to a -NR group where R is sulfonyl.
[0227] "Sulfonate" refers to -OS(O)2R, where R is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted arylalkyl. In exemplary sulfonates, R is C 1-12 Alkyl (e.g., C 1-8 、C 1-6 、C 1-4 、C 2-7 、C 3-12 or C 3-6 Alkyl), C 2-12 Alkenyl (e.g., C 2-8 、C 2-6 、C 2-4 、C 3-12 or C 3-6 alkenyl), carbocyclic C 6-20 Aryl (e.g., C 6-15 、C 6-10 、C 8-20 or C 8-15 Aryl), monocyclic C 1-6Heteroaryl (e.g., C 1-4 and C 2-6 Heteroaryl), C 4-19 Heteroaryl (e.g., C 4-10 Heteroaryl), (C 6-15 )Aryl(C 1-6 )alkyl, (C 4-19 )heteroaryl(C 1-6 )alkyl or (C 1-6 )heteroaryl(C 1-6 Any heteroaryl group present in the sulfonate group has 1-4 heteroatoms independently selected from O, N and S, as defined herein.
[0228] "Sulfonyl" refers to -S(O)2R, where R is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted arylalkyl, or silyl. Preferred R groups for the sulfonyl group are the same as those described above for the sulfonates.
[0229] "Thioacetal" refers to -S-(CHR)-S-, where R is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted arylalkyl.
[0230] "Thioketal" refers to -S-(CR2)-S-, where each R is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted arylalkyl.
[0231] "Triflate" refers to an ester of trifluoromethanesulfonic acid.
[0232] Unless otherwise stated, the pKa values reported herein refer to the conjugated The pKa value of the acid in water.
[0233] Where applicable, reference to a compound described herein includes salts thereof.
[0234] Details The present invention provides compounds and methods that can be used to synthesize halichondrin macrolides and analogs thereof (see Formula 1). Preferably, the halichondrin macrolide analog is eribulin or a salt thereof (e.g., eribulin mesylate). Preferably, the halichondrin macrolide is halichondrin B macrolide. Formula 1 shows the carbon atom numbering scheme for halichondrin macrolides and analogs thereof.
[0235] Formula 1 wherein D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6Saturation or C 2-6 An unsaturated hydrocarbon skeleton which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group, or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) n OP5, wherein P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P5 is H, an optionally substituted alkyl group, or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group, or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the group consisting of: wherein each P′ is independently H or a hydroxyl protecting group; A1, A2 and A3 are each independently H or OP", wherein each P" is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl group; Each Q1 is independently OR A SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)R A NR B (CO)(CO)R A NR B (CO)NRB R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each independently represents H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl, or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; and k is 0 or 1.
[0236] In the halichondrin macrolide and halichondrin macrolide analog structures, when P1 is absent, D and D' are each independently H or an optionally substituted alkyl group, and when P2 is absent, L is -C(O)-.
[0237] Prince reaction In one aspect, the present invention provides a compound of formula (A) and a method for preparing the same. The compound of formula (A) can be prepared from a compound of formula (B), a compound of formula (C), and R5OH, wherein R5 is an optionally substituted acyl group. For example, the compound of formula (B), the compound of formula (C), and R5OH can be subjected to, for example, Prince reaction conditions known in the art. For example, the compound of formula (B), the compound of formula (C), and R5OH can react with a Lewis acid, such as an oxophilic Lewis acid (e.g., boron trifluoride or a solvate thereof).
[0238] The compound of formula (A) is: in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group, or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) n OP5, wherein P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P5 is H, an optionally substituted alkyl group, or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group, or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the group consisting of: wherein each P′ is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2, or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl group; Each Q1 is independently OR A SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)R A NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R Beach independently represents H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl, or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxyl protecting group; R4 is an optionally substituted alkyl group, an optionally substituted alkenyl group, or an optionally substituted alkynyl group, in Each P7 is independently H or a hydroxy protecting group; and R8 is -CH2CH2-COOR C 、-CH=CH-COOR C 、-CH2CH2-SO2R D or -CH=CH-SO2R D ; R5 is an optionally substituted acyl group; R6 is H, optionally substituted alkyl or optionally substituted arylalkyl; Each Y is independently -COOR C or-SO2R D ; Each R C When present, is independently optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; and each R D Where present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl.
[0239] In the compound of formula (A), when P1 is absent, D and D' are each independently H or optionally substituted alkyl, and when P2 is absent, L is -C(O)-.
[0240] The compound of formula (B) is: wherein all variables are as described for formula (A).
[0241] The compound of formula (C) is: R4-R7, (C) in R7 is -CHO or Each R 7A are independently optionally substituted alkyl, and R4 is as described for the compound of formula (A).
[0242] Compounds of formula (B) can be prepared from compounds of formula (D) and compounds of formula (E). For example, compounds of formula (D) and compounds of formula (E) can be subjected to Sakurai reaction conditions, such as those known in the art. In certain embodiments, compounds of formula (D) can be reacted with compounds of formula (E) and a Lewis acid, such as an oxophilic Lewis acid (e.g., boron trifluoride or a solvate thereof), to produce compounds of formula (B).
[0243] The compound of formula (D) is: wherein all variables are as described for compounds of formula (B).
[0244] The compound of formula (E) is: in R S is a silyl group (e.g., Me3Si-); and R6 is as described for the compound of formula (B).
[0245] The Sakurai reaction to produce a compound of formula (B) introduces a secondary alcohol stereocenter into the compound of formula (B). If the stereoselectivity of the Sakurai reaction is unsatisfactory, the Sakurai reaction product can be subjected to epimerization to enrich the product in the compound of formula (B) relative to its diastereomers. In a non-limiting example, the Sakurai reaction product (the compound of formula (B) and its C.27 diastereomer) can be reacted with an oxidant capable of converting an alcohol to a carbonyl (e.g., Dess-Martin periodinane) to provide a compound of formula (F), which can then be subjected to enantioselective 1,2-reduction reaction conditions (e.g., Corey-Bakshi-Shibata reaction). Alternatively, if the diastereoselectivity of the Sakurai reaction favors the formation of diastereomers of the compound of formula (B), the Mitsunobu reaction can be used to convert the secondary alcohol stereocenter in the diastereomeric mixture of Sakurai reaction products.
[0246] The compound of formula (F) is: wherein all variables are as described for formula (B).
[0247] The enantioselective 1,2-reduction reaction conditions are known in the art. In a non-limiting example, the enantioselective 1,2-reduction reaction is a Corey-Bakshi-Shibata reaction. The Corey-Bakshi-Shibata reduction can include reacting a ketone with a CBS catalyst and borane or a solvate thereof. In a non-limiting example, a (S)-CBS-oxazole borane catalyst can be used with borane or a solvate thereof (e.g., BH3·THF) to control the stereochemistry of the resulting secondary alcohol in the preparation of a compound of formula (II) from a compound of formula (F).
[0248] Mitsunobu reaction conditions are known in the art. In a non-limiting example, the diastereomeric Sakurai reaction product mixture can be reacted with an azadicarboxylate compound (e.g., DIAD), a phosphine (e.g., PPh 3 ) and a carboxylic acid (e.g., 3,5-dinitrobenzoic acid) to produce a compound of formula (G): in R Ac is an optionally substituted acyl group; and The remaining variables are as described for formula (B).
[0249] The compound of formula (G) can be converted to the compound of formula (B). In a non-limiting example, the compound of formula (G) can be subjected to alcoholysis or hydrolysis reaction conditions (e.g., Mg(OMe)2 in MeOH) to produce the compound of formula (B). Alternatively, the compound of formula (G) can be reacted with a 1,2-reducing agent to produce the compound of formula (B).
[0250] In the compounds described herein, R6 can be optionally substituted alkyl (eg, methyl).
[0251] In the compounds described herein, D can be H. In the compounds described herein, D' can be OP1 (eg, P1 can be alkyl (eg, methyl)). In the compounds described herein, G can be O.
[0252] In the compounds described herein, k may be 0, and R1 may be -CH2(Y), wherein Y may be -SO2R D , where R D is optionally substituted aryl (eg, phenyl) or optionally substituted non-enolizable alkyl.
[0253] In the compounds described herein, E can be optionally substituted alkyl (eg, methyl).
[0254] In the compounds described herein, D may be H, and A may be:
[0255] In the compounds described herein, k can be 0, and R1 can be -CH(Y)2 or -CH2(Y). In the compounds described herein, R3 can be -(CH2) n NP3P4 or -(CH2) n OP5, where n can be 0.
[0256] In the compounds described herein, A and D may combine to form the following structure: wherein the bond to the oxygen atom originates from the carbon atom connected to D in formula (A) or formula (B). In the compounds described herein, R3 may be -(CH2) n NP3P4 or -(CH2) n OP5, and n is 2.
[0257] In the compounds described herein, k can be 1, and E can be an optionally substituted alkyl group (e.g., methyl). In the compounds described herein, R1 can be -CH2(Y), wherein Y can be -COOR D , where R D An optionally substituted alkyl group (eg, methyl group) may be provided.
[0258] Preparation of Halichondrin Macrolide and Its Analogues Halichondrin macrolide or its analogue can be prepared as described herein and using methods and reactions known in the art. Non-limiting examples of methods and reactions that can be used to prepare halichondrin macrolide or its analogue include U.S. Patent Application Publication Nos. 2016 / 0264594, 2015 / 0158881, 2011 / 0184190, 2011 / 0054194, 2009 / 0203771, and 2009 / 0198074; International Patent Application Publication No. WO 2016 / 179607; U.S. Patent Nos. 5,338,865, 5,436,238, 6,214,865, and 8,445,701; and Towle et al., Annual Meeting of the American Association for Cancer Research Research, April 6-10, 2002, 5721; Wang et al., Bioorg. Med. Chem. Lett., 10:1029-1032, 2000; Aicher et al., J. Am. Chem. Soc., 114:3162-3164, 1992; Ueda et al., J. Am. Chem. Soc., 136:5171-5176; and Yamamoto et al., J. Am. Chem. Soc., 134:893-896, 2012.
[0259] As described herein, one skilled in the art can determine the methods involving hydroxy protecting group removal agents and A reaction sequence of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 67, 68, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 110, 111, 112, 123, 130, 131, 132, 143, 159, 110
[0260] Formula 2 illustrates macrocyclic ring cleavage, which can be used to prepare halichondrin macrolide or its analogs.
[0261] Formula 2 Halichondrin macrolide or its analogues wherein X1 is -O- or -CH2-, and the remaining variables are as described in Formula 1.
[0262] Table 1 lists the retrosynthetic disconnection of the macrocycle shown in Formula 2 and indicates the corresponding exemplary bond-forming reactions as described herein. Any of these various reactions can be used to synthesize halichondrin macrolide or its analogs. For example, these reactions can be used to couple various fragments together or form a macrocycle.
[0263] Table 1
[0264] The methods disclosed herein for preparing a halichondrin macrolide or an analog thereof include a C.23-C.24 bond-forming Prins reaction as a macrocyclization step or as a step in the synthesis of a non-macrocyclic intermediate. In some methods, a halichondrin macrolide or an analog thereof (e.g., eribulin or a salt thereof (e.g., eribulin mesylate)) can be prepared from a compound of formula (IA) using methods and reaction conditions known in the art.
[0265] The compound of formula (IA) can be prepared from a compound of formula (IIA), a compound of formula (IIB), a compound of formula (III) and R5OH. The compound of formula (IA) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; R4 is in Each P7 is independently H or a hydroxyl protecting group; R8 is -CH2CH2-COOR C 、-CH=CH-COOR C 、-CH2CH2-SO2R D or -CH=CH-SO2R D ; Each R C When present, is independently optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; and each R D R5, when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; and R5 is optionally substituted acyl; and the remaining variables are as described for the halichondrin macrolide or an analog thereof (eg, eribulin or a salt thereof (eg, eribulin mesylate)).
[0266] In the compound of formula (IA), when P1 is absent, D and D' are each independently H or optionally substituted alkyl.
[0267] The compound of formula (IIA) is: in R E -CHO or -CH (1+m)(OR F ) (2-m) , in m is 1, and R F is a hydroxyl protecting group, or m is 0, and (i) Each R F are independently alkyl or hydroxy protecting groups, or (ii) Two Rs F Combine to form an alkylene group; and The remaining variables are as described for the compound of formula (IA).
[0268] The compound of formula (IIB) is: where R S is a silyl group (eg Me3Si-).
[0269] The compound of formula (III) is: R4-R7, (1@@) in R7 is -CHO or Each R 7A are independently optionally substituted alkyl, and R4 is as described for the compound of formula (IA).
[0270] The preparation of the compound of formula (IA) may comprise the step of: E is -CHO), a compound of formula (IIB) and a Lewis acid, such as an oxophilic Lewis acid (e.g., boron trifluoride or a solvate thereof), to produce a compound of formula (IIC): wherein the variables are as described for the compound of formula (IA).
[0271] The compound of formula (III) and the compound of formula (IIC) can be reacted under Prince reaction conditions to produce the compound of formula (IA). Prince reaction conditions are known in the art. In a non-limiting example, the compound of formula (III) and the compound of formula (IIC) can be reacted with a Lewis acid (e.g., an oxophilic Lewis acid (e.g., boron trifluoride or a solvate thereof)).
[0272] Exemplary conditions for macrocyclization at the indicated positions are described below. These reaction conditions can also be used to couple two or more fragments prior to macrocyclization.
[0273] C.1-X1 bond formation macrocyclization Halichondrin macrolides or analogs thereof (e.g., eribulin or a salt thereof (e.g., eribulin mesylate)) can be prepared from compounds of formula (VIIB) via macrocyclization via C.0-C.1 or OC.1 bond formation according to the following synthetic strategy: in (i)R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (ii)R 10 is a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (iii)R 10 and R 11 Combine to form a bond, and R 12 is H; L4 is R1 is -OP6, -CH2(Y) or -CH(Y)2, wherein P6 is H or a hydroxy protecting group, and Y is -COOR C or -CHO; each R C and A1 and R are independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; and 14 Combined to form oxo, R 13 is H or a hydroxyl protecting group, and R 15 is H; or A1 is H or -OP", and: (i)R 13 is H or a hydroxyl protecting group, and R 14 and R 15 Combine to form a double bond; or (ii)R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; R5 is an optionally substituted acyl group; R9 is -CHO or -COOP"; Each P" is independently H or a hydroxy protecting group; Each P9 is independently a hydroxy protecting group, and X3 is oxo or X3 together with the carbon atom to which it is attached is -(CH(OP 11 ))-, where P 11is H or a hydroxy protecting group; or two P9 groups and X3 are combined with the atoms to which they are attached to form a ketal; and the remaining variables are as described for the halichondrin macrolide or an analog thereof.
[0274] The compound of formula (VIIB) is converted to the compound of formula (VIIC): in L1 is Wherein L2 and L3 combine to form a bond; X1 is -CH2-, -CH(Y)-, -C(Y)2- or -O-; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxyl protecting group; and the remaining variables are as described for the compound of Formula (VIIB).
[0275] The preparation of the compound of formula (VIIC) may comprise an esterification reaction between R1 (-OP6, wherein P6 is H) and R9 (-COOH). Alternatively, the preparation of the compound of formula (VIIC) may comprise a reaction between R1 (-CH(Y)2 or -CH2(Y)) and R9 (-CHO) (e.g., under Claisen reaction conditions). The Claisen product (X4 together with the atom to which it is attached is -(CH(OP6)) is oxidized with an oxidizing agent capable of converting an alcohol to a carbonyl group) is oxidized with an oxidizing agent capable of converting an alcohol to a carbonyl group. 12 ))-, where P 12 is H) can produce X4 (oxo). Further desulfonation or decarboxylation of the compound of formula (VIIC) can produce the compound of formula (VIIC) wherein X1 is -CH2-.
[0276] Then, the compound of formula (VIIC) is converted to a halichondrin macrolide or its analogue using methods described herein and methods known in the art, for example, methods described in US 5,338,865, US2016 / 0264594, US2009 / 0203771 and WO 2016 / 179607. For example, preparing a halichondrin macrolide or its analogue can include reacting a compound of formula (VIIC) with a hydroxyl protecting group removing agent.
[0277] The compound of formula (VIIB) can be prepared from a compound of formula (VIIA), a compound of formula (IIA), a compound of formula (IIB), a compound of formula (IIIC) and R5OH. The compound of formula (VIIA) is: in (i)R10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (ii)R 10 is a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (iii)R 10 and R 11 combines to form a bond, and R 12 is H; R9 is -CH2-OP", -CHO or -COOP"; R 13 and each P9 is independently a hydroxy protecting group; A1 is H or -OP"; Each P" is independently H or a hydroxy protecting group; and Y1 is chlorine, bromine, iodine, triflate or trialkylsilane.
[0278] The compound of formula (IIIC) is: R 4C -R7, (IIIC) in R7 is -CHO, -CH2OP A or Each R 7A are independently optionally substituted alkyl; and R 4C for in R C is optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl; P A is H or a hydroxyl protecting group; and P7, when present, is independently H or a hydroxy protecting group.
[0279] The preparation of the compound of formula (VIIB) can be accomplished as follows: A compound of formula (IIIC) wherein R7 is -CH2OP A or can be converted into compounds of formula (IIID): R 4D -R7, (IIID) in R 4D for and All remaining variables are as described for the compound of formula (IIIC).
[0280] Compounds of formula (IIID) can be reacted with compounds of formula (VIIA) under Nozaki-Hiyama-Kishi reaction conditions (e.g., with Cr(II) salts and Ni(II) salts as described herein) to form compounds of formula (VIIAa): in R7 is -CH2OP A , -CHO or and all other variables are as described for the compound of formula (VIIB) and the compound of formula (IIID).
[0281] Compounds of formula (VIIAa) wherein R7 is -CHO can be reacted with compounds of formula (IIC) and R5OH under Prince reaction conditions to form compounds of formula (VIIB).
[0282] Alternatively, the preparation of compounds of formula (VIIB) can be achieved by reacting compounds of formula (IG) and compounds of formula (VIIA) under Nozaki-Hiyama-Kishi reaction conditions (e.g., using Cr(II) salts and Ni(II) salts as described herein).
[0283] The compound of formula (IG) is: in R E1 for wherein R5 is an optionally substituted acyl group; and the remaining variables are as described for the compound of Formula (VIIB).
[0284] Compounds of formula (IG) can be formed from compounds of formula (IF): wherein all variables are as described for the compound of formula (IG) and the compound of formula (IIIC).
[0285] R 4C can be reacted with a diol cleavage agent to produce an aldehyde, which can then be reacted with (R C O)2P(O)-CH2-COOR C Reaction to produce R 4C
[0286] R 4C Can react with 1,4-reducing agents to produce R 4C
[0287] R 4C Can react with allylic reducing agents to produce R 4C (For example, to prepare the R 4C It may further include an esterification reaction after reacting with an allylic reducing agent).
[0288] R 4C Can react with 1,2-reducing agents to produce
[0289] R 4C Can be used to convert alcohol into The oxidizing agent reacts with the carbonyl group in the reaction.
[0290] Typically, the methods described herein involve performing an allylic reduction at C.25. This reaction can be performed at any time prior to the formation of the halichondrin macrolide or its analog. For example, an allylic reducing agent can be used to reduce the halichondrin macrolide to Convert to
[0291] C.2-C.3 and C.3-C.4 bond formation macrocyclization In another approach, a halichondrin macrolide or an analog thereof (eg, eribulin or a salt thereof (eg, eribulin mesylate)) can be prepared via C.2-C.3 or C.3-C.4 bond-forming macrocyclization according to the following strategy.
[0292] In some embodiments, the halichondrin macrolide or an analog thereof is prepared from a compound of formula (VIB): in L4 is R1 is -OP6 or -CH(Y), wherein P6 is H or a hydroxy protecting group, and Y is -COOR C or -CHO; R5 is an optionally substituted acyl group; R 10A -CH2-CH=CH2, -(CH2)2-CH=CH2 or -(CH2)3-OP 10 ; R 10 and P 10 Each is independently a hydroxyl protecting group.
[0293] A1 and R14 Combined to form oxo, R 13 is H or a hydroxyl protecting group, and R 15 is H; or A1 is H or -OP", and: (i)R 13 is H or a hydroxyl protecting group, and R 14 and R 15 Combine to form a double bond; or (ii)R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; Each P9 is independently a hydroxy protecting group, and X3 is oxo or X3 together with the carbon atom to which it is attached is -(CH(OP 11 ))-, where P 11 is H or a hydroxy protecting group; or two P9 groups and X3 are combined with the atoms to which they are attached to form a ketal; and The remaining variables are as described for the halichondrin macrolide or analogs thereof.
[0294] The compound of formula (VIB) can be converted to a halichondrin macrolide or an analog thereof (eg, eribulin or a salt thereof (eg, eribulin mesylate)) using art-known reaction conditions, such as those described herein.
[0295] In a specific embodiment, the preparation of a halichondrin macrolide or an analog thereof from a compound of formula (VIB) via macrocyclization of a C.3-C.4 bond comprises preparing a compound of formula (VIC) from a compound of formula (VIB). The compound of formula (VIC) is in L5 is X1 is -CH2- or -O-; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxy protecting group; and the remaining variables are as described for the compound of Formula (VIB).
[0296] The compound of formula (VIB) can be reacted with R 17 -CH2CH=CH2(where R 17 The compound of formula (VIC) can be prepared by reacting a compound of formula (VIB) wherein R1 is -CH2(Y) with a compound of formula (VIB) wherein R 17 R is the metal or metalloid part 17-CH2CH=CH2 reaction to produce a compound of formula (VIC) wherein X1 is -CH2-, and X4 is oxo or -(CH(OP 12 ))-. You can use R 17 -CH2CH=CH2(where R 17 A compound of formula (VIB) wherein R1 is -OP6 and P6 is H is esterified with -COOH) to produce a compound of formula (VIC) wherein X1 is -O-, and X4 is oxo.
[0297] The compound of formula (VIC) is then converted to the compound of formula (VID): in L1 is Wherein L2 and L3 combine to form a bond; and the remaining variables are as described for the compound of formula (VIC).
[0298] The compound of formula (VID) is produced by reacting a compound of formula (VIC) with an olefin metathesis catalyst.
[0299] The compound of formula (VID) can be converted to a halichondrin macrolide or an analog thereof using methods described herein and methods known in the art, such as those described in US 2016 / 0264594, US 2009 / 0203771, and WO 2016 / 179607.
[0300] The preparation of the halichondrin macrolide or its analogue may comprise reacting a compound of formula (VID) with a hydroxy protecting group removing agent. The reaction of the compound of formula (VID) with the hydroxy protecting group removing agent may result in isomerization of the C.3-C.4 double bond, thereby isomerizing the compound upon exposure to a basic (e.g., isomerization mediated by a hydroxy protecting group removing agent such as a fluoride source) or acidic (e.g., isomerization mediated by a hydroxy protecting group removing agent such as a fluoride source) or acidic (e.g., The enoate / enone described herein is obtained under acid-mediated isomerization conditions. The obtained enoate / enone can undergo reaction with -OR 10 reaction of the hydroxyl groups.
[0301] In certain embodiments, the preparation of a halichondrin macrolide or an analog thereof from a compound of formula (VIB) via macrocyclization through C.2-C.3 bond formation comprises preparing a compound of formula (VIE) from a compound of formula (VIB). The compound of formula (VIE) is: in L6 is X1 is -CH2- or -O-; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12))-, where P 12 is H or a hydroxy protecting group; and the remaining variables are as described for the compound of Formula (VIB).
[0302] The compound of formula (VIB) can be obtained by reacting with R 17 -CH=CH2 (where R 17 For example, a compound of formula (VIB) wherein R1 is -CH2(Y) may be reacted with a compound of formula (VIB) wherein R 17 R is the metal or metalloid part 17 -CH2CH=CH2 reaction to obtain a compound of formula (VIE), wherein X1 is -CH2-, and X4 is oxo or -(CH(OP 12 ))-. Alternatively, you can use R 17 -CH2CH=CH2(where R 17 Esterification of a compound of formula (VIB) wherein R1 is -OP6 and P6 is H with -COOH) affords a compound of formula (VIE) wherein X1 is -O- and X4 is oxo.
[0303] Compounds of formula (VIE) can be converted to compounds of formula (VIF): in L1 is Wherein L2 and L3 combine to form a bond; and the remaining variables are as described for Formula (VIE).
[0304] The compound of formula (VIF) can be prepared by reacting a compound of formula (VIE) with an olefin metathesis catalyst.
[0305] Alternatively, compounds of formula (VIF) wherein X4 is oxo can be prepared from compounds of formula (VIG): in L7 is X1 is -CH2- or -O-; Each R C is independently optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; and the remaining variables are as described for the compound of Formula (VIF).
[0306] The compound of formula (VIG) can be prepared by reacting a compound of formula (VIB) with (R C O)2P(O)-CH2-R P Reaction preparation, where each R Care independently optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl, and R P For example, a compound of formula (VIB) wherein R1 is -CH2(Y) may be combined with a compound of formula (VIB) wherein R P (R C O)2P(O)-CH2-R P Reaction under Claisen reaction conditions to produce a compound of formula (VIG). Alternatively, (R C O)2P(O)-CH2-R P (where R P A compound of formula (VIB) wherein R1 is -OP6 (wherein P6 is H) is esterified with -COOH) to produce a compound of formula (VIG).
[0307] The compound of formula (VIG) is then converted to a compound of formula (VIF) wherein all variables are as described for the compound of formula (VIG), for example, by a Horner-Wadsworth-Emmons reaction.
[0308] The compound of formula (VIF) is then converted to a halichondrin macrolide or an analog thereof using methods described herein and methods known in the art, such as those described in US 2016 / 0264594, US 2009 / 0203771, and WO 2016 / 179607.
[0309] The compound of formula (VIB) can be prepared from a compound of formula (VIA), a compound of formula (IIA), a compound of formula (IIB), a compound of formula (IIIC), and R5OH.
[0310] The compound of formula (VIA) is: in R 10 、R 13 and P9 are each independently a hydroxyl protecting group; A1 is H or -OP"; Y1 is chlorine, bromine, iodine, triflate or trialkylsilane; and R 10A As described for the compound of formula (VIB).
[0311] The compound of formula (IIA) is: in R E -CHO or -CH (1+m) (OR F ) (2-m) , in m is 1, and R F is a hydroxyl protecting group, or m is 0, and (i) each R F are independently alkyl or hydroxy protecting groups, or (ii) two R F Combine to form an alkylene group; and the remaining variables are as described for the compound of Formula (VIB).
[0312] The compound of formula (IIB) is: where R S is a silyl group; The compound of formula (IIIC) is: R 4C -R7, (IIIC) in R 4C for where R C is optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl, and each P7 is independently H or a hydroxy protecting group; and R7 is -CHO or Each R 7A is independently optionally substituted alkyl; The preparation of the compound of formula (VIB) comprises R E Sakurai reaction between (-CHO) and a compound of formula (IIB) to produce structure This product can then be reacted with a compound of formula (IIIC) under Prince reaction conditions to produce a structure This group can be converted into As described in this article.
[0313] If the stereochemistry of the secondary alcohol in the product of the Sakurai reaction is different from the desired stereochemistry, this group can be subjected to epimerization reaction conditions as described herein (e.g., oxidation followed by Corey-Bakshi-Shibata reduction; alternatively, a Mitsunobu reaction can be used to invert the stereocenter).
[0314] If R E -CH (1+m) (OR F )(2 - m) , then the preparation of the compound of formula (IVB) may also include the step of reacting the acetal under deprotection conditions, for example, by reacting the acetal with R is converted by reaction with an aqueous acid solution (for example, when m is 0) or by oxidation using an oxidizing agent capable of converting an alcohol into a carbonyl group (for example, when m is 1). E Converted to -CHO.
[0315] R 4C Can be reacted with a diol cleavage agent to produce an aldehyde, which is then reacted with (R C O)2P(O)-CH2-COOR C Reaction to produce R 4C
[0316] R 4C Can react with 1,4-reducing agents to produce R 4C
[0317] R 4C Can react with allylic reducing agents to produce R 4C (For example, to prepare the R 4C It may further include an esterification reaction after the reaction with an allylic reducing agent).
[0318] R 4C Can react with 1,2-reducing agents to produce
[0319] R 4C Can be used to convert alcohol into The oxidizing agent reacts with the carbonyl group in the reaction.
[0320] In some embodiments, a compound of formula (VIB) is prepared from a compound of formula (VIA) and a compound of formula (IG): in R E1 for wherein R5 is an optionally substituted acyl group; and the remaining variables are as described for the compound of Formula (VIB).
[0321] The compound of formula (VIA) is reacted with the compound of formula (IG) under Nozaki-Hiyama-Kishi reaction conditions to produce the compound of formula (VIB). For example, the Nozaki-Hiyama-Kishi reaction of the compound of formula (VIA) and the compound of formula (IG) can include reacting the compound of formula (VIA) and the compound of formula (IG) with a Cr(II) salt and a nickel(II) salt.
[0322] The compound of formula (IG) can be prepared from a compound of formula (IIA), a compound of formula (IIB), a compound of formula (IIIC) and R5OH, wherein R5 is an optionally substituted acyl group.
[0323] In further embodiments, compounds of formula (VIB) can be prepared according to the following strategy. Compounds of formula (IIIC) can be converted to compounds of formula (IIID) as described herein. Additionally, compounds of formula (IIID) can be reacted with compounds of formula (VIA) under Nozaki-Hiyama-Kishi reaction conditions to produce compounds of formula (VIAa): wherein all variables are as described for the compound of formula (VIB) and the compound of formula (IIIC).
[0324] A compound of formula (VIAa) wherein R7 is -CHO can be reacted with a compound of formula (IIC) and R5OH under Prince reaction conditions to form a compound of formula (VIB).
[0325] In another embodiment, the compound of formula (VIC) can be prepared according to the following strategy. E -CH (1+m) (OR F ) (2-m) The compound of formula (IIA) and R 17 -CH2CH=CH2(where R 17 is -COOH or a metal or metalloid moiety) to produce a compound of formula (IID): wherein all variables are as described for the compound of formula (VIC).
[0326] For example, a compound of formula (IIA) wherein R1 is -CH2(Y) may be combined with a compound of formula (IIA) wherein R 17 R is the metal or metalloid part 17 -CH2CH=CH2 reaction to produce a compound of formula (VIC) wherein X1 is -CH2-, and X4 is oxo or -(CH(OP 12))-. You can use R 17 -CH2CH=CH2(where R 17 A compound of formula (IIA) wherein R1 is -OP6 and P6 is H is esterified with -COOH) to produce a compound of formula (IID) wherein X1 is -O-, and X4 is oxo.
[0327] where R E A compound of formula (IID) that is -CHO can be reacted with a compound of formula (IIB) under Sakurai reaction conditions to produce a compound of formula (IIE): wherein all variables are as described for the compound of formula (VIC).
[0328] The compound of formula (IIE) can be reacted with a compound of formula (VIAa) and R5OH under Prince reaction conditions to produce a compound of formula (VIC) wherein L5 is:
[0329] In another embodiment, the compound of formula (VIE) can be prepared according to the following strategy. The compound of formula (IIA) can be prepared by reacting R 17 -CH=CH2 (where R 17 The compound of formula (IIF) is: wherein all variables are as described for the compound of formula (VIE).
[0330] For example, a compound of formula (IIA) wherein R1 is -CH2(Y) may be combined with a compound of formula (IIA) wherein R 17 R is the metal or metalloid part 17 -CH2CH=CH2 reaction to obtain a compound of formula (IIF), wherein X1 is -CH2-, and X4 is oxo or -(CH(OP 12 ))-. Alternatively, you can use R 17 -CH2CH=CH2(where R 17 Esterification of a compound of formula (IIA) wherein R1 is -OP6 and P6 is H with -COOH) affords a compound of formula (IIF) wherein X1 is -O- and X4 is oxo.
[0331] where R E A compound of formula (IIF) that is -CHO can be reacted with a compound of formula (IIB) under Sakurai reaction conditions to produce a compound of formula (IIG): wherein all variables are as described for the compound of formula (VIE).
[0332] The compound of formula (IIF) can be reacted with the compound of formula (VIAa) and R5OH under Prince reaction conditions to produce a compound of formula (VIE), wherein L6 is:
[0333] In some embodiments, compounds of formula (VIG) can be prepared according to the following strategy. Compounds of formula (IIA) can be prepared by reacting with (R C O)2P(O)-CH2-R P The reaction is converted into a compound of formula (IIH), wherein each R C are independently optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl, and R P Is H or -COOH. The compound of formula (IIH) is: in Each R C is independently optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxy protecting group; and all remaining variables are as described for the compound of Formula (VIG).
[0334] The compound of formula (IIH) wherein X4 is oxo can be converted to the compound of formula (IIi) by reacting with the compound of formula (IIB) under Sakurai reaction conditions. The compound of formula (IIi) is: wherein all variables are as described for compounds of formula (IIH).
[0335] The compound of formula (IIi) can be combined with 10A -CH2-CH=CH2 or -(CH2)3-OP 10 to produce a compound of formula (VIGa): in R 10A -CH2-CH=CH2 or -(CH2)3-OP 10 , L7 is and all remaining variables are as described for the compound of formula (VIG).
[0336] where R 10A The compound of formula (VIGa) wherein R 10A -(CH2)3-OP 10 And P 10 The compound of formula (VIGa) is H. Hydroboration / oxidation reactions are known in the art. For example, 9-BBN or trimethylpropylborane (thexyl borane) can be used for R 10A Hydroboration of the alkali-containing ... 10 , and P 10 For H. R 10A -(CH2)3-OP 10 And P 10 The compound of formula (VIGa) where H is converted to the compound of formula (VIG).
[0337] Typically, the methods described herein involve performing an allylic reduction at C.25. This reaction can be performed at any time prior to the formation of the halichondrin macrolide or its analog. For example, an allylic reducing agent can be used to reduce the halichondrin macrolide to Convert to
[0338] C.12-C.13 bond formation macrocyclization In another method, the halichondrin macrolide or an analog thereof can be prepared from a compound of formula (VIIIB): in X1 is -CH2-, -CH(Y)-, -C(Y)2- or -O-, wherein each Y is independently -COOR C or-SO2R D ; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxyl protecting group; each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; Each R D when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; (i)R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R12 is H; (ii)R 10 is a hydroxyl protecting group, and R4 and R5 combine to form a double bond; or (iii)R 10 and R 11 Combine to form a bond, and R 12 is H; Each P9 and R 13 are independently hydroxy protecting groups; R M for in R5 is optionally substituted acyl; and X3 is oxo or X3 together with the carbon atom to which it is attached is -(CH(OP 11 ))-, where P 11 is H or a hydroxyl protecting group; and the remaining variables are as described for the halichondrin macrolide or analogs thereof.
[0339] Compounds of formula (VIIIB) can undergo ring-closing metathesis to produce compounds of formula (VIIIC): in A1 is H or -OP", wherein P" is H or a hydroxyl protecting group; L1 is wherein L2 and L3 combine to form a bond; and and the remaining variables are as described for the compound of Formula (VIIB).
[0340] Then, the halichondrin macrolide or an analog thereof is prepared from the compound of formula (VIIIC), for example according to the method described in WO 2016 / 179607.
[0341] In general, when forming compound (VIIIB), the fragments can be coupled in any order. For example, the C.O-C.1 or C.O.1 bond between fragment (IIA) and fragment (VIIIA) can be formed before or after the Sakurai and / or Prince reaction as described herein. Similarly, the installation of the C.13 olefin can be performed before or after any of the Sakurai, Prince, and C.O-C.1 or C.O.1 bond formation reactions.
[0342] In one embodiment, the compound of formula (VIIIB) is prepared from a compound of formula (VIIIA), a compound of formula (IIA), a compound of formula (IIB), a compound of formula (IIIC), and R5OH. The compound of formula (IIA) is: wherein R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; Each R D and R, when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; E -CHO or -CH (1+m) (OR F ) (2-m) ,in m is 1, and R F is a hydroxyl protecting group, or m is 0, and (i) Each R F are independently alkyl or hydroxy protecting groups, or (ii) Two Rs F Combine to form an alkylene group.
[0343] The compound of formula (VIIIA) is: in (i)R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (ii)R 10 is a hydroxyl protecting group, and R4 and R5 combine to form a double bond; or (iii)R 10 and R 11 Combine to form a bond, and R 12 is H; R9 is -CHO or -COOH; and Each P9 and R 13 are independently hydroxy protecting groups.
[0344] The compound of formula (IIIC) is: R 4C -R7, (IIIC) in R7 is -CHO or Each R 7A are independently optionally substituted alkyl; and R 4C for where R C is optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl; and P7, when present, is independently H or a hydroxy protecting group.
[0345] The compound of formula (IIB) is: where R S It is a silyl group.
[0346] In certain embodiments, the compound of formula (IIC) The compounds of formula (IIA) and (IIB) are prepared, for example, by reaction with a Lewis acid, such as an oxophilic Lewis acid (eg boron trifluoride or a solvate thereof).
[0347] Compounds of formula (IF): It can be prepared from a compound of formula (IIC), a compound of formula (IIIC) and R5OH, for example, by reaction with a Lewis acid, for example an oxophilic Lewis acid such as boron trifluoride or a solvate thereof (which may or may not be different from the Lewis acid used to react the compounds of formula (IIA) and (IIB)).
[0348] Compound of formula (IJ): Can be prepared from compounds of formula (IF). Reaction conditions known in the art can be used to convert compounds of formula (IF) into compounds of formula (IJ). For example, compounds of formula (IF) can be reacted with an allylic reducing agent to obtain compounds of formula (IJ). Non-limiting examples of allylic reducing agents are palladium complexes (e.g., Pd(PPh 3 ) 4 ) in combination with formate (e.g., trialkylammonium formate).
[0349] Compounds of formula (VIIIB) can be prepared from compounds of formula (VIIIA) and compounds of formula (IJ) described herein.
[0350] The preparation of the compound of formula (VIIIB) may comprise an esterification reaction between R1 (-OP6, wherein P6 is H) and R9 (-COOH). Alternatively, the preparation of the compound of formula (VIIIB) may comprise a reaction between R1 (-CH(Y)2 or -CH2(Y)) and R9 (-CHO) (e.g., under Claisen reaction conditions). The Claisen product (X4 together with the atom to which it is attached is -(CH(OP6)) is oxidized with an oxidizing agent capable of converting an alcohol to a carbonyl) is oxidized with an oxidizing agent capable of converting an alcohol to a carbonyl. 12 ))-, where P 12Further desulfonation or decarboxylation of the compound of formula (VIIIB) can produce a compound of formula (VIIIB) wherein X1 is -CH 2- .
[0351] Alternatively, a compound of formula (VIIIB) can be prepared from a compound of formula (IF) and a compound of formula (VIIIA). For example, a compound of formula (VIIID) can be prepared from a compound of formula (IF) and a compound of formula (VIIIA) using the methods described herein. The compound of formula (VIIID) is: in R M1 for R5 is an optionally substituted acyl group; P 13 is H or a hydroxyl protecting group; and the remaining variables are as described for the compound of formula (IF) and the compound of formula (VIIIB).
[0352] Alternatively, a compound of formula (VIIID) can be prepared from a compound of formula (IIC) and a compound of formula (VIIIA) as follows. The compound of formula (IIC) can be protected with a hydroxy protecting group to provide a compound of formula (IIJ): Among them, P 13 is a hydroxy protecting group, and the remaining variables are as described for the compound of Formula (IIC).
[0353] Compounds of formula (IIJ) can be reacted with compounds of formula (VIIIA) using the methods described herein to produce compounds of formula (VIIID), wherein R M1 for: Among them, P 13 It is a hydroxyl protecting group.
[0354] A compound of formula (VIIID) wherein R M1 for and P 13 is H, can be reacted with a compound of formula (IIIC) and R5OH under Prince reaction conditions to produce a compound of formula (VIIID), wherein R M1 for
[0355] Compounds of formula (VIIID) can also be prepared according to the following strategy. Compounds of formula (IIA) and compounds of formula (VIIIA) can be converted to compounds of formula (VIIIE) using the methods described herein. Compounds of formula (VIIIE) are: wherein all variables are as described for the compound of formula (VIIID) and the compound of formula (IIA).
[0356] A compound of formula (VIIID) wherein R M1 for Conversion to compounds of formula (VIIIB) can be as described herein.
[0357] Typically, the methods described herein involve performing an allylic reduction at C. 25. This reaction can be performed at any time prior to the formation of the halichondrin macrolide or its analog.
[0358] In certain embodiments, the method comprises using an allylic reducing agent to Convert to
[0359] In general, the C.12 olefin can be introduced at any time prior to the metathesis reaction by several routes. For example, if R 4C for Then it reacts with an allylic reducing agent to produce R 4C for A compound of the type 1,2-H ...
[0360] If R 4C for This compound can then be reduced with a 1,4-reducing agent (such as Stryker's reagent), and the product can be reduced with a 1,2-reducing agent (such as DIBAL-H) to produce the corresponding aldehyde, which can react with vinyl nucleophiles.
[0361] If R 4C for The compound can be reacted with a diol cleavage agent (e.g., NaIO4), (R C O)2P(O)-CH2-COOR C(Under Horner-Wadsworth-Emmons reaction conditions), a 1,4-reducing agent (e.g., Stryker's reagent) and a 1,2-reducing agent (e.g., DIBAL-H) are reacted to produce the corresponding aldehyde, which can react with a vinyl nucleophile. Vinyl nucleophiles are known in the art. Vinyl nucleophiles can be prepared in situ or in a separate reaction vessel. Reaction conditions for adding vinyl nucleophiles to carbonyl groups are known in the art.
[0362] Compounds of formula (VIIIC) can be formed by reacting a compound of formula (VIIIB) with an olefin metathesis catalyst.
[0363] Halichondrin macrolide can be prepared from compounds of formula (VIIIC) using reaction conditions known in the art and the reaction conditions described herein. For example, compounds of formula (VIIIC) can be reacted with a hydroxyl protecting group removing agent to produce a halichondrin macrolide.
[0364] Typically, the methods described herein involve performing an allylic reduction at C.25. This reaction can be performed at any time prior to the formation of the halichondrin macrolide or its analog. For example, an allylic reducing agent can be used to reduce the halichondrin macrolide to Convert to
[0365] C.13-C.14 bond formation macrocyclization In another method, a halichondrin macrolide or an analog thereof (eg, eribulin or a salt thereof (eg, eribulin mesylate)) can be prepared from a compound of formula (VIID): in (i)R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (ii)R 10 is a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (iii)R 10 and R 11 Combine to form a bond, and R 12 is H; X1 is -CH2-, -CH(Y)-, -C(Y)2- or -O-, wherein each Y is independently -COOR C or-SO2R D ; Each R Cis independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; Each R D when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxyl protecting group; A1 is H or -OP", wherein P" is H or a hydroxyl protecting group; Y1 is chlorine, bromine, iodine, trifluoromethanesulfonate or trialkylsilane; R 13 and each P9 is independently a hydroxy protecting group; R L for in R 18 is -CHO or -CH2OP7; R5 is optionally substituted acyl; and P7, when present, is independently H or a hydroxy protecting group; and the remaining variables are as described for the halichondrin macrolide or analogs thereof.
[0366] The compound of formula (VIID) is then converted to the compound of formula (VIIE): in L1 is Wherein L2 and L3 combine to form a bond; Each P9 is independently a hydroxy protecting group, and X3 is oxo or X3 together with the carbon atom to which it is attached is -(CH(OP 11 ))-, where P 11 is H or a hydroxyl protecting group; and the remaining variables are as described for the compound of Formula (VIID).
[0367] In certain embodiments, wherein R 18 Compounds of formula (VIID) that are -CHO are subjected to Nozaki-Hiyama-Kishi reaction conditions to produce compounds of formula (VIIE).
[0368] The compound of formula (VIIE) can then be converted to a halichondrin macrolide or an analog thereof using methods described herein and methods known in the art, such as those described in US 2009 / 0203771, US 2016 / 0264594, and WO 2016 / 179607.
[0369] In general, when forming compounds of Formula (VIID), the fragments can be coupled in any order. For example, the C.0-C.1 or C.0-1 bond in a compound of Formula (VIID) can be formed before or after a Sakurai and / or Prince reaction as described herein.
[0370] In some embodiments, a compound of Formula (VIID) is prepared from a compound of Formula (IIA), a compound of Formula (IIB), a compound of Formula (IIIC), and R5OH, wherein R5 is optionally substituted acyl.
[0371] The compound of formula (VIIA) is: in R9 is -CHO or -COOH; and The remaining variables are as described for the compound of Formula (VIID).
[0372] The compound of formula (IIA) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; Each R D when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; and R E -CHO or -CH (1+m) (OR F ) (2-m) , in m is 1, and R F is a hydroxyl protecting group, or m is 0, and (i) each R F are independently alkyl or hydroxy protecting groups, or (ii) two R F Combine to form an alkylene group.
[0373] The compound of formula (IIB) is: where R S It is a silyl group.
[0374] The compound of formula (IIIC) is: R 4C -R7, (IIIC) in R 4C for R7 is -CHO or Each R 7A are independently optionally substituted alkyl; and The remaining variables are as described for the compound of Formula (VIID).
[0375] The preparation of the compound of formula (VIID) comprises R E Sakurai reaction between (-CHO) and a compound of formula (IIB) to produce the structure This product can then be reacted with a compound of formula (IIIC) under Prince reaction conditions to produce a group of the following structure: This group can be converted to R as described herein. L .
[0376] If the stereochemistry of the secondary alcohol in the product of the Sakurai reaction is different from the desired stereochemistry, this group can be subjected to epimerization reaction conditions as described herein (e.g., oxidation followed by Corey-Bakshi-Shibata reduction; alternatively, a Mitsunobu reaction can be used to invert the stereocenter).
[0377] If R E -CH (1+m) (OR F ) (2-m) , then the preparation of the compound of formula (VIID) may also include the step of reacting the acetal under deprotection conditions, for example by reacting the acetal with R is converted by reaction with an aqueous acid solution (for example, when m is 0) or by oxidation with an oxidizing agent capable of converting an alcohol into a carbonyl group (for example, when m is 1). E Converted to -CHO.
[0378] The preparation of the compound of formula (VIID) may include an esterification reaction between R1 (-OP6, wherein P6 is H) and R9 (-COOH). Alternatively, the preparation of the compound of formula (VIID) may include a reaction between R1 (-CH(Y)2 or -CH2(Y)) and R9 (-CHO) (e.g., under Claisen reaction conditions). Further desulfonation or decarboxylation of the compound of formula (VIID) may produce a compound of formula (VIID) wherein X1 is -CH2-.
[0379] In some embodiments, the preparation of the compound of formula (VIID) comprises preparing the compound of formula (IIC) from the compound of formula (IIA) and the compound of formula (IIB) (e.g., under Sakurai reaction conditions). The compound of formula (IIC) is: wherein all variables are as described for compounds of formula (IIA).
[0380] A compound of formula (IIC) can be reacted with a compound of formula (IIB), a compound of formula (IIIC) and R5OH to produce a compound of formula (IF): wherein all variables are as described for the compound of formula (IIA), the compound of formula (IIIC), and R5OH.
[0381] The preparation of the compound of formula (IF) may comprise a Prins reaction between a compound of formula (IIC) and R5OH.
[0382] Compounds of formula (IF) can be converted to compounds of formula (IH): wherein all variables are as described for compounds of formula (IF).
[0383] Typically, the methods described herein involve performing an allylic reduction at C.25. This reaction can be performed at any time prior to the formation of the halichondrin macrolide or its analog. For example, an allylic reducing agent can be used to reduce the halichondrin macrolide to Convert to
[0384] In certain embodiments, a compound of Formula (IF) can be reacted with an allylic reducing agent to produce a compound of Formula (IH).
[0385] In the reactions described herein, the group R 4C The necessary transformations can be carried out using reaction conditions known in the art. 4C The transformation was as described herein.
[0386] C.15-C.16 bond formation macrocyclization In one approach, the macrocyclization reaction is a carbon-carbon bond-forming reaction (e.g., olefin metathesis) that provides a C.15-C.16 bond in a halichondrin macrolide or an analog thereof (e.g., eribulin or a salt thereof (e.g., eribulin mesylate)). The non-macrocyclic intermediate in the synthesis of a halichondrin macrolide or an analog thereof (e.g., eribulin or a salt thereof (e.g., eribulin mesylate)) can be a compound of formula (IVB).
[0387] The compound of formula (IVB) is: in Each P9 is independently a hydroxyl protecting group; (a1)R 10 is H or a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (a2)R 10 is H or a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (a3)R 10 and R 11 Combine to form a bond, and R 12 is H; (b1)A1 and R 14 Combined to form oxo, R 13 is H or a hydroxyl protecting group, and R 15 is H; or (b2) A1 is H or -OP", and: (i)R 13 is H or a hydroxyl protecting group, and R 14 and R 15 Combine to form a double bond; or (ii)R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; and (c1)R 16 is H, and P8 is H or a hydroxyl protecting group; or (c2)R 16 Combines with P8 to form a double bond; Each P" when present is independently H or a hydroxy protecting group X1 is -O-, -C(Y)2-, -CH(Y)- or -CH2-, wherein each Y is independently -COOR C or-SO2RD , where each R C When present, is independently optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl, and each R D when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; R G for in R5 is an optionally substituted acyl group, and X2 is H or -CH2-X 2A -CH2-CH=CH2, where X 2A -O-, -C(R H ) 2- or -NR I -, where each R H are independently H or -COOR J , R I is an N-protecting group, and R J C 1-6 alkyl; and X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxyl protecting group; and the remaining variables are as described for the halichondrin macrolide or analogs thereof.
[0388] In some embodiments, the compound of Formula (IVB) is a compound of Formula (IVBa): wherein all variables are as described for the compound of formula (IVB).
[0389] The compound of formula (IVB) (e.g., the compound of formula (IVBa)) is converted to the compound of formula (IVC) by olefin metathesis. The compound of formula (IVC) is: in L1 is Wherein L2 and L3 combine to form a bond; and the remaining variables are as described for the compound of formula (IVB).
[0390] The compound of formula (IVC) is then converted to the compound of formula (IVD): wherein A1 and A2 are each independently H or -OP", and the remaining variables are as described for the compound of formula (IVC).
[0391] Compounds of formula (IVC) can be converted to compounds of formula (IVD) using reaction conditions known in the art. For example, compounds of formula (IVC) can be reacted with a 1,4-reducing agent to give compounds of formula (IVD).
[0392] The preparation of the compound of formula (IVD) may also include making P8 and R 16 A compound of formula (IVA), (IVB) or (IVC) wherein R is H is reacted with an oxidizing agent capable of converting an alcohol to a carbonyl (e.g., a Dess-Martin periodinane or a dimethylsulfonium compound) to give a compound of formula (IVA), (IVB) or (IVC) wherein R 16 and P8 to form a double bond (e.g., a compound of formula IVCa). If P8 is a hydroxy protecting group, the compound of formula (IVA), (IVB) or (IVC) may be treated with a hydroxy protecting group removing agent prior to oxidation. In a non-limiting example, the preparation of the compound of formula (IVD) comprises oxidizing a hydroxy protecting group wherein P9 is H, R, or R with an oxidizing agent capable of converting an alcohol to a carbonyl group (e.g., Dess-Martin periodinane or a dimethylsulfonium compound). 16 A compound of formula (IVC) wherein H is obtained to obtain a compound of formula (IVCa): wherein all variables are as described for the compound of formula (IVC).
[0393] The compound of formula (IVD) is then converted to a halichondrin macrolide or an analog thereof using methods described herein and methods known in the art, such as those described in US 2016 / 0264594 and WO 2016 / 179607.
[0394] If the compound of formula (IVD) includes a hydroxy protecting group as R3 and / or P5, these hydroxy protecting groups can be removed with a hydroxy protecting group removing agent. For example, if the hydroxy protecting group is a silyl group, the hydroxy protecting group removing agent can be a fluoride source.
[0395] In the compound of formula (IVD), if each P9 is H and X3 is oxo, the synthesis may further comprise Acids (e.g., pKa 5±3 acid), for example, after reacting the compound of formula (IVD) with a hydroxy protecting group removing agent (for example, converting P9 from a hydroxy protecting group to H).
[0396] In the compound of formula (IVD), if X3 is oxo, R10 is a hydroxyl protecting group, and R 11 and R 12 Combined to form a double bond, treatment with a hydroxy protecting group removing agent can provide a compound of formula (IVD) wherein R 10 and R 11 combines to form a bond, and R 12 For H.
[0397] In general, when forming compound (IVB), the fragments can be coupled in any order. For example, the C.0-C.1 or C.0-1 bond between fragment (IIA) and fragment (IVA) can be formed before or after the Sakurai and / or Prince reaction as described herein. Similarly, the installation of the C.15 olefin can be performed before or after any of the Sakurai, Prince, and C.0-C.1 or C.0-1 bond formation reactions.
[0398] In certain embodiments, a compound of formula (IVB) is prepared from a compound of formula (IIA), a compound of formula (IIB), a compound of formula (IIIA), a compound of formula (IVA), and R50H.
[0399] The compound of formula (IVA) is: in R9 is -CHO or -COOH, and the remaining variables are as described for the compound of formula (IVB).
[0400] The compound of formula (IIA) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; R E -CHO or -CH (1+m) (OR F ) (2-m) , in m is 1, and R F is a hydroxyl protecting group, or m is 0, and (i) each R F are independently alkyl or hydroxy protecting groups, or (ii) two R F Combine to form an alkylene group; and the remaining variables are as described for the compound of formula (IVB).
[0401] The compound of formula (IIB) is: where R S It is a silyl group.
[0402] The compound of formula (IIIA) is: R 4A -R7, (IIIA) in R7 is -CHO or Each R 7A are independently optionally substituted alkyl; and R 4A for where R C is optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl, and each P7 is independently H or a hydroxy protecting group.
[0403] The preparation of the compound of formula (IVB) comprises R E Sakurai reaction between (-CHO) and a compound of formula (IIB) to produce the structure This product can then be reacted with a compound of formula (IIIA) under Prince reaction conditions to produce a group of the following structure: This group can be converted to R as described herein. G .
[0404] If the stereochemistry of the secondary alcohol in the product of the Sakurai reaction is different from the desired stereochemistry, this group can be subjected to epimerization reaction conditions as described herein (e.g., oxidation followed by Corey-Bakshi-Shibata reduction; alternatively, a Mitsunobu reaction can be used to invert the stereocenter).
[0405] If R E -CH (1+m) (OR F ) (2-m) , then the preparation of the compound of formula (IVB) may also include the step of reacting the acetal under deprotection conditions, for example, by reacting the acetal with R is converted by reaction with an aqueous acid solution (for example, when m is 0) or by oxidation with an oxidizing agent capable of converting an alcohol into a carbonyl group (for example, when m is 1). E Converted to -CHO.
[0406] R G The preparation may include making R4A reacting with a diol cleavage agent and reacting the resulting product with (R C O)2P(O)-CH2-COOR C The Horner-Wadsworth-Emmons reaction was performed to produce R 4A This reaction can be performed after the Sakurai and Prince reactions.
[0407] R G The preparation may further include R 4A The reaction with a 1,2-reducing agent and the resulting product reacted with an allylic halide or allylic pseudohalide. This reaction can be performed after the Sakurai and Prince reactions.
[0408] Before or after the reaction of the compound of formula (IIA) with the compound of formula (IVA), the group R E Can be converted to R G For example, as described herein, prior to the reaction of the compound of formula (IIA) with the compound of formula (IVA), R E Convert to R G This can be done by compounds of formula (IB) and (IC). After the reaction of the compound of formula (IIA) with the compound of formula (IVA), R E Convert to R G This can be done by compounds of formula (IVAa): in X1 is -CH2-, -CH(Y)-, -C(Y)2- or -O-, wherein each Y is independently -COOR C or-SO2R D ; Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; Each R D when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxy protecting group; and the remaining variables are as described for compounds of Formula (IIA) and (IVA).
[0409] where R EA compound of formula (IVAa) that is -CHO can be reacted with a compound of formula (IIB) under Sakurai reaction conditions to produce a compound of formula (IVAb): wherein all variables are as described for compounds of Formula (IVAa).
[0410] The compound of formula (IVAc) can be prepared from the compound of formula (IVAb), the compound of formula (IIIA) and R5OH. The compound of formula (IVAc) is: in R G1 for R5 is an optionally substituted acyl group, and The remaining variables are as described for the compound of formula (IVAb).
[0411] For example, a compound of formula (IVAb) can be reacted with a compound of formula (IIIA) and R5OH under Prince reaction conditions to produce a compound of formula (IVAc) wherein R G1 for
[0412] Compounds of formula (IVAc) can be converted to compounds of formula (IVB) as described herein.
[0413] If the compound described herein (e.g., a Prince reaction product) comprises: The synthesis may also include reacting this compound with an allylic reducing agent to produce the radical
[0414] A non-limiting example of an allylic reducing agent is a palladium complex (eg, Pd(PPh3)4) in combination with a formates (eg, trialkylammonium formates).
[0415] Alternatively, the preparation of the compound of formula (IVB) may comprise preparing the compound of formula (IA) from the compound of formula (IIA), the compound of formula (IIIA) and R5OH. The compound of formula (IA) is: wherein all variables are as described for the compound of formula (IIA), the compound of formula (IIIA), and R5OH.
[0416] A compound of formula (IA) can be reacted with a compound of formula (IVA) to form a compound of formula (IVB). For example, a compound of formula (IA) can be converted to a compound of formula (IB), which can then be converted to a compound of formula (IC). The compound of formula (IB) is: wherein all variables are as described for compounds of formula (IA).
[0417] The preparation of the compound of formula (IB) may comprise reacting the compound of formula (IA) with an allylic reducing agent.
[0418] The compound of formula (IC) is: wherein X2 is as described for the compound of formula (IVB), and the remaining variables are as described for the compound of formula (IB).
[0419] Compounds of formula (IVB) can be prepared from compounds of formula (IC) and compounds of formula (IVA) described herein.
[0420] The preparation of compounds of formula (IVB) wherein X1 is -C(Y)2-, -CH(Y)- or -CH2- may comprise the use of a reaction between an intermediate (e.g., a compound of formula (IVA) wherein R9 is -CHO) and another intermediate (e.g., a compound of formula (IIA), (IA), (IB) or (IC) wherein R1 is -CH(Y)2 or -CH2(Y)). The reaction is treated with a base to produce an intermediate (e.g., a compound of formula (IVB) wherein X1 is -C(Y)2-, -CH(Y)-, or -CH2-). If X1 in the compound of formula (IVB) is -CH 2- , the preparation of the compound of formula (IVB) may further include desulfonation or decarboxylation reaction.
[0421] Alternatively, preparation of a compound of formula (IVB) wherein X1 is -O- may comprise a reaction (e.g., an esterification reaction) between one intermediate (e.g., a compound of formula (IVA) wherein R9 is -COOH) and another intermediate (e.g., a compound of formula (IIA), (IA), (IB), or (IC) wherein R1 is -OP6, wherein P6 is H) to produce the intermediate (e.g., a compound of formula (IVB) wherein X1 is -O-).
[0422] The preparation of certain compounds of formula (IVB) or (IVC) may also include wherein A1 is H and R 14 and R 15The compound of formula (IVB) or (IVC) that is combined to form a double bond is converted to the compound of formula (IVB) or (IVC), respectively, wherein R 14 In a non-limiting example, a nucleophilic peroxide reagent, such as tert-butyl hydroperoxide, can be used to form an oxo group. 14 and R 15 The enone in the compound of formula (IVB) or (IVC) that is bound to form a double bond is converted to a C.12-C.13 epoxide, which can then be converted to a compound wherein A1 and R 14 Compounds of formula (IVB) or (IVC) can be combined to form oxo-groups (see, for example, Muzart, J., Eur. J. Org. Chem., 4717-4741, 2011). Thus, compounds of formula (IVB) or (IVC) wherein A1 is OP" can be prepared. Other transformations can involve α-oxidation to produce compounds of formula (IVB) or (IVC) wherein R 15 For OP".
[0423] Typically, the methods described herein involve performing an allylic reduction at C.25. This reaction can be performed at any time prior to the formation of the halichondrin macrolide or its analog. For example, an allylic reducing agent can be used to reduce the halichondrin macrolide to Convert to
[0424] C.19-C.20 bond formation macrocyclization In another approach, the macrocyclization reaction can be a carbon-carbon bond forming reaction (e.g., olefin metathesis) that provides a C.19-C.20 bond in a halichondrin macrolide or an analog thereof (e.g., eribulin or a salt thereof (e.g., eribulin mesylate)). The non-macrocyclic intermediate in the synthesis of a halichondrin macrolide or an analog thereof (e.g., eribulin or a salt thereof (e.g., eribulin mesylate)) can be a compound of formula (VB).
[0425] The compound of formula (VB) is: in a specifies an (R)-stereocenter, and Z is sulfonate, chloro, bromo, or iodo; or a specifies an (S)-stereocenter, and Z is OR 16 , where R 16 is a hydroxyl protecting group; X1 is -CH2-, -CH(Y)-, -C(Y)2- or -O-, wherein each Y is independently -COOR C or-SO2R D ; Each P9 is independently a hydroxy protecting group, and X3 is oxo; or two P9 groups and X3, together with the atoms to which they are attached, combine to form a ketal; Y1 is iodine, bromine or triflate; Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; Each R D when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; R K for wherein R5 is an optionally substituted acyl group; (a1)R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (a2)R 10 is a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (a3)R 10 and R 11 Combine to form a bond, and R 12 is H; (b1)A1 and R 14 Combined to form oxo, R 13 is a hydroxyl protecting group, and R 15 is H; or (b2) A1 is H or -OP", and: (i)R 13 is a hydroxyl protecting group, and R 14 and R 15 Combine to form a double bond; or (ii)R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; Each P" is independently a hydroxy protecting group; and the remaining variables are as described for the halichondrin macrolide or analogs thereof.
[0426] The compound of formula (VB) is then converted into a compound of formula (VC) using reaction conditions known in the art. For example, the compound of formula (VB) can be subjected to Nozaki-Hiyama-Kishi reaction conditions known in the art to produce a compound of formula (VC). The Nozaki-Hiyama-Kishi reaction of the compound of formula (VB) can include reacting the compound of formula (VB) with a Cr(II) salt and a Ni(II) salt. An auxiliary ligand can be used in conjunction with a metal salt. In a non-limiting example, a substituted 1,10-phenanthroline can be used in conjunction with a Ni(II) salt. A chiral auxiliary ligand can be used to make the reaction stereoselective. In a non-limiting example, a chiral N-(dihydrooxazolyl-phenyl)-sulfonamide can be used with a Cr(II) salt to control the stereochemistry of the carbonyl carbon, to which a vinyl nucleophile is added during the Nozaki-Hiyama-Kishi reaction.
[0427] The compound of formula (VC) is: in L1 is Wherein L2 and L3 combine to form a bond; b specifies the (S)-stereocenter if a specifies the (R)-stereocenter; and b specifies the (R)-stereocenter if a specifies the (S)-stereocenter; and the remaining variables are as described for the compound of formula (IVB).
[0428] The compound of formula (VC) is then converted to a halichondrin macrolide or an analog thereof using methods described herein and methods known in the art, such as those described in US 2016 / 0264594, US 2009 / 0203771, and WO 2016 / 179607.
[0429] Compounds of formula (VC) (wherein Z is OR 16 , R 16 is a hydroxy protecting group ester, a designates the (S)-stereocenter, and b designates the (R)-stereocenter) can be converted to a compound of formula (VD): where a designates the (S)-stereocenter, b designates the (R)-stereocenter, and Z is OR 16 , where R 16 is a hydroxyl protecting group (e.g., R 16 Together with the atoms to which they are attached, they form an ester), R His sulfonyl, and the remaining variables are as described for the compound of Formula (VC).
[0430] Compounds of formula (VC) (wherein Z is OR 16 , R 16 is a hydroxy protecting group ester, a designates the (S)-stereocenter, and b designates the (R)-stereocenter) can be converted to a compound of formula (VD), for example, by reaction with a sulfonyl electrophile such as sulfonyl chloride or sulfonyl anhydride. In the compound of formula (VD), the hydroxy protecting group in Z can be removed, resulting in the formation of a C.16-C.20 furan ring in the structure of the halichondrin macrolide or its analogue (e.g., eribulin or its salt (e.g., eribulin mesylate)). In a non-limiting example, the concomitant removal of the hydroxy protecting group in Z (e.g., if Z is an ester) and the formation of a C.16-C.20 furan ring in the structure of the halichondrin macrolide or its analogue can be achieved by treatment with a strong base (e.g., C 1-6 This is achieved by treating a compound of formula (VD) with an alkoxide (e.g., KOMe).
[0431] Compounds of formula (VB) (wherein Z is sulfonate, chlorine, bromine or iodine, a designates the (S)-stereocenter, and b designates the (R)-stereocenter) can be converted to a halichondrin macrolide or an analog thereof (e.g., eribulin or a salt thereof (e.g., eribulin mesylate)) during the direct formation of compounds of formula (VC), for example, during post-reaction workup and / or purification (e.g., on silica gel).
[0432] If the compound of formula (VD) includes hydroxy protecting groups as R3 and / or P5, these hydroxy protecting groups can be removed with a hydroxy protecting group removing agent. For example, if the hydroxy protecting group is a silyl group, the hydroxy protecting group removing agent can be a fluoride source.
[0433] In the compound of formula (VC), if each P9 is H and X3 is oxo, the synthesis may further comprise Acids (e.g., pKa 5±3 acid), for example after formation of the C.16-C.20 furan ring.
[0434] In the compounds of formula (VC), (VD) or their C.16-C.20 furan cyclization products, if X3 is oxo, R 13 is a hydroxyl protecting group, and R 14 and R 15 Combined to form a double bond, treatment with a hydroxy protecting group removal agent can provide a compound of formula (VC), (VD) or its C.16-C.20 furan cyclization product, wherein R 13 and R 14 Combine to form a bond, and R 15 For H.
[0435] The preparation of halichondrin macrolide or its analogues can further comprise the steps of: reacting a compound of formula (VC), (VD) or a C.16-C.20 furan cyclization product thereof (wherein A1 is H, and R 14 and R 15 Combined to form a double bond) are respectively converted into compounds of formula (VC), (VD) or their C.16-C.20 furan cyclization products, wherein R 14 In a non-limiting example, the enone in the compound of formula (VC), (VD) or its C.16-C.20 furan cyclization product (wherein X3 is oxo, and R 14 and R 15 The epoxides can be converted to C.12-C.13 epoxides using nucleophilic peroxide reagents (e.g., tert-butyl hydroperoxide), which can then be converted to compounds of formula (VC), (VD), or C.16-C.20 furan cyclization products thereof using methods known in the art, such as by reaction with a bidentate phosphine ligand and a Pd(0) source. 14 Combined to form an oxo group (see, for example, Muzart, J., Eur. J. Org. Chem., 4717-4741, 2011). Thus, compounds of formula (VC), (VD) or C.16-C.20 furan cyclization products thereof, wherein A1 is OP", can be prepared. Other transformations may include α-oxidation to produce compounds of formula (VC), (VD) or C.16-C.20 furan cyclization products thereof, wherein R 15 For OP".
[0436] In general, when forming compound (VB), the fragments can be coupled in any order. For example, a C.0-C.1 or C.0-1 bond can be formed between fragment (IIA) and fragment (VA) before or after a Sakurai and / or Prince reaction, as described herein.
[0437] In some embodiments, a compound of formula (VB) is prepared from a compound of formula (IIA), a compound of formula (IIB), a compound of formula (IIIB), and R5OH, wherein R5 is optionally substituted acyl.
[0438] The compound of formula (VA) is: in R9 is -CHO or -COOH; and the remaining variables are as described for the compound of Formula (VB).
[0439] The compound of formula (IIA) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; Each R D when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; R E -CHO or -CH (1+m) (OR F ) (2-m) , in m is 1, and R F is a hydroxyl protecting group, or m is 0, and (i) each R F are independently alkyl or hydroxy protecting groups, or (ii) two R F Combine to form an alkylene group; and the remaining variables are as described for the compound of Formula (VB).
[0440] The compound of formula (IIB) is: where R S It is a silyl group.
[0441] The compound of formula (IIIB) is: R 4B -R7, (IIIB) in R7 is -CHO or Each R 7A are independently optionally substituted alkyl, and R 4B is but-3-en-1-yl, wherein each P7 is independently H or a hydroxyl protecting group.
[0442] The preparation of the compound of formula (VB) comprises R E Sakurai reaction between (-CHO) and a compound of formula (IIB) to produce the structure This product can then be reacted with a compound of formula (IIIB) under Prince reaction conditions to produce a group of the following structure: This group can be converted to R as described herein. K .
[0443] If the stereochemistry of the secondary alcohol in the product of the Sakurai reaction is different from the desired stereochemistry, this group can be subjected to epimerization reaction conditions as described herein (e.g., oxidation followed by Corey-Bakshi-Shibata reduction; alternatively, a Mitsunobu reaction can be used to invert the stereocenter).
[0444] If R E -CH (1+m) (OR F ) (2-m) , then the preparation of the compound of formula (VB) may also include the step of acetal deprotection, for example, by reacting with R is converted by reaction with an aqueous acid solution (for example, when m is 0) or by oxidation with an oxidizing agent capable of converting an alcohol into a carbonyl group (for example, when m is 1). E Converted to -CHO.
[0445] When R 4B When but-3-en-1-yl is present, the preparation of the compound of formula (VB) comprises converting but-3-en-1-yl into -(CH2)2-CHO. For example, but-3-en-1-yl may be reacted with a dihydroxylating agent to produce R 4B and cleaved using a diol cleavage agent.
[0446] When R 4B for When the compound of formula (VB) is prepared, Conversion to -(CH2)2-CHO, for example, by reaction with an oxidizing agent capable of converting the alcohol to a carbonyl group.
[0447] When R 4B for When the compound of formula (VB) is prepared, Conversion to -(CH2)2-CHO, for example using a diol splitting agent.
[0448] If at least one P7 in the compound of formula (IIIB) is a hydroxy protecting group, the preparation of the compound of formula (VB) may further comprise treatment with a hydroxy protecting group removing agent.
[0449] Before or after the reaction of the compound of formula (IIA) with the compound of formula (VA), the group R E Can be converted to R K For example, as described herein, prior to reacting the compound of formula (IIA) with the compound of formula (VA), RE Convert to R K This can be done by compounds of formula (ID) and (IE). After the reaction of the compound of formula (IIA) with the compound of formula (VA), R E Convert to R K This can be done via compounds of formula (VAa): wherein all variables are as described for compounds of formula (IIA) and (VA).
[0450] Compounds of formula (VAa) can be reacted with compounds of formula (IIB) under Sakurai reaction conditions to produce compounds of formula (VAb): wherein all variables are as described for compounds of formula (VA).
[0451] The compound of formula (VAc) can be prepared from the compound of formula (VAb), the compound of formula (IIIB) and R5OH by the Prince reaction. The compound of formula (VAc) is: in R K1 for and the remaining variables are as described for the compound of formula (VA) and the compound of formula (IIIB).
[0452] Compounds of formula (VAc) can be converted to compounds of formula (VB) as described herein.
[0453] In a particular embodiment, the Sakurai reaction product is a compound of formula (IIC): wherein all variables are as described for compounds of formula (IIA).
[0454] In certain embodiments, the Prince reaction product is a compound of formula (ID): wherein all variables are as described for the compound of formula (IIA), the compound of formula (IIIB) and R5OH.
[0455] In a further embodiment, a compound of formula (IE) can be prepared from a compound of formula (ID) (e.g., by reacting a compound of formula (ID) with an allylic reducing agent to produce a compound of formula (IE)). The compound of formula (IE) is: wherein all variables are as described for compounds of formula (ID).
[0456] As described herein, a compound of formula (IE) can be reacted with a compound of formula (VA) to produce a compound of formula (VB).
[0457] The preparation of compounds of formula (VB) wherein X1 is -C(Y)2-, -CH(Y)- or -CH2- may comprise the use of a reaction between an intermediate (e.g., a compound of formula (VA) wherein R9 is -CHO) and another intermediate (e.g., a compound of formula (IIA), (ID), (IIC) or (IE) wherein R1 is -CH(Y)2 or -CH2(Y)-). The reaction of the base treatment to produce an intermediate (e.g., a compound of formula (VB) wherein X 1 is -C(Y) 2 -, -CH(Y)- or -CH 2 -). If X 1 in the compound of formula (VB) is -CH 2 -, the preparation of the compound of formula (VB) may further include a desulfonation or decarboxylation reaction.
[0458] Alternatively, preparation of a compound of formula (VB) wherein X1 is -O- may comprise a reaction (e.g., an esterification reaction) between one intermediate (e.g., a compound of formula (VA) wherein R9 is -COOH) and another intermediate (e.g., a compound of formula (IIA), (ID), (IIC), or (IE) wherein R1 is -OP6, wherein P6 is H) to produce the intermediate (e.g., a compound of formula (VB) wherein X1 is -O-).
[0459] Typically, the methods described herein involve performing an allylic reduction at C.25. This reaction can be performed at any time prior to the formation of the halichondrin macrolide or its analog. For example, an allylic reducing agent can be used to reduce the halichondrin macrolide to Convert to
[0460] C.23-C.24 macrocyclization In another method, the halichondrin macrolide or its analogs can be prepared from the compound of formula (IXB): Wherein X1 is -CH2-, -CH(Y)-, -C(Y)2- or -O-, and each Y is independently -COOR C or-SO2R D ; Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; Each R Dwhen present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; L1 is Wherein L2 and L3 combine to form a bond; R5 is an optionally substituted acyl group; A1 and R 14 Combined to form oxo, R 13 is H or a hydroxyl protecting group, and R 15 is H; or A1 is H or -OP", and (i) R 13 is H or a hydroxyl protecting group, and R 14 and R 15 Together with the atoms to which they are attached, they form double bonds; or (ii)R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; each P9 is independently H or a hydroxyl protecting group, X3 is oxo, or X3 and the atom to which it is attached combine to form -(CH(OP 11 ))-, where P 11 is H or a hydroxy protecting group; or two P9 and X3 are combined with the atoms to which they are attached to form a ketal; and R 19A is H, -OP" or Y, and R 19B H; or R 19A and R 19B Together with the atoms to which they are attached they form double bonds.
[0461] The compound of formula (IXB) can be prepared from a compound of formula (IXA), a compound of formula (IIB), a compound of formula (IIA), a compound of formula (IIIE) and R5OH. The compound of formula (IXA) is: in R9 is -CHO or -COOP"; (a1)R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (a2)R 10 is a hydroxyl protecting group, and R 11 and R 12 Combined to form a double bond; or (a3) R 10 and R 11 Combine to form a bond, and R 12 is H; A1 and R 14 Combined to form oxo, R 13 is H or a hydroxyl protecting group, and R 15 is H; or A1 is H or -OP", and: (i)R 13 is H or a hydroxyl protecting group, and R 14 and R 15 Combine to form a double bond; or (ii)R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; R O is -CHO, -CH2OP”, -CH=CH2, -CH(OP”)CH2OP”, -C(O)-CH2P(O)(OR C )2 or halogen; Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; Each P" is independently H or a hydroxy protecting group; and Each P9 is independently a hydroxy protecting group.
[0462] The compound of formula (IIA) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; Each R D when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; R E -CHO or -CH (1+m) (OR F ) (2-m) ,in m is 1, and R F is a hydroxyl protecting group, or m is 0, and (i) Each R F are independently alkyl or hydroxy protecting groups, or (ii) Two Rs F Combine to form an alkylene group.
[0463] The compound of formula (IIIE) is: R 4E -R7, (IIIE) where R 4E for wherein each P7 is independently H or a hydroxy protecting group; and R8 is -CH2CH2-COOR C 、-CH=CH-COOR C 、-CH2CH2-SO2R D or -CH=CH-SO2R D ;and R7 is -CHO or Each R 7A is independently optionally substituted alkyl.
[0464] The compound of formula (IIB) is: where R S It is a silyl group.
[0465] In some embodiments, the compound of formula (IXB) is prepared according to the following strategy. For example, the compound of formula (IXC) can be prepared from the compound of formula (IXA), the compound of formula (IIA) (wherein R E -CH (1+m) (OR F ) (2-m) ), a compound of formula (IIB) and R5OH are prepared as follows. A compound of formula (IXA) can be reacted with a compound of formula (IIA) to produce a compound of formula (IXC): in X1 is -CH2-, -CH(Y)-, -C(Y)2- or -O-; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxy protecting group; and the remaining variables are as described for the compound of Formula (IXA) and the compound of Formula (IIA).
[0466] The preparation of the compound of formula (IXC) may comprise an esterification reaction between R1 (-OP6, wherein P6 is H) and R9 (-COOP", wherein P" is H). Alternatively, the preparation of the compound of formula (IXC) may comprise a reaction between R1 (-CH(Y)2 or -CH2(Y)) and R9 (-CHO) (e.g., under Claisen reaction conditions). In addition, wherein X4 together with the atom to which it is attached is -(CH(OP 12 ))-and where P 12 Compounds of formula (IXC) wherein X is H can be oxidized to produce compounds of formula (IXC) wherein X is oxo. Reaction conditions useful for such oxidations are known in the art. Further desulfonation or decarboxylation of compounds of formula (IXC) can produce compounds of formula (IXC) wherein X is -CH-.
[0467] Compounds of formula (IXC) can be converted to compounds of formula (IXD): in R7 is -CHO, -CH2OP A or and The remaining variables are as described for the compound of formula (IXB).
[0468] The compound of formula (IXD) can be prepared from the compound of formula (IXC) and the compound of formula (IIIE) as follows. The compound of formula (IIIE) can be converted into the compound of formula (IIIF): R 4F -R7, (IIF) where R 4F for Where R8 is -CH2CH2-COOR C or -CH2CH2-SO2R D ;and R7 is -CHO or Each R 7A is independently optionally substituted alkyl.
[0469] R 4E A diol cleavage agent can be used to convert the 4F
[0470] R8(-CH=CH-COOR C or -CH=CH-SO2R D) can react with a 1,4-reducing agent to produce R8(-CH2CH2-COOR C or -CH2CH2-SO2R D ).
[0471] R 4E Can react with allylic reducing agents to produce It can be reduced with a 1,2-reducing agent to produce R 4F
[0472] The compound of formula (IXE) can be prepared from the compound of formula (IIIF) and the compound of formula (IXC). The compound of formula (IXE) is: wherein all variables are as described for the compound of formula (IXC) and the compound of formula (IXD).
[0473] R 4F Where R8 is -CH2CH2-COOR C or -CH2CH2-SO2R D ) can be combined with R O (-CHO) under Claisen reaction conditions. This reaction can produce a compound of formula (IXE) wherein R 19A is Y.
[0474] R 4F Can be used with halogen R O The reaction is carried out under Nozaki-Hiyama-Kishi reaction conditions. The reaction can produce a compound of formula (IXE) wherein X3 and the atom to which it is attached combine to form -(CH(OP 11 ))-, where P 11 For H.
[0475] R 4F Can be combined with R0(-C(O)-CH2P(O)(OR C ) 2) reacting under Horner-Wadsworth-Emmons reaction conditions. This reaction can produce a compound of formula (IXE), wherein R 19A and R 19B Together with the atoms to which they are attached they form double bonds.
[0476] Compounds of formula (IXE) can be converted to compounds of formula (IXD) by reaction with compounds of formula (IIB) under Sakurai reaction conditions.
[0477] Compounds of formula (IXD) wherein R7 is -CHO can be reacted with R5OH under Prince reaction conditions to produce compounds of formula (IXB) wherein L1 is:
[0478] In a further embodiment, the compound of formula (IXD) may be prepared by making R E It is prepared by reacting a compound of formula (IXC) wherein -CHO is -CHO with a compound of formula (IIB) to produce a compound of formula (IXF): Among them, P 13 is H or a hydroxy protecting group; and the remaining variables are as described for the compound of Formula (IXC).
[0479] The compound of formula (IXD) can be prepared from the compound of formula (IXF) and the compound of formula (IIIF) described herein. The preparation of the compound of formula (IXD) can also include the addition of a P-hydroxy protecting group to the 13 P converted into H 13 .
[0480] In another embodiment, the compound of formula (IXD) can be prepared as follows. The compound of formula (IXG) can be prepared from the compound of formula (IXA) and the compound of formula (IIIF) using the methods described herein. The compound of formula (IXG) is: wherein all variables are as described for compounds of formula (IXD) and compounds of formula (IXA).
[0481] Compounds of formula (IXE) can be prepared from compounds of formula (IXG) and compounds of formula (IIA) using methods described herein. Compounds of formula (IXD) are then prepared from compounds of formula (IXE) as described herein.
[0482] Compounds of formula (IXD) can be prepared from compounds of formula (IXG) and compounds of formula (IIC). For example, compounds of formula (IIC) can be protected with a hydroxy protecting group to produce compounds of formula (IIJ): Among them, P 13 is a hydroxy protecting group, and the remaining variables are as described for the compound of Formula (IIC).
[0483] Compounds of formula (IXD) can be prepared from compounds of formula (IIJ) and compounds of formula (IXG) using the methods described herein.
[0484] Generally, the methods described herein may comprise making R E Reacting with a compound of formula (IIB) and a first Lewis acid (e.g., an oxophilic Lewis acid) to produce a group of the structure: It can react with R7, R5OH and a second Lewis acid (e.g., an oxophilic Lewis acid) (same or different from the first Lewis acid) to produce a group of the following structure:
[0485] In other embodiments, R1 that is -OP6 reacts with R9 under esterification reaction conditions to produce a group of structure -X1-C(O)-, wherein P6 is H, R9 is -COOH, and X1 is -O-. Alternatively, R1 that is -CH(Y)2 or -CH2(Y) reacts with R9 under Claisen reaction conditions to produce a group of structure -X1-C(O)-, wherein R9 is -CHO, and X1 is -C(Y)2- or -CH(Y)-.
[0486] Compounds of formula (IXB) can also be obtained using the methods and compounds described in PCT / US17 / 40401.
[0487] Typically, the methods described herein include performing an allylic reduction at C.25. This reaction can be performed at any time before the formation of the halichondrin macrolide or its analog. In certain embodiments, the compound of formula (IXB) is reacted with an allylic reducing agent to produce halichondrin or its analog.
[0488] Typically, the methods described herein involve performing an allylic reduction at C.25. This reaction can be performed at any time prior to the formation of the halichondrin macrolide or its analog. For example, an allylic reducing agent can be used to reduce the halichondrin macrolide to Convert to
[0489] Compounds of formula (Z) and (Z8) In the syntheses described herein, compounds of formula (Z) and (Z8) can be used as compounds of formula (III).
[0490] Compounds of formula (Z) The compound of formula (Z) is: Wherein R7 is -CHO or and Each R 7A are independently an alkyl or hydroxy protecting group; or Two R's 7A Combined to form an optionally substituted alkylene group.
[0491] Compounds of formula (Z) can be prepared as described herein. For example, a compound of formula (Z2) can be prepared from a compound of formula (Z1) and (where each R 19 are independently optionally substituted alkyl).
[0492] The compound of formula (Z1) is: in Each R 20A are independently a hydroxy protecting group, or two R 20A Together with the atoms to which they are attached, they form an acetal, ketal, cyclic carbonate, dicarbonyl-dioxy group, or silylene-dioxy group; Each R 20B are independently a hydroxy protecting group, or two R 20B Together with the atoms to which they are attached, they form an acetal, ketal, cyclic carbonate, dicarbonyl-dioxy group, or silylene-dioxy group; P 12A is H; P 12B is H or a hydroxyl protecting group.
[0493] The compound of formula (Z2) is: wherein all variables are as described for compounds of formula (Z1).
[0494] The compound of formula (Z1) can be The reaction is carried out under Horner-Wadsworth-Emmons reaction conditions to produce a compound of formula (Z2).
[0495] The compound of formula (Z3) can be prepared by combining the compound of formula (Z2) and (where each R 21 The compound of formula (Z3) is: wherein all variables are as for compounds of formula (Z2) and As stated.
[0496] The compound of formula (Z2) can be The reaction is carried out under Horner-Wadsworth-Emmons reaction conditions to produce a compound of formula (Z3).
[0497] Compounds of formula (Z3) can be converted to compounds of formula (Z4): wherein X5 is a halogen, and The remaining variables are as described for compounds of formula (Z3).
[0498] As described herein, the free hydroxyl group in the compound of formula (Z3) can be substituted by halogen (e.g., iodine). The reaction conditions for halogen substitution with halogen are known in the art. In non-limiting examples, the compound of formula (Z3) can be reacted with a sulfonyl anhydride (e.g., trifluoromethanesulfonic anhydride or methanesulfonic anhydride) to produce a corresponding sulfonate (e.g., trifluoromethanesulfonic acid ester or methanesulfonic acid ester), which, when reacted with a halide source (e.g., alkali metal iodide), can produce a compound of formula (Z4).
[0499] Compounds of formula (Z4) can be converted to compounds of formula (Z5): wherein all variables are as described for compounds of formula (Z4).
[0500] The compound of formula (Z4) can be subjected to reducing metal conditions to produce a compound of formula (Z5). Reducing metal conditions are known in the art. In a non-limiting example, the compound of formula (Z4) can be reacted with a metal capable of inserting a carbon-halogen bond (e.g., Zn(0) or an alkyllithium (e.g., t-BuLi)) and When the metal is Zn(0), The acid is a component of the reaction mixture. When the reaction is carried out with an alkyl lithium, the addition Acid is added to quench the reaction.
[0501] The compound of formula (Z5) can be combined with R 7A OH to produce a compound of formula (Z6): (Z6) where R 7A As described for compounds of formula (Z).
[0502] The compound of formula (Z5) can be combined with R 7A OH in The reaction is carried out in the presence of an acid to produce a compound of formula (Z6).
[0503] The compound of formula (Z7) can be prepared by combining the compound of formula (Z6) and (where each R 22 (wherein Z7 is an optionally substituted alkyl radical) is reacted. wherein all variables are as for compounds of formula (Z) and As stated.
[0504] Compounds of formula (Z6) can be reacted with a diol cleavage agent to produce the aldehyde (Z6A): wherein all variables are as described for compounds of formula (Z5).
[0505] Aldehyde (Z6A) can be reacted with (where each R 22 is independently optionally substituted alkyl) under Horner-Wadsworth-Emmons reaction conditions to produce a compound of formula (Z7).
[0506] Compounds of formula (Z) can be prepared from compounds of formula (Z7). In a non-limiting example, a compound of formula (Z7) can be reacted with a 1,4-reducing agent to produce a compound of formula (Z).
[0507] Compound of formula (Z8) The compound of formula (Z8) is: in R7 is -CHO or and Each R 7A are independently an alkyl or hydroxy protecting group; or Two R's 7A Combined to form an optionally substituted alkylene group; R8 is -CH2CH2-COOR C , -CH=CH-COOR C , -CH2CH2-SO2R D or -CH=CH-SO2R D ; R C and R, when present, is independently optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; D Where present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl.
[0508] Compounds of formula (Z8) can be prepared from compounds of formula (Z5) as follows.
[0509] The compound of formula (Z5) can be combined with R 7A OH in The reaction is carried out in the presence of an acid to produce a compound of formula (Z5A): in P 20A is H or a hydroxyl protecting group; Each R 20B are independently H or a hydroxyl protecting group, or two R 20B Together with the atoms to which they are attached, they form an acetal, a ketal, a cyclic carbonate, a dicarbonyl-dioxy group, or a silylene-dioxy group; and All remaining variables are as described for compounds of formula (Z8).
[0510] Compounds of formula (Z5A) can be converted to compounds of formula (Z5B): in R 23 H or -OR 20A ;and All other variables are as described for compounds of formula (Z8). 20B Compounds of formula (Z5A) where both are H can be reacted with a diol cleavage agent to produce compounds of formula (Z5B). 20A Converted into a compound of formula (Z5B) (R 23 H) can be deoxygenated using allylic methods known in the art, for example, when R 20A When it is a hydroxy protecting group, i.e., an ester, an allyl reducing agent is used. Alternatively, when R 20A When H is present, deoxygenation reactions known in the art can be used to convert -OR 20A Convert to H. Deoxygenation reactions are known in the art, such as Barton-McCombie deoxygenation and its tin-free form (see, for example, Chenneberg and Ollivier, Chimia, 70: 67-76, 2016). Replace -OR with H 20A The reaction can be carried out before or after diol cleavage.
[0511] The compound of formula (Z5B) can be prepared by (where each R 22 is independently optionally substituted alkyl) under Horner-Wadsworth-Emmons reaction conditions to convert to wherein R8 is -CH=CH-COOR C or -CH=CH-SO2R D A compound of formula (Z8) wherein R8 is -CH=CH-COOR C or -CH=CH-SO2R D The compound of formula (Z8) can be converted into wherein R8 is -CH2CH2-COOR by reaction with a 1,4-reducing agent C or -CH2CH2-SO2R D The compound of formula (Z8) is replaced by H.20A The reaction can be carried out before or after the Horner-Wadsworth-Emmons reaction and / or the reaction with the 1,4-reducing agent.
[0512] Other compounds The present invention provides a compound of formula (II): in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group, or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) n OP5, wherein P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P5 is H, an optionally substituted alkyl group, or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group, or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the group consisting of: wherein each P′ is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl group; Each Q1 is independently OR A SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)R A NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each independently represents H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl, or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxyl protecting group; R6 is H, optionally substituted alkyl or optionally substituted aryl; and Y is independently -COOR C or-SO2R D ; R C When present, is optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; and R D Where present, is optionally substituted aryl or optionally substituted non-enolizable alkyl.
[0513] The present invention also provides compounds of Formula (IID), (IIE), (IIF), (IIG), (IIH), (IIi), (IVAb), (VAb), (VIIAa), (VIAa), (VIIID), (IXD), (IXF), (IXG), (Z), (Z1), (Z2), (Z3), (Z4), (Z5), (Z5A), (Z5B), or (Z6).
[0514] Amination As described herein, wherein R3 is -(CH2) n The compounds disclosed herein of OP5 can be aminated to provide eribulin. Amination conditions can be those known in the art. In a non-limiting example, the C.35 hydroxyl group in the compounds disclosed herein can be sulfonylated (e.g., by reaction with a sulfonyl anhydride or sulfonyl chloride) and reacted with a nitrogen source (e.g., ammonia, azide, aminosulfonic acid, urea (H2NCONH2) or thiourea (H2NCSNH2)) to provide eribulin or a pharmaceutically acceptable salt thereof after optional demasking of the amino group (if the nitrogen source is azide, urea or thiourea). In another non-limiting example, the C.35 hydroxyl group in the compounds disclosed herein can be halogenated (e.g., by Appel reaction or reaction with thionyl chloride, sulfuryl chloride, phosphorus(III) chloride, or phosphorus(V) oxychloride) and reacted with a nitrogen source (e.g., ammonia, azide, sulfamic acid, phthalimide salt, urea (H2NCONH2), or thiourea (H2NCSNH2)) to provide eribulin or a pharmaceutically acceptable salt thereof after optional demasking of the amino group (if the nitrogen source is azide, phthalimide salt, urea, or thiourea). Amino group demasking agents are further described herein. The amination reaction can directly provide a pharmaceutically acceptable salt of eribulin. Alternatively, the amination reaction can provide eribulin in the form of a free base. Pharmaceutically acceptable salts of eribulin can be prepared from eribulin by a salt-forming reaction as described herein.
[0515] Masked amines and amine unmasking agents The compounds used in the methods of the present invention may contain masked or unmasked amines (e.g., at the C.35 carbon of the structure of a halichondrin macrolide analog such as eribulin). An unmasked amine is -NH2. Amines can be masked using methods known in the art, such as by protecting the amine with an N-protecting group. Alternatively, the amine can be masked as a nitrogen-containing group that can react with an amine demasking agent to provide an amine. Non-limiting examples of nitrogen-containing moieties include azides and imides (e.g., phthalimide). The amine demasking agent can be those known in the art for removing N-protecting groups from amines. In one non-limiting example, the Boc group can be removed using an amine demasking agent known in the art, such as Acid (e.g., HCl in 1,4-dioxane or trifluoroacetic acid). When the amine is masked as an azide, the amine can be unmasked by subjecting the compound containing the masked amine to Staudinger reaction conditions (e.g., by contacting with a phosphine, such as a trialkylphosphine, a dialkylarylphosphine, an alkyldiarylphosphine, or a triarylphosphine) or reacting the compound containing the masked amine with a reducing agent (e.g., LiAlH4). When the amine is masked as an imide (e.g., phthalimide), the amine can be unmasked by reaction with an amine unmasking agent known in the art, such as hydrazine.
[0516] Oxidants capable of converting alcohols to carbonyls The oxidizing agent that can convert alcohol into carbonyl is known in the art.The limiting examples of these oxidizing agents comprise Dess-Martin periodinane, TEMPO (in the presence of bleach or BAIB), dimethyl sulfonium compound (for example monochlorodimethyl sulfonium chloride), aluminum trialkoxide and excess ketone (for example acetone) and catalytic tetrapropylammonium perruthenate (TPAP) (in the presence of N-methylmorpholine oxide).Dimethyl sulfonium compound can be prepared in situ under the conditions known for Parikh-Doering oxidation, Swern oxidation, Corey-Kim oxidation or Pfitzner-Moffatt oxidation.Or, dimethyl sulfonium compound can be prepared in situ by the reaction between trichloroacetic anhydride and dimethyl sulfoxide.Can, under the conditions known in the art for Oppenauer oxidation, use aluminum trialkoxide and excess ketone (for example acetone) to carry out the oxidation reaction of alcohol to carbonyl (for example ketone).Also can use MnO2 oxidation allyl and benzyl alcohol.
[0517] reducing agent The reducing agent that can be used in the method of the present invention is those known in the art. The reducing agent can be an electron transfer reducing agent, a metal hydride or a metalloid hydride. Non-limiting examples of electron transfer reducing agents include alkali metals in oxidation state (0), alkaline earth metals in oxidation state (0), alkaline arsenides, lanthanide (II) salts (e.g., SmI2), Zn(0), Fe(0) and Mn(0). Non-limiting examples of metal hydrides and metalloid hydrides include borohydride compounds (e.g., NaBH4, LiBH4, LiHBEt3, selectrides (e.g., lithium tri-sec-butylborohydride (L-selectride)) and boranes (e.g., 9-BBN and alpine borane)), aluminum hydride compounds (e.g., LiAlH4, Examples of the reducing agents include alumina (e.g., diisobutylaluminum hydride (DIBAL)), hydrosilanes (e.g., PMHS and Ph2SiH2), hydrostannanes (e.g., Bu3SnH), copper hydride complexes (e.g., Stryker's reagent), palladium hydride complexes, platinum hydride complexes, iridium hydride complexes, rhodium hydride complexes, and ruthenium hydride complexes. The reducing agent can be formed in situ, for example, a copper hydride complex can be formed by the reaction of a copper salt with, for example, a borohydride compound or a hydrosilane. Thus, some reducing agents (e.g., borohydride compounds, hydrosilanes, and hydrostannanes) can be used in combination with a catalytic amount of a metal salt (e.g., a Cu, Pd, Pt, Ir, Rh, or Ru salt). Alternatively, the catalytic reducing agent can be a metal salt (e.g., aluminum isopropoxide or a ruthenium complex) in combination with an alcohol, which performs transfer hydrogenation of the carbonyl-containing compound without the need for an intermediate metal hydride. Non-limiting examples of transfer hydrogenation reactions include Meerwein-Ponndorf-Verley reduction (eg, using aluminum isopropoxide / isopropanol) and Ru-catalyzed transfer hydrogenation (eg, Hashiguchi et al., J. Am. Chem. Soc., 117:7562-7563, 1995).
[0518] When the substrate is an α,β-unsaturated carbonyl or sulfone compound (e.g., α,β-enone or vinylsulfone), the reducing agent can be a 1,2-reducing agent or a 1,4-reducing agent. For example, the reaction between an α,β-unsaturated carbonyl compound and a 1,2-reducing agent can provide, for example, allyl alcohol (or allylamine, if the starting compound is an enamide), while the reaction between an α,β-unsaturated carbonyl compound and a 1,4-reducing agent can provide an α,β-saturated compound and can keep the carbonyl group intact after post-treatment of the reaction mixture. Non-limiting examples of 1,2-reducing agents include metal hydrides and metalloid hydrides, such as aluminum hydride compounds, borohydride compounds (e.g., CeCl3 containing NaBH4), and ruthenium hydride complexes. Non-limiting examples of 1,4-reducing agents include borohydride compounds (e.g., LiHBEt3 and lithium tri-sec-butylborohydride (L-selectride)), stannane hydrides, copper hydride complexes (e.g., Stryker reagent), palladium hydride complexes, platinum hydride complexes, iridium hydride complexes, rhodium hydride complexes, and ruthenium hydride complexes. Non-limiting examples of 1,4-reducing agents include copper (I) hydride, which can be isolated (e.g., Stryker reagent) or prepared in situ (e.g., from a copper (I) or copper (II) salt and a hydride source). A catalytic amount of a copper salt (copper (I) or copper (II) salt) is combined with a stoichiometric or superstoichiometric amount of a hydride source (e.g., a borohydride salt, borane, PMHS, or a hydrosilane (e.g., Ph2SiH2)). Non-limiting examples of reaction conditions useful for 1,4-reduction are described, for example, in Baker et al., Org. Lett., 10:289-292, 2008, the disclosure of which is incorporated herein by reference. Other metals can be used to catalyze 1,4-reduction, such as Ru, Pd, and Ir compounds.
[0519] The methods of the present invention may include the use of selective reduction techniques to reduce some reactive groups while retaining other reactive groups. For example, carboxylic acids can be reduced using sodium borohydride and iodine in the presence of esters and / or olefins. Alternatively, carboxylic acids can be reduced in the presence of esters and / or 1,1-disubstituted olefins by converting the carboxylic acid to a mixed anhydride (e.g., using N-methylmorpholine and isobutyl chloroformate) and reducing the resulting mixed anhydride using a borane reducing agent (e.g., 9-BBN).
[0520] Compounds with allylic leaving groups (e.g., carboxylate, halide, or sulfonate) can be treated with allylic reducing agents to replace the leaving group with a hydrogen atom. Non-limiting examples of allylic reducing agents are palladium salts or complexes (e.g., Pd(PPh3)4) in combination with formate (e.g., trialkylammonium formate).
[0521] Hydroxyl protecting groups and hydroxyl protecting group removers Hydroxy protecting group can be as defined herein.Especially, hydroxy protecting group can be acyl group, sulfonyl, arylalkyl (for example, benzyl or p-methoxybenzyl), aryl (for example, p-methoxyphenyl) or the silyl (for example, TMS, TES, TBS, TIPS, TBDPS or TPS) of optional replacement.Can select hydroxy protecting group, hydroxy protecting agent and hydroxy protection reaction conditions with the specific hydroxyl group in the selective protection compound, keep other hydroxyls unprotected simultaneously.Select the hydroxy protecting group of compound and can contribute to follow-up deprotection strategy, because some hydroxy protecting groups can utilize suitable hydroxy protecting group remover to remove in the presence of other hydroxy protecting groups.Relate to some of selection silyl hydroxy protecting group in these strategies and be described in for example Silicon-Based Blocking Agents, Gelest, Inc., 2011.
[0522] Hydroxyl protecting group removers are those reagents that can react with compounds having protected hydroxyl groups to provide compounds having deprotected hydroxyl groups. Hydroxyl protecting group removers and deprotection reaction conditions can be those known in the art. In a non-limiting example, a hydroxyl masked as a silyl ether can be demasked by reacting with a fluoride source (e.g., a fluoride salt, such as KF or TBAF). Alternatively, a hydroxyl protected as a TMS or TES ether can be demasked by reacting with a fluoride source (e.g., a fluoride salt, such as KF or TBAF). In another non-limiting example, a hydroxyl group protected as an ester can be deprotected by reacting with a base (e.g., an alkali metal hydroxide (such as lithium hydroxide, sodium hydroxide or potassium hydroxide) or C 1-6 Alkoxides (e.g., alkali metal C 1-6 Alkoxide or alkaline earth metal C 1-6 Alternatively, a hydroxyl group protected as an ester (e.g., a pivaloyl ester) can be deprotected by reaction with a 1,2-reducing agent (e.g., DIBAL-H). In yet another non-limiting example, a hydroxyl group protected as an aryl alkyl ether (e.g., 1-arylalkyl-1-yl ether) can be deprotected using a reduction reaction (e.g., with Pd / C and H2, or with Na / NH3). Alternatively, a hydroxyl group protected as an alkoxy-aryl alkyl ether (e.g., MPM ether) can be deprotected by reaction with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ). In yet another non-limiting example, a hydroxyl group protected as an alkoxyalkyl ether (e.g., 1-alkoxyalkyl-1-yl) or THP ether can be deprotected by reaction with Cyclic protected diols (e.g., acetals or ketals (e.g., 2-alkyl-1,3-dioxolanes, 2,2-dialkyl-1,3-dioxolanes, 2-alkyl-1,3-dioxanes, or 2,2-dialkyl-1,3-dioxanes)) can be deprotected by reacting with The deprotection reaction is carried out with an acid (eg, carboxylic acid).
[0523] Decarboxylation and desulfonation The conditions for the decarboxylation reaction may be those known in the art, such as Krapcho decarboxylation or a sequence including deprotection. C If it is not H, then by changing R C Converted to H and then undergo decarboxylation protonation (protodecarboxylation). The conditions for the desulfonation reaction can be those known in the art. For example, the desulfonation reaction may include contacting a compound of formula (IA) or formula (IB) or a downstream intermediate of a compound of formula (IA) or formula (IB) with an electron transfer reducing agent (e.g., SmI2; Cr(III) salt and Mn(0); or Mg(0)). For exemplary desulfonation conditions, see WO2009 / 064029.
[0524] Nozaki-Hiyama-Kishi reaction The Nozaki-Hiyama-Kishi reaction conditions that can be used for the conversion described herein can be those known in the art. The Nozaki-Hiyama-Kishi reaction can include reacting a substrate (aldehyde and vinyl halide or pseudohalide) with a Cr(II) salt and a Ni(II) salt. An auxiliary ligand can be used in combination with a metal salt. In a non-limiting example, substituted 1,10-phenanthroline can be used in combination with a Ni(II) salt. A chiral auxiliary ligand can be used to make the reaction stereoselective. In a non-limiting example, chiral N-(dihydrooxazolyl-phenyl)-sulfonamides can be used together with a Cr(II) salt to control the stereochemistry of the carbonyl carbon, to which a vinyl nucleophile is added during the Nozaki-Hiyama-Kishi reaction.
[0525] Olefin metathesis Olefin metathesis catalysts are known in the art and include Ru-carbene complexes (e.g., Grubbs and Hoveyda-Grubbs catalysts). Catalysts with olefin metathesis reactivity that can be used for the olefin metathesis reaction described herein are known in the art (e.g., second-generation Hoveyda-Grubbs type catalysts, such as those in which the Ru-benzylidene moiety is modified to include electron-withdrawing and / or electron-donating groups). Non-limiting examples of useful olefin metathesis reaction conditions are provided in, for example, U.S. Patent Application Publication No. 2016 / 0264594 and International Patent Application Publication No. WO 2016 / 179607.
[0526] salt formation As described herein, eribulin mesylate can be prepared by eribulin salification. The salification reaction conditions are known in the art. The salification of eribulin can provide a pharmaceutically acceptable salt of eribulin (e.g., eribulin mesylate). In particular, the salification reaction can include reacting eribulin with Acids (e.g., pharmaceutically acceptable The product is then contacted with an acid (e.g., methanesulfonic acid) to provide a pharmaceutically acceptable salt of eribulin (e.g., Handbook of Pharmaceutical Salts: Properties, Selection and Use, ed.: Stahl and Wermuth, Wiley-VCH / VHCA, Weinheim / Zurich, 2002). Pharmaceutically acceptable salts of eribulin, such as eribulin mesylate, can be formed by methods known in the art, such as in situ formation during the final isolation and purification of the compound, or separately by reacting the free base group with a suitable organic acid. In one example, eribulin is treated with a solution of MsOH and NH4OH in water and acetonitrile. The mixture is concentrated. The residue is dissolved in DCM-pentane, and the solution is added to anhydrous pentane. The resulting precipitate is filtered and dried under high vacuum to provide eribulin mesylate.
[0527] epimerization Epimerization reactions can be used to invert stereocenters with undesirable stereochemistry. For example, an R stereocenter can be converted to an S stereocenter and vice versa through epimerization. 3 -Carbon epimerization can be achieved by a reaction sequence comprising oxidation of a hydroxyl group to a carbonyl group followed by a 1,2-reduction reaction. The 1,2-reduction reaction can provide the desired stereochemical properties diastereoselectively, or the reaction can be carried out using a chiral catalyst, a chiral auxiliary, or a chiral reducing agent. Non-limiting examples of chiral reducing agents include alpine borane and prapine borane. Non-limiting examples of 1,2-reduction reactions involving chiral catalysts are Corey-Bakshi-Shibata reduction, Noyori hydrogenation, and Noyori transfer hydrogenation. The oxidation / reduction reaction sequence can be carried out in situ using dynamic kinetic resolution. Dynamic kinetic resolution can further include reaction with a hydroxyl protecting agent that removes the desired stereoisomer from the reduction / oxidation equilibrium. In a non-limiting example, the dynamic kinetic resolution of a chiral secondary alcohol can include: utilizing η 5- Combination of the reduction / oxidation equilibrium of Ph5CpRu(CO)2H with enantioselective esterification with isopropenyl acetate catalyzed by a lipase (e.g., lipase B from Candida Antarctica, see, e.g., Martin-Matute et al., J. Am. Chem. Soc., 127:8817-8825, 2005).
[0528] The following examples are intended to illustrate the present invention. They are not intended to limit the present invention in any way. Example
[0529] Example 1 The exemplary compound of formula (IA) can be prepared as shown in the above scheme. This compound can be used as an intermediate for the synthesis of halichondrin macrolide. Compound 1 is treated with compound 2 in the presence of BF3·OEt2 (exemplary Sakurai reaction conditions) to obtain compound 3.
[0530] Compound 5 can be prepared by treating compound 3 with compound 4 in the presence of BF3.OEt2 and methoxyacetic acid (exemplary Prins reaction conditions). Compound 7 can be prepared by treating compound 3 with compound 6 in the presence of BF3.OEt2 and methoxyacetic acid (exemplary Prins reaction conditions).
[0531] Halichondrin macrolides can be prepared from compounds 5 or 7 using, for example, the methods and intermediates disclosed in WO 2016 / 179607 (the synthesis of which is hereby incorporated by reference and described herein). For example, compounds 5 and 7 can be converted to halichondrin macrolides as described in WO 2016 / 179607 for compounds of formula (VIIIC).
[0532] Example 2 As shown in this example, an exemplary compound of formula (IA) for the synthesis of halichondrin macrolide analogs can be prepared. Compound 8 is treated with compound 2 in the presence of BF3.OEt2 (exemplary Sakurai reaction conditions) to provide compound 9.
[0533] The above schemes illustrate two exemplary synthetic routes that can be used to obtain compound 11 from compound 9. In one method, compound 9 is reacted with Dess-Martin periodinane to provide enone 10, which, upon reduction with (S)-(-)-2-methyl-CBS-oxazaborolidine and BH3·THF or Zn(BH4), provides compound 11 as the major diastereomer. (S)-(-)-2-methyl-CBS-oxazaborolidine is:
[0534] Trimethyl(2-methylbuta-2,3-dien-1-yl)silane. Lithium chloride (4.0 g, 94 mmol) was charged into a round-bottom flask and heated to dryness under vacuum. After cooling to room temperature, diethyl ether (100 mL) and copper (I) cyanide (4.0 g, 45 mmol) were charged into the flask. The mixture was cooled to 0 ° C and treated with 1M TMSCH2MgCl (45.0 mL, 45.0 mmol) over 10 min, keeping the internal temperature below 5 ° C. The mixture was stirred at 0 ° C for 1 h. After cooling to -78 ° C, the mixture was treated with 2-butynyl p-toluenesulfonate (10.0 g, 44.5 mmol) in 3 portions. The mixture was slowly warmed to room temperature over 18 h. The reaction mixture was filtered through a celite pad and rinsed with diethyl ether. The filtrate was concentrated under a slight vacuum (bath: 10 ° C) to give the title compound (4.09 g, 65.3%).
[0535] 1 H NMR (400 MHz, CHLOROFORM-d) δ 4.51-4.58 (m, 2H), 1.70 (t, J = 3.13 Hz, 3H), 1.33 (t, J = 2.54 Hz, 2H), 0.06 (s, 9H).
[0536] (S)-3-((2R,3R,4S,5S)-5-((S)-2-hydroxy-4-methyl-3-methylenepent-4-en-1-yl)-3-methoxy-4-((phenylsulfonyl)methyl)tetrahydrofuran-2-yl)propane-1,2-diyl dibenzoate. A mixture of (S)-3-((2R,3R,4S,5S)-3-methoxy-5-(2-oxoethyl)-4-((phenylsulfonyl)methyl)tetrahydrofuran-2-yl)propane-1,2-diyl dibenzoate (1.61 g, 2.77 mmol) and trimethyl(2-methylbuta-2,3-dien-1-yl)silane (0.78 g, 5.5 mmol) in CHCl (32 mL) was cooled to -78 ° C, treated with BF3·OEt2 (0.70 mL, 5.5 mmol), and stirred at -78 ° C for 1 h. The reaction was quenched with saturated aqueous NaHCO3 solution (80 mL), and the mixture was extracted twice with MTBE (30 mL). The organic layers were combined, washed with brine (32.1 mL), and concentrated in vacuo. The residue was purified by silica gel column chromatography (ethyl acetate / n-heptane=10% to 50%) to give the title compound (960 mg, 53.5%) and a 1:1 mixture of the title compound and its epimer (631 mg, 35%).
[0537] 1 H NMR (400 MHz, chloroform-d) δ 8.04-8.10 (m, 2H), 7.97-8.04 (m, 2H), 7.88-7.96 (m, 2H), 7.64-7.72 (m, 1H), 7.50-7.62 (m, 4H), 7.37-7.48 (m, 4H), 5.54-5.70 (m, 1H), 5.27 (s, 1H), 5.17 (s, 1H), 4.99 (s, 1H), 4.95 (s, 1H), 4.63 (br d,J=8.60Hz,1H),4.57(d,J=5.08Hz,2H),3.87-3.97(m,2H),3.76-3.85(m,1H),3.41(s,3H),3.01-3 .19(m,2H),2.52-2.63(m,1H),2.19-2.35(m,2H),1.93-2.03(m,1H),1.88(s,3H),1.68-1.79(m,1H).
[0538] (S)-3-((2R,3R,4S,5S)-3-methoxy-5-(4-methyl-3-methylene-2-oxopent-4-en-1-yl)-4-((phenylsulfonyl)methyl)tetrahydrofuran-2-yl)propane-1,2-diyl dibenzoate. A solution of (S)-3-((2R,3R,4S,5S)-5-((S)-2-hydroxy-4-methyl-3-methylenepent-4-en-1-yl)-3-methoxy-4-((phenylsulfonyl)methyl)tetrahydrofuran-2-yl)propane-1,2-diyl dibenzoate (0.63 g, 0.97 mmol) in CHCl (12.6 mL) was treated with sodium bicarbonate (0.16 g, 1.9 mmol) and Dess-Martin periodinane (0.495 g, 1.17 mmol). After stirring at room temperature for 1 h, the reaction was quenched with saturated NaHCO (6.3 mL) and 20% (w / v) aqueous NaSO (6.3 mL) and extracted twice with MTBE (12.6 mL). The organic layers were combined, washed with brine (6.3 mL), and concentrated in vacuo. The residue was purified by silica gel column chromatography (ethyl acetate / n-heptane=10% to 40%) to give the title compound (378 mg, 60%).
[0539] 1H NMR (400 MHz, chloroform-d) δ 7.98-8.11 (m, 4H), 7.89-7.97 (m, 2H), 7.62-7.72 (m, 1H), 7.50-7.62 (m, 4H), 7.35-7.49 (m, 4H), 5.54-5.69 (m, 3H), 5.08 (s, 1H), 4.97 (s, 1H), 4.57 (d, J = 5.08 Hz, 2H), 3.9 7-4.05(m,2H),3.90-3.96(m,1H),3.49(dd,J=3.91,14.07Hz,1H),3.42(s,3H),3.05-3.24(m, 2H), 2.98 (dd, J=7.03, 17.58Hz, 1H), 2.47-2.58 (m, 1H), 2.18-2.35 (m, 2H), 1.82-1.91 (s, 3H).
[0540] (S)-3-((2R,3R,4S,5S)-5-((R)-2-hydroxy-4-methyl-3-methylenepent-4-en-1-yl)-3-methoxy-4-((phenylsulfonyl)methyl)tetrahydrofuran-2-yl)propane-1,2-diyl dibenzoate. (S)-CBS oxazaborolidine (0.056 g, 0.20 mmol) was dissolved in THF (5.8 mL) and treated with 1 M BH3·THF in THF (0.90 mL, 0.90 mmol). The mixture was stirred at room temperature for 1 h. After cooling to -40 ° C, the mixture was treated with a solution of (S)-3-((2R,3R,4S,5S)-3-methoxy-5-(4-methyl-3-methylene-2-oxopent-4-en-1-yl)-4-((phenylsulfonyl)methyl)tetrahydrofuran-2-yl)propane-1,2-diyl dibenzoate (0.29 g, 0.45 mmol) in THF (5.8 mL) and stirred at a temperature of -30 to -15 ° C for 3 h. The reaction was quenched with methanol (0.18 mL) and saturated NH4Cl aqueous solution (15 mL). The mixture was extracted twice with MTBE (29 mL), washed with brine, and concentrated in vacuo. The residue was purified by silica gel column chromatography (ethyl acetate / n-heptane = 10% to 50%) to give the title compound (120 mg, 41%).
[0541] 1H NMR (400MHz, chloroform-d) δ7.95-8.09(m,4H),7.86-7.93(m,2H),7.62-7.72(m,1H),7.49-7.60(m,4H),7.3 5-7.45(m,4H),5.49-5.59(m,1H),5.30-5.37(m,1H),5.15-5.21(m,1H),4.99(s,1H),4.96(s,1H),4 .58-4.65(m,1H),4.49-4.57(m,2H),3.83-3.97(m,2H),3.77-3.82(m,1H),3.36(s,3H),3.03-3.15( m,2H),2.60-2.70(m,1H),2.26(t,J=6.44Hz,2H),2.03-2.11(m,1H),1.89(s,3H),1.71-1.83(m,1H).
[0542] In another method, compound 9 is subjected to a Mitsunobu reaction with 3,5-dinitrobenzoic acid, DIAD, and PPh3 to afford compound 13. Compound 13 is alcoholyzed with Mg(OMe)2 to afford compound 11.
[0543] (S)-3-((2R,3R,4S,5S)-5-((R)-2-((3,5-dinitrobenzoyl)oxy)-4-methyl-3-methylenepent-4-en-1-yl)-3-methoxy-4-((phenylsulfonyl)methyl)tetrahydrofuran-2-yl)propane-1,2-diyl dibenzoate. A solution of (S)-3-((2R,3R,4S,5S)-5-((S)-2-hydroxy-4-methyl-3-methylenepent-4-ene-1-yl)-3-methoxy-4-((phenylsulfonyl)methyl)tetrahydrofuran-2-yl)propane-1,2-diyl dibenzoate (0.33 g, 0.51 mmol) in THF (13.2 mL) was treated with 3,5-dinitrobenzoic acid (0.65 g, 3.1 mmol) and triphenylphosphine (0.80 g, 3.1 mmol). The mixture was treated with DIAD (0.49 mL, 2.5 mmol) and stirred at room temperature for 20 h. The reaction was quenched with saturated NaHCO3 aqueous solution (6.6 mL) and extracted twice with MTBE (9.9 mL). The organic layers were combined, washed with brine, and concentrated in vacuo. The residue was purified by column chromatography (ethyl acetate / n-heptane=10% to 30%) to give the title compound (235 mg, 55%).
[0544] 1H NMR (400 MHz, chloroform-d) δ 9.13-9.17 (m, 2H), 9.10-9.13 (m, 1H), 7.89-7.99 (m, 6H), 7.65-7.72 (m, 1H), 7.50-7.62 (m, 4H), 7.35-7.45 (m, 4H), 5.98-6.08 (m, 1H), 5.36-5.46 (m, 1H), 5.31 (s, 1H), 5.29 ( s,1H),5.27(s,1H),5.11(s,1H),4.43-4.49(m,2H),3.83-3.92(m,2H),3.69-3.77(m,1H),3.31( s,3H),3.01-3.17(m,2H),2.64-2.75(m,1H),2.28-2.37(m,2H),2.07-2.28(m,2H),1.94(s,3H).
[0545] (S)-3-((2R,3R,4S,5S)-5-((R)-2-hydroxy-4-methyl-3-methylenepent-4-en-1-yl)-3-methoxy-4-((phenylsulfonyl)methyl)tetrahydrofuran-2-yl)propane-1,2-diyl dibenzoate. A solution of (S)-3-((2R,3R,4S,5S)-5-((R)-2-((3,5-dinitrobenzoyl)oxy)-4-methyl-3-methylenepent-4-en-1-yl)-3-methoxy-4-((phenylsulfonyl)methyl)tetrahydrofuran-2-yl)propane-1,2-diyl dibenzoate (0.235 g, 0.279 mmol) in methanol (4.7 mL) and THF (0.24 mL) was treated with 6-10% Mg(OMe)2 in methanol (0.22 g, 0.17 mmol) and stirred at room temperature for 1 h. The reaction mixture was diluted with MTBE (23.5 mL) and washed with saturated aqueous NaHCO3 (4.7 mL) and brine. The aqueous layer was extracted with MTBE (5 ml). The organic layers were combined, concentrated in vacuo, and purified by silica gel column chromatography (ethyl acetate / n-heptane = 10% to 40%) to give the title compound (40 mg, 22%).
[0546] 1H NMR (400MHz, chloroform-d) δ7.95-8.09(m,4H),7.86-7.93(m,2H),7.62-7.72(m,1H),7.49-7.60(m,4H),7.3 5-7.45(m,4H),5.49-5.59(m,1H),5.30-5.37(m,1H),5.15-5.21(m,1H),4.99(s,1H),4.96(s,1H),4 .58-4.65(m,1H),4.49-4.57(m,2H),3.83-3.97(m,2H),3.77-3.82(m,1H),3.36(s,3H),3.03-3.15( m,2H),2.60-2.70(m,1H),2.26(t,J=6.44Hz,2H),2.03-2.11(m,1H),1.89(s,3H),1.71-1.83(m,1H).
[0547] (S)-3-((2R,3R,4S,5S)-5-(((2S,6R)-6-((R)-3,4-bis(benzoyloxy)butyl])-3-((2-methoxyacetoxy)methyl)-4-methyl-5,6-dihydro-2H-pyran-2-yl)methyl)-3-methoxy-4-((phenylsulfonyl)methyl)tetrahydrofuran-2-yl)propane-1,2-diyl dibenzoate. A mixture of (S)-3-((2R,3R,4S,5S)-5-((S)-2-hydroxy-4-methyl-3-methylenepent-4-en-1-yl)-3-methoxy-4-((phenylsulfonyl)methyl)tetrahydrofuran-2-yl)propane-1,2-diyl dibenzoate (0.035 g, 0.054 mmol) and (R)-5,5-dimethoxypentane-1,2-diyl dibenzoate (0.030 g, 0.081 mmol) in CHCl (2.1 mL) was cooled to -30°C and treated with methoxyacetic acid (0.062 mL, 0.81 mmol) and BF3-OEt2 (0.021 mL, 0.162 mmol). The mixture was stirred at a temperature of -30 to -20 ° C for 1.5 h, quenched with saturated NaHCO aqueous solution (3.5 mL) and extracted twice with MTBE (3.5 mL). The organic layers were combined, washed with brine (1.8 mL), and concentrated in vacuo. The residue was purified by silica gel column chromatography (ethyl acetate / n-heptane=20% to 50%) to give the title compound (21 mg, 37%).
[0548] 1H NMR (400 MHz, chloroform-d) δ 7.91-8.06 (m, 8H), 7.87 (d, J = 7.42 Hz, 2H), 7.60 (m, 1H), 7.45-7.55 (m, 6H), 7.30-7.41 (m, 8H), 5.53-5.65 (m, 1H), 5.42-5.52 (m, 1H), 4.62-4.70 (m, 1H), 4.40-4.57 (m, 5H), 4.05-4.18 (m, 1H), 3.9 8(s,2H),3.90(s,2H),3.71-3.80(m,1H),3.40(s,3H),3.37(s,3H),3.28-3.36(m,1H),2.97-3.11(m,2H),2 .45-2.55(m,1H),2.10-2.28(m,2H),1.82-1.99(m,3H),1.72-1.82(m,1H),1.67(s,3H),1.44-1.63(m,4H).
[0549] Compound 14 can be prepared by treating compound 11 with compound 4 in the presence of BF3.OEt2 and methoxyacetic acid (exemplary Prince reaction conditions): (S)-3-((2R,3R,4S,5S)-3-methoxy-5-(((2R,6S)-3-((2-methoxyacetyloxy)methyl)-4-methyl-6-(2-(((2S,5S))-3-methylene-5-(3-(pivaloyloxy)propyl)tetrahydrofuran-2-yl)ethyl)-5,6-dihydro-2H-pyran-2-yl)methyl)-4-((phenylsulfonyl)methyl)tetrahydrofuran-2-yl)propane-1,2-diyl dibenzoate. A mixture of (S)-3-((2R,3R,4S,5S)-5-((R)-2-hydroxy-4-methyl-3-methylenepent-4-en-1-yl)-3-methoxy-4-((phenylsulfonyl)methyl)tetrahydrofuran-2-yl)propane-1,2-diyl dibenzoate (71 mg, 0.11 mmol) and 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propyl pivalate (43 mg, 0.15 mmol) in CHCl (3 mL) was cooled to -30°C and treated with methoxyacetic acid (0.13 ml, 1.6 mmol) and BF3·OEt2 (0.042 ml, 0.33 mmol). After stirring at -20 to -30 ° C for 2 h, the reaction was quenched with saturated NaHCO 3 (3.6 mL), and the resulting mixture was extracted twice with MTBE (3.6 mL). The organic layers were combined, dried over MgSO 4, and concentrated in vacuo. The residue was purified by column chromatography (ethyl acetate / n-heptane = 10% to 40%) to give the title compound (4 mg, 4%). Mass (M+Na + ):757.4.
[0550] Compound 15 can be prepared by treating compound 14 with an allylic reducing agent (eg, Pd(PPh3)4 / HCO2H / Et3N).
[0551] Alternatively, compound 16 can be prepared by treating compound 11 with compound 6 in the presence of BF3.OEt2 and methoxyacetic acid (exemplary Prince reaction conditions). Compound 17 can be prepared by treating compound 16 with an allylic reducing agent (e.g., Pd(PPh3)4 / HCO2H / Et3N).
[0552] Halichondrin macrolide analogs can be prepared from compounds 15 or 17 using, for example, the methods and intermediates disclosed in WO 2015 / 066729 (the synthesis of which is hereby incorporated by reference and described herein). For example, compounds 15 and 17 can be converted to halichondrin macrolide analogs as described in WO 2015 / 066729 for compounds of formula (VIIE).
[0553] Example 3 Exemplary compounds of formula (III) can be prepared as shown in the above scheme. Compound 18 is subjected to aldol condensation with HCHO in the presence of K2CO3 to afford compound 19. Compound 19 is treated with triethyl phosphonoacetate deprotonated by Cs2CO3 to afford compound 20.
[0554] Compound 21 can be prepared from compound 20 by treatment with a 1,2-reducing agent such as DIBAL-H, followed by treatment with an alkoxymethylphosphonate such as diethyl (methoxymethyl)phosphonate under Wittig reaction conditions. Compound 22 can be prepared from compound 21 by treatment with a sulfonyl halide or sulfonyl anhydride such as Tf2O, followed by treatment with a halide salt such as NaI or KI. Compound 23 can be prepared from compound 21 by treatment with a reducing metal such as elemental zinc and Compound 24 can be prepared by treating compound 22 with an acid such as acetic acid. Compound 23 can be prepared by reaction with methanol in the presence of an acid such as HCl. Compound 25 can be prepared from compound 24 by reaction with a diol cleavage agent (e.g., NaIO4) followed by a Horner-Wadsworth-Emmons reaction with an alkylated phosphonoacetate (e.g., trimethyl phosphonoacetate) that has been deprotonated by a base (e.g., NaH or Cs2CO3). Compound 26 can be prepared from compound 25 by treatment with a 1,4-reducing agent (e.g., Stryker reagent) followed by a cyclization reaction. The cyclization reaction may proceed spontaneously after 1,4-reduction, for example, during workup or purification.
[0555] Example 4 Exemplary intermediates of formula (IA) can be prepared from compounds 3 and 26. Compound 3 can be treated with compound 26 in the presence of BF3·OEt2 and methoxyacetic acid (exemplary Prince reaction conditions) to provide compound 27. Compound 27 can be treated with an allylic reducing agent (e.g., Pd(PPh3)4 / HCO2H / Et3N) to provide compound 28. Compound 28 can be converted to compound 29 using methods known in the art, for example, using NaBH4 / I2, or by converting the carboxylic acid in compound 28 into a mixed anhydride (e.g., using N-methylmorpholine and isobutyl chloroformate) and reducing the resulting mixed anhydride using a borane reducing agent (e.g., 9-BBN).
[0556] Halichondrin macrolide can be prepared from compound 29 using, for example, the methods and intermediates disclosed in WO 2016 / 179607 (the synthesis of which is hereby incorporated by reference and described herein). For example, compound 29 can be converted to the halichondrin macrolide as described in WO 2016 / 179607 for compounds of formula (VIIID).
[0557] Example 5 Exemplary intermediates of formula (IA) can be prepared from compounds 11 and 26. Compound 11 can be treated with compound 26 in the presence of BF3·OEt2 and methoxyacetic acid (exemplary Prince reaction conditions) to provide compound 30. Compound 30 can be treated with an allylic reducing agent (e.g., Pd(PPh3)4 / HCO2H / Et3N) to provide compound 31. Compound 31 can be converted to compound 15 using methods known in the art, for example, using NaBH4 / I2, or by converting the carboxylic acid in compound 28 into a mixed anhydride (e.g., using N-methylmorpholine and isobutyl chloroformate) and reducing the resulting mixed anhydride using a borane reducing agent (e.g., 9-BBN).
[0558] Halichondrin macrolide analogs can be prepared from compound 15 using, for example, the methods and intermediates disclosed in WO 2015 / 066729 (the synthesis of which is hereby incorporated by reference). For example, compound 15 can be converted to a halichondrin macrolide analog as described in WO 2015 / 066729 for compounds of formula (VIIE).
[0559] Example 6 2-Methoxyacetic acid (4-methyl-2,6-cis-diphenyl-5,6-dihydro-2H-pyran-3-yl) methyl ester. A mixture of trimethyl (2-methylbut-2,3-dien-1-yl) silane (0.050 g, 0.36 mmol) and benzaldehyde (0.11 mL, 1.1 mmol) in CH2Cl2 (4.0 mL) was cooled to -78 ° C and treated with BF3·OEt2 (0.14 mL, 1.1 mmol). The mixture was stirred at -78 ° C for 1.5 h. After adding methoxyacetic acid (0.41 mL, 5.4 mmol), the mixture was warmed to -40 ° C and then slowly warmed to -20 ° C over 2 h with stirring. The reaction was quenched with saturated NaHCO3 aqueous solution (5.0 mL) and extracted twice with MTBE (5.0 mL). The organic layers were combined, washed with brine (2.5 mL), and concentrated in vacuo. The residue was purified by silica gel column chromatography (ethyl acetate / n-heptane=5% to 15%) to give the title compound (53 mg, 42%).
[0560] 1 H NMR (400 MHz, CHLOROFORM-d) δ 7.34-7.44 (m, 4H), 7.20-7.33 (m, 6H), 5.31 (br s, 1H), 4.65-4.76 (m, 2H), 4.13-4.23 (m, 1H), 3.87 (d, J = 16.41 Hz, 1H), 3.72 (d, J = 16.41 Hz, 1H), 3.36 (s, 3H), 2.48-2.63 (m, 1H), 2.16-2.31 (m, 1H), 1.85 (s, 3H).
[0561] (R)-4-((2R,6S)-5-((2-methoxyacetoxy)methyl)-4-methyl-6-phenyl-3,6-dihydro-2H-pyran-2-yl)butane-1,2-diyl dibenzoate. A mixture of trimethyl(2-methylbuta-2,3-dien-1-yl)silane (0.057 g, 0.41 mmol) and benzaldehyde (0.034 mL, 0.34 mmol) in CHCl (2 mL) was cooled to -78°C and treated with BF·OEt (0.13 mL, 1.0 mmol). The mixture was stirred at -78°C for 1.5 h. After adding methoxyacetic acid (0.39mL, 5.1mmol) and dibenzoic acid (R) -5,5- dimethoxypentane -1,2- diyl ester (0.16g, 0.44mmol) in CH2Cl2 (1.2mL), the mixture was stirred at -35 ° C for 10min and warmed to -10 ° C over 2h. The reaction was quenched with saturated NaHCO3 aqueous solution, extracted twice with MTBE (3.6mL), washed with brine (1.8mL), and concentrated in vacuo. The residue was purified by silica gel column chromatography (ethyl acetate / n-heptane = 10%, 20% and 30%) to give the title compound (82mg, 42%).
[0562] 1H NMR (400 MHz, CHLOROFORM-d) δ 7.91-8.06 (m, 4H), 7.46-7.59 (m, 2H), 7.32-7.45 (m, 6H), 7.19-7.31 (m, 3H), 5.84-5.93 (m, 1H), 5.07-5.17 (m, 2H), 3.95-4.08 (m, 1H), 3.78-3.87 (m, 2H), 3.70-3.77 (m, 2H), 3.64-3.78 (m, 1H), 3.34 (s, 3H), 2.15-2.31 (m, 2H), 1.95-2.07 (m, 1H), 1.82-1.94 (m, 2H), 1.78 (s, 3H), 1.58-1.76 (m, 1H).
[0563] N-((4-methyl-2,6-cis-diphenyl-5,6-dihydro-2H-pyran-3-yl)methyl)acetamide. A mixture of trimethyl(2-methylbut-2,3-dien-1-yl)silane (0.098 g, 0.70 mmol) and benzaldehyde (0.21 mL, 2.1 mmol) in CH2Cl2 (2 mL) and acetonitrile (2 mL) was cooled to -40 ° C and treated with BF3·OEt2 (0.27 mL, 2.1 mmol). The mixture was slowly warmed to -10 ° C over 3 h. The reaction was quenched with saturated NaHCO3 aqueous solution (3.9 mL) and extracted twice with MTBE (3.92 mL). The organic layers were combined, washed with brine (4.90 mL), and concentrated in vacuo. The residue was purified by silica gel column chromatography (ethyl acetate / n-heptane = 10% to 90%) to give the title compound (60 mg, 27%).
[0564] 1 H NMR (400MHz, chloroform-d) δ7.28-7.49(m,10H),5.21(br s,1H),4.72(dd,J=3.12,10.93Hz,1H),4.50(br s,1H),3.93(dd,J=6.44,14.25Hz,1H),3.41(dd,J=3.51,14.06Hz,1H),2.44-2.64(m,1H),2.15-2.28(m,1H),1.83(s,3H),1.64(s,3H).
[0565] The experiments described here demonstrate that the Sakurai and Prince reactions can be performed as a one-pot Sakurai-Prince cascade.
[0566] Other implementation plans Without departing from the scope and spirit of the present invention, various modifications and variations of the compositions and methods of the present invention will be apparent to those skilled in the art. Although the present invention has been described in conjunction with specific embodiments, it will be understood that the claimed invention should not be unduly limited to these specific embodiments. In fact, various modifications of the described modes for carrying out the present invention that would be apparent to those skilled in the art are intended to fall within the scope of the present invention.
[0567] Other embodiments are within the claims. Specifically, it involves the following implementation plans: Scheme 1. A method for preparing a compound of formula (B), comprising preparing a compound of formula (B) from a compound of formula (D) and a compound of formula (E); The compound of formula (B) is: in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton, which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group, or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) n OP5, wherein P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group, and P5 is H, optionally substituted alkyl, or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group, or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the following: wherein each P' is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl group; Each Q1 is independently OR A SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)R A NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each independently represents H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl, or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxyl protecting group; R6 is H, optionally substituted alkyl or optionally substituted aryl; and Y is independently -COOR C or-SO2R D ; R C When present, is optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; and R Dwhen present, optionally substituted aryl or optionally substituted non-enolizable alkyl; The compound of formula (D) is: and The compound of formula (E) is: where R S It is a silyl group. Scheme 2. The method of Scheme 1, wherein preparing the compound of formula (B) comprises reacting a compound of formula (D), a compound of formula (E), and a Lewis acid. Scheme 3. The method of Scheme 2, wherein the Lewis acid is an oxophilic Lewis acid. Scheme 4. The method of Scheme 3, wherein the oxophilic Lewis acid is boron trifluoride or a solvate thereof. Scheme 5. The method of any one of Schemes 2 to 4, further comprising epimerizing the reaction product of the compound of formula (D), the compound of formula (E), and the Lewis acid. Scheme 6. Method for preparing the following compounds: Halichondrin macrolide or its analogues, in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton, which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group, or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2)n OP5, wherein P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group, and P5 is H, optionally substituted alkyl, or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group, or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the following: wherein each P' is independently H or a hydroxyl protecting group; A1, A2 and A3 are each independently H or OP", wherein each P" is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl group; Each Q1 is independently OR A SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)R A NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each independently represents H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl, or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; and X1 is -CH2- or -O-; The method comprises: (A) preparing a compound of formula (IVB) from a compound of formula (IIA), a compound of formula (IIB), a compound of formula (IIIA), a compound of formula (IVA) and R5OH, The compound of formula (IIA) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; Each R D when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; R E -CHO or -CH (1+m) (OR F ) (2-m) , in m is 1, and R F is a hydroxyl protecting group, or m is 0, and (i) Each R F are independently alkyl or hydroxy protecting groups, or (ii) Two Rs F Combine to form an alkylene group; The compound of formula (IIB) is: where R S is a silyl group; The compound of formula (IIIA) is: R 4A -R7, (IIIA) in R 4A for where R C is optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl, and each P7 is independently H or a hydroxy protecting group; R7 is -CHO or Each R 7A is independently optionally substituted alkyl; The compound of formula (IVA) is: in Each P9 is independently a hydroxyl protecting group; R9 is -CHO or -COOH; (a1)R 10 is H or a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (a2)R 10 is H or a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (a3)R 10 and R 11 Combine to form a bond, and R 12 is H; (b1)A1 and R 14 Combined to form oxo, R 13 is H or a hydroxyl protecting group, and R 15 is H; or (b2) A1 is H or -OP", and: (i)R 13 is H or a hydroxyl protecting group, and R 14 and R 15 Combine to form a double bond; or (ii)R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; and (c1)R 16 is H, and P8 is H or a hydroxyl protecting group; or (c2)R 16 Combines with P8 to form a double bond; and Each P" when present is independently H or a hydroxy protecting group; The compound of formula (IVB) is: in X1 is -O-, -C(Y)2-, -CH(Y)- or -CH2-; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxyl protecting group; and R G for in R5 is optionally substituted acyl; and X2 is H or -CH2-X 2A -CH2-CH=CH2, where X 2A -O-, -C(R H )2-or-NR I -, where each R H are independently H or -COOR J , R I is an N-protecting group, and R J C 1-6 alkyl; and (B) preparing a compound of formula (IVC) from a compound of formula (IVB), wherein the compound of formula (IVC) is: in L1 is Wherein L2 and L3 combine to form a bond; (C) preparing a compound of formula (IVD) from a compound of formula (IVC), wherein the compound of formula (IVD) is: wherein A1 and A2 are each independently H or -OP"; and (D) Preparation of halichondrin macrolide or its analogues from the compound of formula (IVD). Scheme 7. The method of Scheme 6, wherein step (A) comprises: (E) preparing a compound of formula (IA) from a compound of formula (IIA), a compound of formula (IIIA) and R5OH, wherein the compound of formula (IA) is: and (F) Preparation of a compound of formula (IVB) from a compound of formula (IF) and a compound of formula (IVA). Scheme 8. The method of Scheme 7, wherein step (E) comprises reacting a compound of formula (IIA), a compound of formula (IIIA), R5OH, and a Lewis acid. Scheme 9. The method of Scheme 8, wherein the Lewis acid is an oxophilic Lewis acid. Scheme 10. The method of Scheme 9, wherein the oxophilic Lewis acid is boron trifluoride or a solvate thereof. Scheme 11. The method of any one of Schemes 7 to 10, wherein step (F) comprises R 4A reacting with a diol cleavage agent, and reacting with (R CO)2P(O)-CH2-COOR C The Horner-Wadsworth-Emmons reaction was performed to produce R 4A . Scheme 12. The method of any one of Schemes 7 to 10, wherein step (F) comprises R 4A Reaction with a 1,2-reducing agent and further reaction with an allylic halide or allylic pseudohalide. Scheme 13. The method of any one of Schemes 6 to 10, wherein R9 is -CHO, X1 is -C(Y)2-, -CH(Y)-, or -CH2-, and step (A) comprises Base treatment reacts R9 with R1 which is -CH(Y)2 or -CH2(Y). Scheme 14. The process of any one of Schemes 6 to 10, wherein X1 is -O-, and step (A) comprises esterifying R1 with R9 which is -COOH to -OP6, wherein P6 is H. Scheme 15. The process of any one of Schemes 6 to 10, wherein step (B) comprises reacting a compound of formula (IVB) with an olefin metathesis catalyst. Scheme 16. The method of any one of Schemes 6 to 10, wherein P9 is H, R 16 is H, and step (C) comprises: Oxidation of a compound of formula (IVC) to produce a compound of formula (IVCa): and reacting the compound of formula (IVCa) with a 1,4-reducing agent to produce the compound of formula (IVD). Scheme 17. The method of any one of Schemes 6 to 10, wherein prior to preparing the compound of formula (IVC), the compound of formula (IVB) is or is converted to a compound of formula (IVBa), wherein the compound of formula (IVBa) is: Scheme 18. The method of any one of Schemes 6 to 10, wherein preparing the halichondrin macrolide or an analog thereof comprises reacting the compound of formula (IVD) with a hydroxy protecting group removing agent. Scheme 19. Method for preparing the following compounds: Halichondrin macrolide or its analogues, in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton, which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group, or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) n OP5, wherein P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group, and P5 is H, optionally substituted alkyl, or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group, or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the following: wherein each P' is independently H or a hydroxyl protecting group; A1, A2 and A3 are each independently H or OP", wherein each P" is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl group; Each Q1 is independently OR A SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)R A NR B (CO)(CO)R A NRB (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each independently represents H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl, or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; and X1 is -CH2- or -O-; The method comprises: (A) preparing a compound of formula (VB) from a compound of formula (IIA), a compound of formula (IIB), a compound of formula (IIIB), a compound of formula (VA) and R5OH, wherein R5 is an optionally substituted acyl group; The compound of formula (IIA) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; R D when present, optionally substituted aryl or optionally substituted non-enolizable alkyl; R E -CHO or -CH (1+m) (OR F ) (2-m) , in m is 1, and R F is a hydroxyl protecting group, or m is 0, and (i) Each R F are independently alkyl or hydroxy protecting groups, or (ii) Two Rs F Combine to form an alkylene group; The compound of formula (IIB) is: where R S is a silyl group; The compound of formula (IIIB) is: R 4B -R7, (IIIB) in R 4B is but-3-en-1-yl, wherein each P7 is independently H or a hydroxyl protecting group; and R7 is -CHO or Each R 7A is independently optionally substituted alkyl; The compound of formula (VA) is: in a specifies an (R)-stereocenter and Z is sulfonate, chloro, bromo or iodo; or a specifies an (S)-stereocenter and Z is OR 16 , where R 16 is a hydroxyl protecting group; (a1)R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (a2)R 10 is a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (a3)R 10 and R 11 Combine to form a bond, and R 12 is H; (b1)A1 and R 14 Combined to form oxo, R 13 is a hydroxyl protecting group, and R 15 is H; or (b2) A1 is H or -OP", and: (i)R 13 is a hydroxyl protecting group, and R 14 and R 15 Combine to form a double bond; or (ii)R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; Y1 is iodine, bromine or triflate; R9 is -CHO or -COOH; Each P9 is independently a hydroxy protecting group, and X3 is oxo; or two P9 groups and X3, together with the atoms to which they are attached, combine to form a ketal; and each P" is independently a hydroxy protecting group; and The compound of formula (VB) is: in X1 is -CH2-, -CH(Y)-, -C(Y)2- or -O-, wherein each Y is independently -COOR C or-SO2R D ; Each R C is independently, when present, optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl; Each R D and , when present, is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; and R K for (B) preparing a compound of formula (VC) from a compound of formula (VB), wherein the compound of formula (VC) is: in L1 is Wherein L2 and L3 combine to form a bond; b specifies the (S)-stereocenter if a specifies the (R)-stereocenter; and b specifies the (R)-stereocenter if a specifies the (S)-stereocenter; and (C) Preparation of halichondrin macrolide or its analogues from the compound of formula (VC). Item 20. The method of Item 19, wherein step (A) comprises: (D) preparing a compound of formula (ID) from a compound of formula (IIA), a compound of formula (IIB), a compound of formula (IIIB) and R5OH, wherein the compound of formula (ID) is: and (E) Preparation of a compound of formula (VB) from a compound of formula (ID) and a compound of formula (VA). Scheme 21. The method of Scheme 20, wherein preparing the compound of formula (ID) comprises reacting a compound of formula (IIC), a compound of formula (IIIB), R5OH, and a Lewis acid. Scheme 22. The process of Scheme 21, wherein the Lewis acid is boron trifluoride or a solvate thereof. Scheme 23. The method of any one of Schemes 20 to 22, wherein step (D) comprises a Sakurai reaction between a compound of formula (IIA) and a compound of formula (IIB) to produce a compound of formula (IIC), and a Prince reaction between a compound of formula (IIC), a compound of formula (IIIB), and R5OH, wherein the compound of formula (IIC) is: Scheme 24. The method of any one of Schemes 19 to 22, wherein X1 is -CH2-, -CH(Y)-, or -C(Y)2-, and step (A) comprises Base treatment reacts R9, wherein R9 is -CHO, with R1 being -CH(Y)2 or -CH2(Y) to produce -CO-X1-. Scheme 25. The process of any one of Schemes 19 to 22, wherein X1 is -O-, and step (A) comprises esterifying R9 to -COOH with R1 being -OP6, wherein P6 is H, to produce -CO-X1-. Scheme 26. The process of any one of Schemes 19 to 22, wherein step (B) comprises reacting a compound of formula (VB) with a Cr(II) salt and a Ni(II) salt. Scheme 27. The process of any one of Schemes 19 to 22, wherein step (C) comprises a step of nucleophilic ring closure of the compound of formula (VC). Scheme 28. The method of any one of Schemes 19 to 22, wherein the two P9 groups and X3, together with the atoms to which they are attached, combine to form a ketal. Scheme 29. The method of any one of Schemes 19 to 22, wherein R 10 and R 11 Combine to form a bond, and R 12 For H. Scheme 30. The method of any one of Schemes 19 to 22, wherein R 4B is but-3-en-1-yl, and step (A) comprises reacting but-3-en-1-yl with a dihydroxylating agent to produce R 4B , and cleavage by reaction with a diol cleavage agent Scheme 31. The method of any one of Schemes 19 to 22, wherein R 4B for And step (A) comprises making Reacts with an oxidizing agent capable of converting the alcohol into a carbonyl. Scheme 32. The method of any one of Schemes 19 to 22, wherein R 4B for And step (A) comprises cleaving by reacting with a diol cleavage agent Scheme 33. Method for preparing the following compounds: Halichondrin macrolide or its analogues, in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton, which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group, or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl group, or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) n OP5, wherein P2 is absent, H, optionally substituted alkyl, or a hydroxy protecting group, and P5 is H, optionally substituted alkyl, or a hydroxy protecting group; or P2 and P5, together with the...
Claims
1. A method for preparing a compound of formula (B), the method comprising preparing a compound of formula (B) from a compound of formula (D) and a compound of formula (E); The compound of formula (B) is: in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton, which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl or hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) n OP5, wherein P2 is absent, H, optionally substituted alkyl or a hydroxy protecting group, and P5 is H, optionally substituted alkyl or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the following: wherein each P' is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl; Each Q1 is independently OR A , SR A、SO2R A 、OSO2R A NR B R A NR B (CO)R A NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each is independently H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxyl protecting group; R6 is H, optionally substituted alkyl or optionally substituted aryl; and Y is independently -COOR C or-SO2R D ; R C when present, is optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl; and R D when present, optionally substituted aryl or optionally substituted non-enolizable alkyl; The compound of formula (D) is: and The compound of formula (E) is: Where R S It is a silyl group.
2. A method for preparing the following compounds: Halichondrin macrolide or its analogs, in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton, which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl or hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) n OP5, wherein P2 is absent, H, optionally substituted alkyl or a hydroxy protecting group, and P5 is H, optionally substituted alkyl or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the following: wherein each P' is independently H or a hydroxyl protecting group; A1, A2 and A3 are each independently H or OP", wherein each P" is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl; Each Q1 is independently OR A , SR A 、SO2R A 、OSO2R A NR B R ANR B (CO)R A NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each is independently H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; and X1 is -CH2- or -O-; The method comprises: (A) preparing a compound of formula (IVB) from a compound of formula (IIA), a compound of formula (IIB), a compound of formula (IIIA), a compound of formula (IVA) and R5OH, The compound of formula (IIA) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; Each R C when present is independently optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl; Each R D when present is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; R E -CHO or -CH (1+ m ) (OR F ) (2 -m ) , in m is 1, and R F is a hydroxyl protecting group, or m is 0, and (i) Each R F are independently alkyl or hydroxy protecting groups, or (ii) Two Rs F Combine to form alkylene; The compound of formula (IIB) is: Where R S is a silyl group; The compound of formula (IIIA) is: R 4A -R7, (IIIA) in R 4A for Where R C is optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl, and each P7 is independently H or a hydroxy protecting group; R7 is -CHO or Each R 7A is independently optionally substituted alkyl; The compound of formula (IVA) is: in Each P9 is independently a hydroxyl protecting group; R9 is -CHO or -COOH; (a1)R 10 is H or a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (a2)R 10 is H or a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (a3)R 10 and R 11 Combine to form a bond, and R 12 is H; (b1)A1 and R 14 Combined to form oxo, R 13 is H or a hydroxyl protecting group, and R 15 is H; or (b2) A1 is H or -OP", and: (i)R 13 is H or a hydroxyl protecting group, and R 14 and R 15 Combine to form a double bond; or (ii) R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; and (c1)R 16 is H, and P8 is H or a hydroxyl protecting group; or (c2)R 16 Combines with P8 to form a double bond; and Each P" when present is independently H or a hydroxy protecting group; The compound of formula (IVB) is: in X1 is -O-, -C(Y)2-, -CH(Y)- or -CH2-; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxyl protecting group; and R G for in R5 is optionally substituted acyl; and X2 is H or -CH2-X 2A -CH2-CH=CH2, where X 2A -O-, -C(R H ) 2- or -NR I -, where each R H are independently H or -COOR J , R I is an N-protecting group, and R J C 1-6 Alkyl; and (B) preparing a compound of formula (IVC) from a compound of formula (IVB), wherein the compound of formula (IVC) is: in L1 is Wherein L2 and L3 combine to form a bond; (C) preparing a compound of formula (IVD) from a compound of formula (IVC), wherein the compound of formula (IVD) is: wherein A1 and A2 are each independently H or -OP"; and (D) Preparation of halichondrin macrolide or its analogues from the compound of formula (IVD).
3. A method for preparing the following compounds: Halichondrin macrolide or its analogs, in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton, which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl or a hydroxy protecting group; (ii) R3 is -(CH2)nNP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2)nOP5, wherein P2 is absent, H, optionally substituted alkyl or a hydroxy protecting group, and P5 is H, optionally substituted alkyl or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the following: wherein each P' is independently H or a hydroxyl protecting group; A1, A2 and A3 are each independently H or OP", wherein each P" is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl; Each Q1 is independently OR A , SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)R A NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each is independently H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; and X1 is -CH2- or -O-; The method comprises: (A) preparing a compound of formula (VB) from a compound of formula (IIA), a compound of formula (IIB), a compound of formula (IIIB), a compound of formula (VA) and R5OH, Wherein R5 is an optionally substituted acyl group; The compound of formula (IIA) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; Each R C when present is independently optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl; R D when present, optionally substituted aryl or optionally substituted non-enolizable alkyl; R E -CHO or -CH (1+ m ) (OR F ) (2 -m ) , in m is 1, and R F is a hydroxyl protecting group, or m is 0, and (i) Each R F are independently alkyl or hydroxy protecting groups, or (ii) Two Rs F Combine to form alkylene; The compound of formula (IIB) is: Where R S is a silyl group; The compound of formula (IIIB) is: R 4B -R7, (IIIB) in R 4B is but-3-en-1-yl, wherein each P7 is independently H or a hydroxyl protecting group; and R7 is -CHO or Each R 7A is independently optionally substituted alkyl; The compound of formula (VA) is: in a specifies an (R)-stereocenter and Z is sulfonate, chloro, bromo or iodo; or a specifies an (S)-stereocenter and Z is OR 16 , where R 16 is a hydroxyl protecting group; (a1)R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (a2)R 10 is a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (a3)R 10 and R 11 Combine to form a bond, and R 12 is H; (b1)A1 and R 14 Combined to form oxo, R 13 is a hydroxyl protecting group, and R 15 is H; or (b2) A1 is H or -OP", and: (i)R 13 is a hydroxyl protecting group, and R 14 and R 15 Combine to form a double bond; or (ii) R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; Y1 is iodine, bromine or triflate; R9 is -CHO or -COOH; Each P9 is independently a hydroxy protecting group, and X3 is oxo; or two P9 groups and X3, together with the atoms to which they are attached, combine to form a ketal; and each P" is independently a hydroxy protecting group; and The compound of formula (VB) is: in X1 is -CH2-, -CH(Y)-, -C(Y)2- or -O-, wherein each Y is independently -COOR C or-SO2R D ; Each R C when present is independently optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl; Each R D when present is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; and R K for (B) preparing a compound of formula (VC) from a compound of formula (VB), wherein the compound of formula (VC) is: in L1 is Wherein L2 and L3 combine to form a bond; b specifies the (S)-stereocenter if a specifies the (R)-stereocenter; and b specifies the (R)-stereocenter if a specifies the (S)-stereocenter; and (C) Preparation of halichondrin macrolide or its analogues from the compound of formula (VC).
4. A method for preparing the following compounds: Halichondrin macrolide or its analogs, in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton, which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl or hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) nOP5, wherein P2 is absent, H, optionally substituted alkyl or a hydroxy protecting group, and P5 is H, optionally substituted alkyl or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the following: wherein each P' is independently H or a hydroxyl protecting group; A1, A2 and A3 are each independently H or OP", wherein each P" is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl; Each Q1 is independently OR A , SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)R A NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each is independently H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; and X1 is -CH2- or -O-; The method comprises: (A) preparing a compound of formula (IF) from a compound of formula (IIA), a compound of formula (IIB), a compound of formula (IIIC) and R5OH, Wherein R5 is an optionally substituted acyl group; The compound of formula (IF) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; Each R C when present is independently optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl; Each R D when present is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; R 4C for Where R C is optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl, and each P7 is independently H or a hydroxy protecting group; and R5 is an optionally substituted acyl group; The compound of formula (IIA) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; Each R C when present is independently optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl; R D when present, optionally substituted aryl or optionally substituted non-enolizable alkyl; R E -CHO or -CH (1+m) (OR F ) (2-m) , in m is 1, and R F is a hydroxyl protecting group, or m is 0, and (i) Each R F are independently alkyl or hydroxy protecting groups, or (ii) Two Rs F Combine to form alkylene; The compound of formula (IIB) is: Where R S is a silyl group; and The compound of formula (IIIC) is: R 4C -R7, (IIIC) Wherein R7 is -CHO or Each R 7A is independently optionally substituted alkyl; (B) preparing a compound of formula (IG) from a compound of formula (IF), wherein the compound of formula (IG) is: in R E1 for and (C) preparing a halichondrin macrolide or an analog thereof from a compound of formula (IG) and one or more intermediates.
5. A method for preparing the following compounds: Halichondrin macrolide or its analogs, in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton, which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl or a hydroxy protecting group; (ii) R3 is -(CH2) n NP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl or hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2) n OP5, wherein P2 is absent, H, optionally substituted alkyl or a hydroxy protecting group, and P5 is H, optionally substituted alkyl or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the following: wherein each P' is independently H or a hydroxyl protecting group; A1, A2 and A3 are each independently H or OP", wherein each P" is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl; Each Q1 is independently OR A , SR A 、SO2R A 、OSO2R ANR B R A NR B (CO)R A NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each is independently H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; and X1 is -CH2- or -O-; The method comprises: (A) preparing a compound of formula (VIID) from a compound of formula (IIA), a compound of formula (IIB), a compound of formula (IIIC), a compound of formula (VIIA) and R5OH, Wherein R5 is an optionally substituted acyl group; The compound of formula (IIA) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; Each R C when present is independently optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl; Each R D when present is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; R E -CHO or -CH (1+m) (OR F ) (2-m) , in m is 1, and R F is a hydroxyl protecting group, or m is 0, and (i) Each R F are independently alkyl or hydroxy protecting groups, or (ii) Two Rs F Combine to form alkylene; The compound of formula (IIB) is: Where R S is a silyl group; The compound of formula (IIIC) is: R 4C -R7, (IIIC) in R7 is -CHO or Each R 7A is independently optionally substituted alkyl; R 4C for wherein each P7, when present, is independently H or a hydroxy protecting group; The compound of formula (VIIA) is: in (i)R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (ii) R 10 is a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (iii) R 10 and R 11 Combine to form a bond, and R 12 is H; R9 is -CHO or -COOH; R 13 and each P9 is independently a hydroxy protecting group; A1 is H or -OP", wherein P" is H or a hydroxyl protecting group; and Y1 is chlorine, bromine, iodine, trifluoromethanesulfonate or trialkylsilane; The compound of formula (VIID) is: in X1 is -CH2-, -CH(Y)-, -C(Y)2- or -O-, wherein each Y is independently -COOR C or-SO2R D ; X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxyl protecting group; R L for in R 18 is -CHO or -CH2OP7; R5 is an optionally substituted acyl group; (B) preparing a compound of formula (VIIE) from a compound of formula (VIID), wherein the compound of formula (VIIE) is: in L1 is Wherein L2 and L3 combine to form a bond; Each P9 is independently a hydroxy protecting group, and X3 is oxo or X3 together with the carbon atom to which it is attached is -(CH(OP 11 ))-, where P 11 is H or a hydroxyl protecting group; and (C) Preparation of halichondrin macrolide or its analogues from the compound of formula (VIIC).
6. A method for preparing the following compounds: Halichondrin macrolide or its analogs, in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton, which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl or a hydroxy protecting group; (ii) R3 is -(CH2)nNP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2)nOP5, wherein P2 is absent, H, optionally substituted alkyl or a hydroxy protecting group, and P5 is H, optionally substituted alkyl or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the following: wherein each P' is independently H or a hydroxyl protecting group; A1, A2 and A3 are each independently H or OP", wherein each P" is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl; Each Q1 is independently OR A , SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)RA NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each is independently H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; and X1 is -CH2- or -O-; The method comprises: (A) preparing a compound of formula (VIIIB) from a compound of formula (VIIIA), a compound of formula (IIA), a compound of formula (IIB), a compound of formula (IIIC), and R5OH, Wherein R5 is an optionally substituted acyl group; The compound of formula (IIA) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; Each R C when present is independently optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl; Each R D when present is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; R E -CHO or -CH (1+m) (OR F ) (2-m) , in m is 1, and R F is a hydroxyl protecting group, or m is 0; (i) Each R F are independently alkyl or hydroxy protecting groups, or (ii) Two Rs F Combine to form alkylene; The compound of formula (IIB) is: Where R S is a silyl group; The compound of formula (IIIC) is: R 4C -R7, (IIIC) in R 4C for in Each R C when present is independently optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl; Each P7, when present, is independently H or a hydroxy protecting group; R7 is -CHO or Each R 7A is independently optionally substituted alkyl; and The compound of formula (VIIIA) is: in (i)R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (ii) R 10 is a hydroxyl protecting group, and R4 and R5 combine to form a double bond; or (iii) R 10 and R 11 Combine to form a bond, and R 12 is H; R9 is -CHO or -COOH; and Each P9 and R 13 are independently a hydroxyl protecting group, The compound of formula (VIIIB) is: in X1 is -CH2-, -CH(Y)-, -C(Y)2- or -O-, wherein each Y is independently -COOR C or-SO2R D ; R M for in R5 is optionally substituted acyl; and X3 is oxo or X3 together with the carbon atom to which it is attached is -(CH(OP 11 ))-, where P 11 is H or a hydroxyl protecting group; and X4 is oxo, or X4 together with the atom to which it is attached is -(CH(OP 12 ))-, where P 12 is H or a hydroxyl protecting group; (B) preparing a compound of formula (VIIIC) from a compound of formula (VIIIB), wherein the compound of formula (VIIIC) is: in L1 is Wherein L2 and L3 combine to form a bond; A1 is H or -OP", wherein P" is H or a hydroxyl protecting group; and (C) Preparation of halichondrin macrolide or its analogues from the compound of formula (VIIIC).
7. A method for preparing the following compound: Halichondrin macrolide or its analogs, in D and D' are each independently H, optionally substituted alkyl or OP1, provided that only one of D and D' is OP1, wherein P1 is H, alkyl, a hydroxy protecting group, and A is C 1-6 Saturation or C 2-6 An unsaturated hydrocarbon skeleton, which is unsubstituted or has 1 to 10 substituents independently selected from cyano, halogen, azido, oxo and Q1, or A is a group of the following formula (1): in L is -(CH(OP2))-, -(C(OH)(OP2))- or -C(O)-; R2 is H and P1 is absent, H, an alkyl group or a hydroxy protecting group, or R2 and P1 are combined to form a bond; (i) R3 is H, and P2 is absent, H, optionally substituted alkyl or a hydroxy protecting group; (ii) R3 is -(CH2)nNP3P4, wherein P3 is H or an N-protecting group, and (a) P2 is absent, H, an optionally substituted alkyl or a hydroxy protecting group, and P4 is H or an N-protecting group, (b) P2 and P4 combine to form an alkylidene group, or (c) P2 and P4 are each H; (iii) R3 is -(CH2)nOP5, wherein P2 is absent, H, optionally substituted alkyl or a hydroxy protecting group, and P5 is H, optionally substituted alkyl or a hydroxy protecting group; or P2 and P5, together with the atoms to which they are attached, combine to form a ketal, a cyclic carbonate, a dicarbonyl-dioxy group or a silylene-dioxy group; or (iv) R3 and P2 combine to form an optionally substituted ethylene group or a structure selected from the following: wherein each P' is independently H or a hydroxyl protecting group; A1, A2 and A3 are each independently H or OP", wherein each P" is independently H or a hydroxyl protecting group; E is H, optionally substituted alkyl or optionally substituted alkoxy; G is O, S, CH2 or NR N , where R N is H, an N-protecting group or an optionally substituted alkyl; Each Q1 is independently OR A , SR A 、SO2R A 、OSO2R A NR B R A NR B (CO)RA NR B (CO)(CO)R A NR B (CO)NR B R A NR B (CO)OR A 、(CO)OR A 、O(CO)R A 、(CO)NR B R A or O(CO)NR B R A , where R A and R B each is independently H, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, aryl, haloaryl, hydroxyaryl, alkoxyaryl, arylalkyl, alkylaryl, haloarylalkyl, alkylhaloaryl, (alkoxyaryl)alkyl, heterocyclyl or heterocyclyl-alkyl; n, when present, is 0, 1, or 2; k is 0 or 1; and X1 is -CH2- or -O-; The method comprises: (A) preparing a compound of formula (IXB) from a compound of formula (IXA), a compound of formula (IIB), a compound of formula (IIA), a compound of formula (IIIE) and R5OH, Wherein R5 is an optionally substituted acyl group; The compound of formula (IXA) is: in R9 is -CHO or -COOP"; (a1)R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (a2)R 10 is a hydroxyl protecting group, and R 11 and R 12 Combine to form double bonds, or (a3)R 10 and R 11 Combine to form a bond, and R 12 is H; A1 and R 14 Combined to form oxo, R 13 is H or a hydroxyl protecting group, and R 15 is H; or A1 is H or -OP", and: (i)R 13 is H or a hydroxyl protecting group, and R 14 and R 15 Combine to form a double bond; or (ii) R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; R O is -CHO, -CH2OP”, -CH=CH2, -CH(OP”)CH2OP”, -C(O)-CH2P(O)(OR C )2 or halogen; Each R C when present is independently optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl; and Each P" is independently H or a hydroxy protecting group; and Each P9 is independently a hydroxyl protecting group; The compound of formula (IIA) is: in R1 is -OP6, -CH(Y)2 or -CH2(Y), wherein P6 is H or a hydroxy protecting group, and each Y is independently -COOR C or-SO2R D ; Each R D when present is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; R E -CHO or -CH (1+m) (OR F ) (2-m) , in m is 1, and R F is a hydroxyl protecting group, or m is 0, and (i) Each R F are independently alkyl or hydroxy protecting groups, or (ii) Two Rs F Combine to form alkylene; The compound of formula (IIIE) is: R 4E -R7, (IIIE) in R 4E for in Each P7 is independently H or a hydroxy protecting group; and R8 is -CH2CH2-COOR C 、-CH=CH-COOR C 、-CH2CH2-SO2R D or -CH=CH-SO2R D ; and R7 is -CHO or Each R 7A is independently optionally substituted alkyl; The compound of formula (IIB) is: Where R S is a silyl group; and The compound of formula (IXB) is: in X1 is -CH2-, -CH(Y)-, -C(Y)2- or -O-; L1 is Wherein L2 and L3 combine to form a bond; R5 is an optionally substituted acyl group; A1 and R 14 Combined to form oxo, R 13 is H or a hydroxyl protecting group, and R 15 is H; or A1 is H or -OP", and: (i)R 13 is H or a hydroxyl protecting group, and R 14 and R 15 Together with the atoms to which they are attached they form double bonds; or (ii) R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; Each P9 is independently H or a hydroxy protecting group, and X3 is oxo, or X3 and the atom to which it is attached are combined to form -(CH(OP 11 ))-, where P 11 is H or a hydroxyl protecting group; or The two P9 and X3 combine with the atoms to which they are attached to form a ketal; and R 19A is H, -OP” or Y, and R 19B H; or R 19A and R 19B Together with the atoms to which they are attached they form double bonds; and (B) Preparation of halichondrin macrolide or its analogues from the compound of formula (IXB).
8. A method for preparing the following compound: Wherein R7 is -CHO or and Each R 7A are independently an alkyl or hydroxy protecting group; or Two R's 7A Combined to form an optionally substituted alkylene group; The method comprises: (A) a compound of formula (Z1) and Preparation of a compound of formula (Z2) wherein each R O is independently an optionally substituted alkyl group, wherein the compound of formula (Z1) is: in Each R 20A are independently a hydroxyl protecting group, or two R 20A Together with the atoms to which they are attached, they form an acetal, ketal, cyclic carbonate, dicarbonyl-dioxy or silylene-dioxy group; Each R 20B are independently a hydroxyl protecting group, or two R 20B Together with the atoms to which they are attached, they form an acetal, ketal, cyclic carbonate, dicarbonyl-dioxy or silylene-dioxy group; P 12A is H; P 12B is H or a hydroxyl protecting group; And the compound of formula (Z2) is: (B) a compound of formula (Z2) and Prepare a compound of formula (Z3) wherein each R 21 is independently an optionally substituted alkyl group, wherein the compound of formula (Z3) is: (C) preparing a compound of formula (Z4) from a compound of formula (Z3), wherein the compound of formula (Z4) is: Wherein X5 is a halogen; (D) preparing a compound of formula (Z5) from a compound of formula (Z4), wherein the compound of formula (Z5) is: in R 20A is H or a hydroxyl protecting group; and Each R 20B are independently H or a hydroxyl protecting group, or two R 20B Together with the atoms to which they are attached, they form an acetal, ketal, cyclic carbonate, dicarbonyl-dioxy or silylene-dioxy group; (E) A compound of formula (Z5) and R 7A OH to prepare a compound of formula (Z6) (F) a compound of formula (Z6) and Prepare a compound of formula (Z7) wherein each R 22 is independently an optionally substituted alkyl, and the compound of formula (Z7) is: and (G) Preparing a compound of formula (Z) from a compound of formula (Z7).
9. A method for preparing the following compound: in R7 is -CHO or and Each R 7A are independently an alkyl or hydroxy protecting group; or Two R's 7A Combined to form an optionally substituted alkylene group; R8 is -CH2CH2-COOR C 、-CH=CH-COOR C 、-CH2CH2-SO2R D or -CH=CH-SO2R D ; R C and when present is independently optionally substituted alkyl, optionally substituted aryl or optionally substituted arylalkyl; and R D when present is independently optionally substituted aryl or optionally substituted non-enolizable alkyl; The method comprises: (A) a compound of formula (Z1) and Preparation of a compound of formula (Z2) wherein each R O is independently an optionally substituted alkyl group, wherein the compound of formula (Z1) is: in Each R 20A are independently a hydroxyl protecting group, or two R 20A Together with the atoms to which they are attached, they form an acetal, ketal, cyclic carbonate, dicarbonyl-dioxy or silylene-dioxy group; Each R 20B are independently a hydroxyl protecting group, or two R 20B Together with the atoms to which they are attached, they form an acetal, ketal, cyclic carbonate, dicarbonyl-dioxy or silylene-dioxy group; P 12A is H; P 12B is H or a hydroxyl protecting group; And the compound of formula (Z2) is: (B) a compound of formula (Z2) and Prepare a compound of formula (Z3) wherein each R 21 is independently an optionally substituted alkyl group, wherein the compound of formula (Z3) is: (C) preparing a compound of formula (Z4) from a compound of formula (Z3), wherein the compound of formula (Z4) is: Wherein X5 is a halogen; (D) preparing a compound of formula (Z5) from a compound of formula (Z4), wherein the compound of formula (Z5) is: in R 20A is H or a hydroxyl protecting group; and Each R 20B are independently H or a hydroxyl protecting group, or two R 20B Together with the atoms to which they are attached, they form an acetal, ketal, cyclic carbonate, dicarbonyl-dioxy or silylene-dioxy group; (E) A compound of formula (Z5) and R 7A OH prepares a compound of formula (Z5A), wherein the compound of formula (Z5A) is: in R 20A is H or a hydroxyl protecting group; and Each R 20B are independently H or a hydroxyl protecting group, or two R 20B Together with the atoms to which they are attached, they form an acetal, ketal, cyclic carbonate, dicarbonyl-dioxy or silylene-dioxy group; (F) preparing a compound of formula (Z5B) from a compound of formula (Z5A), wherein the compound of formula (Z5B) is: Where R 23 H or -OR 20A ; and (G) a compound of formula (Z5B) and Preparation of a compound of formula (Z8) wherein each R 22 is independently optionally substituted alkyl.
10. Compounds of formula (VIIAa): in R7 is -CH2OP A , -CHO or Each R 7A is independently optionally substituted alkyl; R9 is -CH2-OP", -CHO or -COOP"; (i)R 10 is a hydroxyl protecting group, R 11 is an alkyl ether, and R 12 is H; (ii) R 10 is a hydroxyl protecting group, and R 11 and R 12 Combine to form a double bond; or (iii) R 10 and R 11 Combine to form a bond, and R 12 is H; A1 and R 14 Combined to form oxo, R 13 is H or a hydroxyl protecting group, and R 15 is H; or A1 is H or -OP", and: (i)R 13 is H or a hydroxyl protecting group, and R 14 and R 15 Combine to form a double bond; or (ii) R 13 and R 14 Combine to form a bond, and R 15 is H or -OP"; Each P" is independently H or a hydroxy protecting group; and Each P9 is independently a hydroxy protecting group, and X3 is oxo or X3 together with the carbon atom to which it is attached is -(CH(OP 11 ))-, where P 11is H or a hydroxyl protecting group; or two P9 groups and X3 are combined with the atoms to which they are attached to form a ketal.
Citation Information
Patent Citations
Intermediates and methods for the synthesis of halichondrin b analogs
US20090198074A1
Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate
US20090203771A1
Halichondrin B Analogs
US20110054194A1
Compounds useful in the synthesis of halichondrin b analogs
US20110184190A1
Methods useful in the synthesis of halichondrin b analogs
US20150158881A1
